



HONG KONG ACADEMY OF MEDICINE  
香港醫學專科學院



2025  
ANNUAL REPORT  
年度報告

## About the Academy

The Hong Kong Academy of Medicine (Academy) was formally established under the Hong Kong Academy of Medicine Ordinance (Cap 419), to address the need for postgraduate medical and dental education and training in Hong Kong.

The Academy is an independent institution with statutory power to organise, monitor, assess and accredit all medical specialist training and to oversee the provision of continuing medical education in Hong Kong.

## Objects of the Academy

Objects of the Academy are:

- to promote the advancement of the art and science of medicine;
- to foster the development of continuing medical education;
- to promote integrity, ethical conduct and standards in the practice of medicine and its specialties;
- to promote the improvement of health care for Hong Kong citizens;
- to foster a spirit of cooperation among medical practitioners; and
- to facilitate the exchange of information and ideas in medicine and matters concerning the medical profession.

## 關於醫專

香港醫學專科學院（醫專）根據《香港醫學專科學院條例》（第419章）正式成立，以滿足社會對大學以上程度醫學及牙科教育與培訓的需求。

醫專乃一所獨立的法定機構，有權組織、監察及評核所有醫學專科訓練，並頒授有關資格，同時亦負責提供延續醫學教育。

## 醫專的宗旨

醫專的宗旨為：


- 促進醫學技術的發展；
- 鼓勵延續醫學教育；
- 提高專業及道德操守與專科執業水平；
- 促進改善香港市民健康護理；
- 提升執業醫生之間的合作精神；以及
- 促進醫學資訊及意見交流。

# Contents

## 目錄

<b>President's Foreword</b> 主席序言	<b>2</b>	<b>The Academy's Divisions / Initiatives</b> 醫專支部／項目	<b>48</b>
<b>Members of the Academy Council</b> 醫專院務委員會委員	<b>9</b>	• Hong Kong Academy of Medicine Press 香港醫學專科學院出版社	49
<b>Key Figures at a Glance</b> 主要數字一覽	<b>10</b>	• Jockey Club Institute for Medical Education and Development 賽馬會醫學教育發展中心	53
<b>Major Events of the Year</b> 主要年度盛事	<b>11</b>	• SZ-HK Medical Specialist Training Centre 深港醫學專科培訓中心	65
<b>Council and Committee Reports</b> 院務委員會及其他委員會報告	<b>18</b>	<b>Honorary Treasurer's Report</b> 名譽司庫報告	<b>68</b>
• Council 院務委員會	19	<b>Independent Auditor's Report and Financial Statements</b> 獨立核數師報告及財務報表	<b>70</b>
• Committees 委員會	25	<b>Appendices</b> 附錄	<b>106</b>
o Education Committee 教育委員會	25	1. Membership of the Academy's Committees and Subcommittees 醫專轄下各委員會及小組委員會的成員 名單	107
o Finance and Investment Committee 財務委員會	29	2. Representation of the Academy 醫專的代表	122
o House Committee 內務委員會	29	3. Fellowship Statistics 院士數據	128
o Membership Committee 會籍委員會	38	4. List of New Fellows in 2024 2024年的新增院士名單	129
o Professionalism and Ethics Committee 專業及道德倫理委員會	38	5. Organisational Structure of the Academy 醫專的組織架構	140
o Task Force on Sports and Exercise Medicine 運動及體育醫學專責小組	43		
o Task Force on Organ Donation 器官捐贈專責小組	43		
o Young Fellows Chapter 年青院士分會	44		
• Election 選舉	47		

## President's Foreword 主席序言



I am extremely honoured to embark as the 9<sup>th</sup> President of the Academy. I wish to convey my profound appreciation to the Immediate Past President, Prof. Gilberto Ka-kit Leung, for his trust in me, and to all the predecessors who have built such a strong foundation for the Academy to flourish. The continued support from Academy Officers, Council members and all our Fellows is deeply valued and the beginning of a new term of Officers marks an exciting chapter.

我非常榮幸能夠擔任醫專第九任主席。謹向上屆主席梁嘉傑教授致以深切謝意，感謝他對我的信任，同時亦感謝歷屆主席為醫專奠定堅實基礎。衷心感激醫專幹事、院務委員會成員及全體院士一直以來的鼎力支持與信任。新一屆幹事任期的展開，標誌一個令人興奮的新篇章。

### Strategic Planning Retreat

To identify the directions and set some priorities for the Academy in the years ahead, a Strategic Planning Retreat was organised in March 2025, with participation of the whole Academy Council, Education Committee and our Young Fellows Chapter. Key directions and a number of actionable items have been devised and are being followed up on. These include (1) further engagement of our Fellows and specialist trainees, (2) strengthening the Academy's position in Chinese Mainland, regionally and globally, (3) reinforcing the mutual support between the Academy and Colleges, as well as (4) continual efforts in advancing our mandate in medical education.

### Funding for advancing the development of medical education in Hong Kong

I am grateful that the Academy has secured two significant project fundings from the Hong Kong Jockey Club Charities Trust (HKJC) and the Government respectively last year, amounting to nearly HK\$100 million over a period of 3 to 5 years. I extend my gratitude to my predecessor in the funding applications, and the HKJC and the Government for their unwavering support and trust in the Academy.

### 策略規劃退修會

為確立醫專未來數年的發展方向及優先工作重點，醫專於2025年3月舉行了策略規劃退修會，院務委員會、教育委員會及年青院士分會代表均有參與。退修會確立了醫專主要的發展方向及多項重點工作，並將持續推進，包括：(1)進一步促進院士和專科培訓學員的參與，(2)加強醫專於中國內地、區域及國際上的地位，(3)鞏固醫專與各分科學院之間的相互支持，以及(4)持續推動醫專教育的使命。

### 推動香港醫學教育發展的撥款

醫專感謝去年分別從香港賽馬會慈善信託基金及政府獲得兩項重要的項目撥款，金額合共接近一億港元，為期三至五年。我謹向申請撥款的上屆主席及一直支持和信任醫專的香港賽馬會慈善信託基金及政府致以衷心感謝。

## Establishment of Jockey Club Institute for Medical Education and Development (JCIMED)

With the funding support from the HKJC, the Jockey Club Institute for Medical Education and Development (JCIMED) was formally inaugurated on 27 November 2024, marking a major leap forward for postgraduate medical education and specialist training in Hong Kong. The Academy is committed to enhancing medical education through JCIMED's multidisciplinary training, advanced simulation technologies and emphasis on innovative means such as extended reality and artificial intelligence. JCIMED, the "education arm" of the Academy, serves as a hub for developing holistic specialist skills and collaborative practice, strengthening our position in healthcare education for Hong Kong and the region.

## Competency-Based Medical Education

The Workplace-Based Assessment (WBA) workshops, organised by the Jockey Club Institute for Medical Education and Development (JCIMED), aim to integrate advanced assessment methodologies, enhance faculty development and focus on providing feedback to trainees effectively at the workplace. Between September 2024 and August 2025, JCIMED held 9 WBA workshops. JCIMED will continue to collaborate with different Academy Colleges to run these workshops, supporting continuous professional development in medical education.

## Resources for addressing the needs of Academy and Colleges

The three-year Government funding supports the Academy's development of Professional Qualifications and Standards, particularly in light of the earlier introduction of alternative pathway for non-locally trained doctors to practise in Hong Kong, with which the Academy has reviewed and strengthened relevant mechanisms for vetting and certifying specialist qualifications.

Apart from designated funding allocated to the Academy for specific purposes, a notable portion of project funding is set aside for shared use by Colleges to support their enhancement in different areas, including capacity building in artificial intelligence, review of training curricula and assessment methods, initiatives for promoting the well-being of Fellows and specialist trainees; professionalism and ethics-related work, etc.

## 賽馬會醫學教育發展中心的成立

在香港賽馬會慈善信託基金的支持下，賽馬會醫學教育發展中心於2024年11月27日正式成立，標誌着香港持續提升大學本科以上程度之醫學教育及專科培訓的一大里程碑。醫專致力透過賽馬會醫學教育發展中心提升不同醫學專業範疇的培訓、先進模擬技術以及擴增實境和人工智能等創新技術推動醫學教育。賽馬會醫學教育發展中心作為醫專「教育支柱」，展開全方位培訓並促進跨專業協作，進一步鞏固醫專在香港及區域醫學教育的領導地位。

## 以能力為本的醫學教育

賽馬會醫學教育發展中心舉辦的工作坊進行評估工作坊，致力結合先進的評估方法，提升師資培訓水平，並專注於有效地提供回饋予受訓學員。2024年9月至2025年8月期間，中心共舉辦了9場工作坊。教育發展中心將繼續與各分科學院攜手合作，合辦多場工作坊，以支持醫學教育的持續專業發展。

## 支持醫專及各分科學院發展所需的資源

在政府的支持下，醫專獲得為期三年的撥款，推動專業資格及標準的持續發展，特別是因應早前引入的非本地受訓醫生在香港執業的替代途徑。醫專進行了全面檢討，並進一步完善專科資格評審及認證機制。

除撥款用於醫專指定的資助項目外，部分款項亦預留予分科學院，以支援其在多個領域的持續提升工作，包括人工智能的應用與發展、培訓課程及評核模式的優化、促進院士及專科培訓學員的身心健康，以及加強專業水平與醫學倫理等方面的工作。

## Renewal of continued collaboration with Chinese Mainland counterparts

The Academy has continued to strengthen ties and foster collaborations with regional and international academic counterparts. In March 2025, a delegation visited Beijing for meaningful dialogues with the National Health Commission (NHC), Chinese Medical Association (CMA) and Chinese Medical Doctor Association (CMDA). The visit featured discussions on strengthening collaboration in specialist training, medical education and cross border healthcare development. The Academy also renewed Memoranda of Understanding with NHC and CMA to solidify the participations and set new directions for cross-border cooperation. On the other hand, the Academy also co-organised the Hong Kong-Shenzhen-Shanghai Young Specialists Study and Exchange Summit during the year, providing a dynamic platform for more than 40 young specialists from Hong Kong, Shenzhen and Shanghai with different training backgrounds to share experiences in specialist training and medical innovation.

At the same time, in order to strengthen collaboration and promote specialist training in line with international standards in the Greater Bay Area, the Academy continues to support the development of specialist training system in Shenzhen and the region through the Academy's Shenzhen-Hong Kong Medical Specialists Training Centre.

## Best Practice Guidelines on Advance Medical Directives

The Professionalism and Ethics Committee (PEC) has published a set of Best Practice Guidelines on Advance Medical Directives (AMD), responding proactively to the Government's introduction of the Advance Decision on Life-Sustaining Treatment Ordinance earlier. The set of guidelines aims to equip Academy Fellows and healthcare professionals with the knowledge and skills needed to navigate the legal, ethical and practical aspects of AMDs. A seminar was organised by the PEC in April 2025 for stakeholders to discuss these guidelines and more seminars are planned to prepare healthcare professionals for the Ordinance's coming into effect in May 2026, reinforcing the Academy's commitment to upholding high standards of medical professionalism and ethics.

## 持續深化與中國內地的協作

醫專持續加強與區域及國際學術機構的聯繫與協作。2025年3月，醫專代表團到訪北京，與國家衛生健康委員會（國家衛健委）、中華醫學會及中國醫師協會進行了富有成果的交流，就加強專科培訓、醫學教育及跨境醫療發展等議題進行深入探討。醫專並與國家衛健委及中華醫學會續簽合作備忘錄，進一步鞏固合作基礎，並開拓跨境協作的新方向。此外，醫專年內亦聯同多個單位合辦「港深滬年青專科醫生學習與交流峰會」，為來自香港、深圳及上海、具不同培訓背景的逾四十位年青專科醫生提供交流平台，促進專科培訓與醫學創新的發展。

同時，為加強合作並推動大灣區專科培訓邁向國際標準，醫專將透過深港醫學專科培訓中心，繼續支持深圳及區內專科培訓制度的發展。

## 《預設醫療指示的良好作業指引》

專業及道德倫理委員會因應政府即將實施的《維持生命治療的預作決定條例》，制訂了《預設醫療指示的良好作業指引》，旨在協助醫專院士及醫療人員掌握相關法律、倫理及實務知識與技能。委員會於2025年4月舉辦研討會，向業界介紹並探討該指引，並計劃舉辦更多講座，協助醫療人員為條例於2026年5月正式生效作好準備，進一步彰顯醫專堅守專業精神與醫學倫理的承諾。

## Advancement of Sports and Exercise Medicine

In response to the rising importance of sports medicine, the Academy established the Task Force on Sports and Exercise Medicine in 2024 to drive the development of this specialty in the profession and design comprehensive multidisciplinary training programmes. Notably, collaboration with the Hong Kong Sports Institute was strengthened through the signing of a formal Memorandum of Understanding following the Government's 2024 Policy Address. The successful Sports and Exercise Medicine Summit held in December 2024 marked a major milestone. The task force continued its vital work in 2025, including formulating different levels of certificate and diploma courses for our Fellows and other healthcare professionals to equip them better in treating their patients.

## Promotion of Organ Donation

To further raise awareness and promote organ donation, the Academy and the Hong Kong Society of Transplantation co-organised a thanksgiving event in March 2025 to honour organ donors and highlight the life-changing impact of transplantation to patients and their families, demonstrating our passionate commitment to this cause.

The Academy Council deliberated and established a "Task Force on Organ Donation" earlier in 2025, which brings together representatives from different Colleges and experts across related fields to review current global and local trends in organ donation, develop training initiatives for promoting organ donation, organise public outreach programmes, community events etc. The Academy remains firmly dedicated to advancing education and advocacy on organ donation for Fellows and specialist trainees, while raising awareness among healthcare professionals and the general public.

## 運動及體育醫學的發展

為應對運動及體育醫學日益發展的趨勢，醫專於2024年成立運動及體育醫學專責小組，致力推動運動及體育醫學的持續專業發展，並從跨學科的角度設計相關的培訓課程。隨着政府在2024年施政報告中提出有關政策後，醫專與香港體育學院簽訂合作備忘錄，進一步鞏固雙方的協作關係。醫專於2024年12月成功舉辦了運動及體育醫學論壇，標誌着一個重要里程碑。專責小組於2025年持續積極推展相關工作，並會為院士及其他醫療人員開辦不同層級的相關證書及文憑課程，以進一步提升病人服務質素。

## 推廣器官捐贈

為進一步提升公眾人士對器官捐贈的認識與支持，醫專與香港移植學會於2025年3月合辦感恩活動，向器官捐贈者致敬，並帶出器官移植對病人及家屬的重要意義，展現醫專對推廣器官捐贈的堅定承擔與熱誠。

醫專於2025年初成立「器官捐贈專責小組」，匯集不同分科學院的代表及相關領域的專家，共同檢視本地及國際器官捐贈的最新趨勢，並推動外展計劃，公眾教育及社區活動。醫專將持續致力推動院士及專科培訓學員的器官捐贈教育與倡議的工作，同時提升醫療人員和公眾對器官捐贈的認識。

## Doctors' Well-being and Social Activities

The Academy continues its commitment in promoting the well-being of our Fellows and specialist trainees. Since the launch of the Well-being Charter in 2021, we have actively advocated for comprehensive wellness through diverse initiatives. Notable efforts include hosting the "Using Laughter to Improve Well-Being" Workshop, which highlighted laughter as a healing power for enhancing physical and mental health. The Academy's ongoing Mindfulness Induction Group programme, now in its sixth session and continues to provide essential mental health training.

Furthermore, we have revamped our well-being webpage to expand resources and improve user experience, introducing new sections as well as social and wellness activities. These initiatives reflect our strong dedication to fostering an environment where doctors are supported in their well-being, ultimately benefiting the community through better healthcare delivery.

The Academy continued to foster fellowship and strengthen professional bonds through a diverse range of social activities. Highlights included a special field visit to the Hong Kong Jockey Club racecourse, where Fellows gained unique insights into turf management from industry experts. Our tradition of regular Yum Cha gatherings that coincide with Mother's Day and Father's Day continues, alongside a sharing session by a senior Fellow that encouraged meaningful dialogue across generations. These initiatives reflect our commitment to creating opportunities for engagement, learning and fellowship in the Academy.

## Growing prominence of Hong Kong Medical Journal

The Hong Kong Medical Journal (HKMJ) has strengthened its standing within the medical community. In the last year, the Journal Impact Factor of HKMJ reached 2.6 (Clarivate, 2025), maintaining its position in Quartile 1 under "Medicine, General and Internal" in the Journal Citation Reports. This achievement is a testament to the dedication and sustained efforts of our Editorial Board members, authors and reviewers.

## 提倡醫生身心健康與社交活動

醫專持續致力促進院士及專科培訓學員的身心健康。自2021年推出《身心健康約章》以來，醫專積極透過多項活動推廣全方位的健康理念，其中包括舉辦「以歡笑提升身心健康」工作坊，帶出以笑聲作為促進身體與心理健康的有效方式。此外，醫專繼續舉辦的「靜觀體驗小組」精神健康課程，並已順利開展第六期培訓，以持續推廣精神健康培訓。

同時，醫專亦全面優化了身心健康網頁，提升使用體驗並擴充資源內容，新增版面及社交和健康活動等專欄。這些工作體現醫專致力營造支持醫生身心健康的環境，促進社會的優質醫療服務。

醫專亦透過舉辦多元化的社交活動，促進院士之間的聯繫及凝聚力，包括到香港賽馬會馬場的專題考察活動，讓院士親身了解草地管理的專業知識與實務。醫專亦繼續舉辦慶祝母親節及父親節的茶聚活動，以及資深院士分享的活動，促進跨代交流與承傳。這些活動充分展現醫專致力為院士建立交流、學習與聯誼的平台，促進專業互動並深化彼此的友誼與連繫。

## 《香港醫學雜誌》影響力持續提升

《香港醫學雜誌》在醫學界的地位日益鞏固。在去年，根據Clarivate於2025年發布的期刊相關的報告，《香港醫學雜誌》的期刊影響力指數達到2.6，並繼續位列Medicine, General and Internal領域的第一分區。這項成就充分彰顯編輯委員會成員、作者及審稿人的持續努力與卓越貢獻。

## The Way Forward

In September 2026, the Academy is going to organise the inaugural Quadripartite Medical Education Conference in conjunction with the two medical schools in Hong Kong and the Hospital Authority. As the host of this landmark event in 2026, the Academy will bring together medical educators, researchers and healthcare professionals from both local and international communities to exchange ideas, share insights and foster best practices.

The Academy will also maintain its momentum in advancing sports and exercise medicine. With the support from the Task Force on Sports and Exercise Medicine, the Sports and Exercise Medicine Summit will be held at the Hong Kong Sports Institute in first quarter of 2026, marking the official launch of the Diploma and Certificate Courses in Sports Medicine, designed respectively for medical specialists and healthcare professionals. These efforts reflect the Academy's sustained commitment to enhancing multidisciplinary training and fostering professional development in sports and exercise medicine.

In tandem, to support the implementation of the Advance Decision on Life-sustaining Treatment Ordinance, which is set to take effect in May 2026, the Academy will organise a series of seminars to prepare healthcare professionals to be well-equipped under the new ordinance.

For cross-border healthcare development, the Academy has been working closely with the schools of Public health of The University of Hong Kong, The Chinese University of Hong Kong, the Hospital Authority and the Department of Health, to support the "National Capacity Building Programme for Human Resources for Health". The programme, initiated by the National Health Commission and funded by the Institute of Philanthropy of Hong Kong Jockey Club, aims to enhance the leadership skills of elite healthcare professionals in the Chinese Mainland, commencing in December 2025 with a training period of six months.

## 展望未來

醫專將於2026年9月，聯同香港兩所醫學院及醫院管理局，舉辦首屆四方醫學教育會議。作為這項具有里程碑意義的活動之主辦機構，醫專將匯聚本地及海外的醫學教育學者、研究人員和醫療專業人士，促進交流，並推動卓越實踐的發展與相互分享。

醫專將持續推動運動醫學的發展。在運動及體育醫學專責小組的支持下，將聯同香港體育學院在2026年第一季舉辦運動及體育醫學論壇，相關的運動醫學文憑課程及證書課程亦隨之正式啟動。兩項課程分別為醫生及醫療人員而設，彰顯醫專在促進跨專業培訓及推進運動與運動醫學專業發展方面的堅定承諾。

此外，為配合《維持生命治療的預作決定條例》於2026年5月正式生效，醫專將舉辦一系列研討會，協助醫療人員充分掌握條例內容及相關專業應對，為新法例的實施作好準備。

在推動跨境醫療發展方面，醫專與香港大學及香港中文大學的公共衛生學院、醫院管理局及衛生署緊密合作，共同支持「國家衛生健康人才能力建設項目—第一類健康中國建設菁英賦能計劃」。該項目由國家衛生健康委員會主導，並獲香港賽馬會轄下公益慈善研究院的資助，旨在提升中國內地菁英醫療人員的領導及管理能力。項目將於2025年12月啟動，為期六個月。

Environmental, Social, and Governance (ESG) is becoming a core focus of the Academy's development. Apart from provision of recycling facilities at different floors of the building and major event venues, electric vehicle (EV) chargers were installed during the year to support low-carbon mobility and reduce our carbon footprint. Looking ahead, the Academy will further explore and implement initiatives, thereby strengthening our corporate social responsibility and amplifying our positive impact within the community at a corporate level. The Academy will continue to strive diligently to uphold and advance ESG principles in our operations, ensuring that sustainability and social responsibility remain integral to our mission and culture.

Together, these initiatives demonstrate the Academy's unwavering dedication to excellence in medical and dental education, professional development and healthcare collaboration. By fostering innovation, strengthening partnerships and advancing training at regional and international levels, the Academy remains committed to enhancing healthcare outcomes for the communities it serves.

I would like to also extend my gratitude to our dedicated Fellows and the Secretariat for their unwavering commitment and collaborative efforts that have contributed to the successful development and implementation of numerous initiatives. I warmly invite everyone to support the Academy in striving toward building a resilient and sustainable healthcare system for Hong Kong.

Prof. Philip Kam-tao Li  
President

李錦滔教授  
主席

環境、社會及企業管治正日益成為是醫專發展的核心焦點之一。除了在大樓不同樓層及主要活動場地設置回收設施外，年內醫專亦安裝了電動車充電設施，支持低碳出行，減少碳排放。醫專將繼續策劃並舉辦活動，進一步強化企業社會責任，增加對社會的正面影響。醫專將持續推動及落實環境、社會及企業管治原則，讓可持續發展與社會責任融入整體使命及文化之中。

這些工作充分展現醫專在醫學與牙科教育、專業發展及醫療協作方面的堅定承擔與持續追求。醫專將繼續推動創新思維、鞏固合作夥伴關係，並在區域及國際層面深化專業培訓，致力提升整體醫療服務及健康水平。

我謹向全體院士及秘書處致以衷心謝意，感謝他們持續的支持及配合，促成多項重要項目的成功推行。我誠邀各界人士繼續支持醫專，攜手建設堅實及可持續發展的香港醫療體系。

# Members of the Academy Council

## 醫專院務委員會委員

(as of August 2025 截至2025年8月)

### Officers 幹事

<b>President</b> 主席	Prof. Philip Kam-tao Li 李錦滔教授	<b>Honorary Secretary</b> 名譽秘書	Dr. Wing-cheong Leung 梁永昌醫生
<b>Vice-President (General Affairs)</b> 一般事務副主席	Dr. Yu-fat Chow 周雨發醫生	<b>Honorary Treasurer</b> 名譽司庫	Prof. Eric Wai-choi Tse 謝偉財教授
<b>Vice-President (Education and Examinations)</b> 教育及考試事務副主席	Prof. Clement Chee-yung Tham 譚智勇教授	<b>Editor</b> 編輯	Prof. Martin Chi-sang Wong 黃至生教授

### Immediate Past President 上屆主席

Prof. Gilberto Ka-kit Leung  
梁嘉傑教授

### Ex Officio Members (President of each Academy College)

#### 當然委員 (各分科學院院長)

<b>Anaesthesiologists</b> 麻醉科	Dr. Hing-yu So 蘇慶餘醫生	<b>Otorhinolaryngologists</b> 耳鼻喉科	Dr. Chi-man Ngai 魏智文醫生
<b>Community Medicine</b> 社會醫學	Dr. Fei-chau Pang 彭飛舟醫生	<b>Paediatricians</b> 兒科	Prof. Yiu-fai Cheung 張耀輝教授
<b>Dental Surgeons</b> 牙科	Prof. Wai-keung Leung 梁惠強教授	<b>Pathologists</b> 病理科	Dr. Siu-ming Mak 麥兆銘醫生
<b>Emergency Medicine</b> 急症科	Dr. Clara Wing-yee Wu 胡詠儀醫生	<b>Physicians</b> 內科	Prof. Daniel Tak-mao Chan 陳德茂教授
<b>Family Physicians</b> 家庭醫學	Dr. David Vai-kiong Chao 周偉強醫生	<b>Psychiatrists</b> 精神科	Dr. Wing-chung Chang 張穎宗醫生
<b>Obstetricians and Gynaecologists</b> 婦產科	Dr. Tse-ngong Leung 梁子昂醫生	<b>Radiologists</b> 放射科	Dr. Yiu-chung Wong 王耀忠醫生
<b>Ophthalmologists</b> 眼科	Dr. Hon-wah Yung 容瀚華醫生	<b>Surgeons</b> 外科	Prof. Kent-man Chu 朱建民教授
<b>Orthopaedic Surgeons</b> 骨科	Dr. Ying-kei Chan 陳英琪醫生		

### Elected Members 選任委員

Dr. Benny Chun-pong Cheng  
鄭振邦醫生

Dr. Julian Chun-yan Fong  
方俊仁醫生

Dr. Hung-to Luk  
陸洪滔醫生

Dr. Sut-yee Tse  
謝雪兒醫生

### Co-opted Member 增選委員

Dr. Christina Man-tung Cheung  
張敏彤醫生

### Honorary Legal Advisor 名譽法律顧問

Ms. Jaime Lam  
林趣怡律師

## Key Figures at a Glance 主要數字一覽

9,716

Fellows<sup>#</sup>  
名院士

(as of August 2025)  
(截至2025年8月)

355

New  
Fellows<sup>#</sup>  
名新院士

(2024)

CME Programme for Practising  
Doctors who are not taking CME  
Programme for Specialists  
普通科醫生自願延續醫學教育計劃

The Academy organised  
醫專舉辦了

1,740

CME activities  
項延續醫學教育活動  
(09/2024-08/2025)

Accumulated up to  
累積達

3,253

hours  
小時  
(09/2024-08/2025)

<sup>#</sup> 91 Fellows possess two or more Fellowships in different specialties  
九十一位院士擁有兩個或以上的專科院士資格

### CME / CPD Programme of the Academy 醫專的延續醫學教育／持續專業發展課程

Since 1996, launched  
自1996年起，推行了

10<sup>cycles</sup>  
個週期

of CME / CPD Programme  
的延續醫學教育／  
持續專業發展課程

The 10<sup>th</sup> cycle started in January 2023. After the second year of  
the current cycle:  
第十個週期已於2023年1月開始。目前週期的第二年結束時：

96%

of the Fellows obtained at least  
40 points  
的院士獲得最少四十個學分

74%

of the Fellows obtained 90 points or  
above  
的院士已獲得九十個學分或以上

## Major Events of the Year 主要年度盛事

### Medical Education Conference 2024

The Medical Education Conference 2024, held on 7 September 2024 at the Academy Building, successfully brought together over 300 medical professionals, educators and researchers to share knowledge and explore latest advancements in medical education under the theme “Innovation and Technology in Medical Education,” with a special emphasis on Artificial Intelligence. Featuring distinguished speakers from leading institutions, the conference covered cutting-edge topics including AI-driven simulation and training tools, ethical considerations and future training developments. The event fostered rich discussions, networking, and collaboration, emphasizing the importance of continued innovation and collaboration in medical education.

### 2024醫學教育會議

2024年醫學教育會議於2024年9月7日在醫專大樓順利舉行，會議匯聚了來自超過300位醫療專業人員、教育工作者及研究人員，交流分享並探討以「醫學教育中的創新與科技」為主題，聚焦於人工智能的最新發展。會議邀請了多位來自知名學府的傑出講者，涵蓋議題包括人工智能驅動與培訓工具、倫理考量與未來培訓發展。此次活動促進了深入討論、廣泛交流與緊密合作，彰顯了持續創新與協作對醫學教育發展的關鍵作用。

### 31<sup>st</sup> Annual General Meeting

The Academy's 31<sup>st</sup> Annual General Meeting (AGM) was held at its Lim Por Yen Lecture Theatre on 6 December 2024. During the AGM, the report of Academy Council, Honorary Treasurer's report, audited accounts and balance sheet were all received. Appointment of auditors, as well as admission of new Fellows, were also endorsed.

### 第三十一屆周年全體大會

醫專第三十一屆周年全體大會（大會）於2024年12月6日在林百欣演講廳舉行。大會上通過院務委員會報告、名譽司庫報告和核數賬目、核數師任命，以及納入醫專新院士。



(From left) Prof. Martin Chi-sang Wong, Dr. Yu-fat Chow, Prof. Gilberto Ka-kit Leung, Prof. Philip Kam-tao Li, and Dr. Wing-cheong Leung  
(由左起) 黃至生教授、周雨發醫生、梁嘉傑教授、李錦滔教授及梁永昌醫生



The AGM on 6 December 2024  
周年全體大會

In accordance with the Hong Kong Academy of Medicine Ordinance, 6 Officers were elected to serve a two-year term of office until December 2026. Results were announced in the meeting as follows:

根據《香港醫學專科學院條例》，六位幹事經由選舉產生，並履行任期兩年至2026年12月。選舉結果於大會上公佈，詳情如下：

Post 職位	Officer 幹事
President 主席	Prof. Philip Kam-tao Li 李錦滔教授
Vice-President (General Affairs) 一般事務副主席	Dr. Yu-fat Chow 周雨發醫生
Vice-President (Education and Examinations) 教育及考試事務副主席	Prof. Clement Chee-yung Tham 譚智勇教授
Honorary Secretary 名譽秘書	Dr. Wing-cheong Leung 梁永昌醫生
Honorary Treasurer 名譽司庫	Prof. Eric Wai-choi Tse 謝偉財教授
Editor 編輯	Prof. Martin Chi-sang Wong 黃至生教授

## 31<sup>st</sup> Annual Fellowship Conferment Ceremony

The 31<sup>st</sup> Annual Fellowship Conferment Ceremony was held at the Run Run Shaw Hall on 6 December 2024, with the presence of Academy past presidents and distinguished guests. In 2024, the Academy conferred a total of 355 Fellows.

## 第三十一屆院士頒授儀式

第三十一屆院士頒授儀式（儀式）於2024年12月6日假邵逸夫堂舉行。醫專歷屆主席及一眾嘉賓撥冗參與儀式。醫專於2024年納入共三百五十五位院士。



The conferment ceremony was graced by distinguished guests.  
醫專邀得一眾嘉賓參與儀式，生色不少。

## Appreciation and Recognition

During the ceremony, the Academy presented plaques of appreciation to the following Ex-Council Members in recognition of their services and contributions:

- Dr. Simon Ho, Ex Officio Member  
(December 2022 to December 2023)
- Professor Simon Lam, Ex Officio Member  
(December 2021 to November 2024)

## 感謝與嘉許

儀式上，醫專頒發感謝牌予下列院務委員會前委員，以表揚他們對醫專的服務和貢獻。

- 何錦源醫生—當然委員  
(2022年12月至2023年12月)
- 林鴻生教授—當然委員  
(2021年12月至2024年11月)

### Prize for Best Original Paper Award (BOPA)

Presented by the Editorial Board of Hong Kong Medical Journal, the Prize for Best Original Paper Award encourages high-quality original writing by doctors. The outstanding author teams in 2024 were recognised in the ceremony.

Awardee (Academy College) 得獎者 (分科學院)	Title of the Paper 論文題目
Dr. Pauline Y Ng* and her co-authors (Medicine) 吳楊珮寧醫生及其共同作者 (內科)	Ten-year territory-wide trends in the utilisation and clinical outcomes of extracorporeal membrane oxygenation in Hong Kong
Dr. Swan Lau* and her co-authors (Anesthesiology) 劉詩韻醫生及其共同作者 (麻醉科)	Prediction of hospital mortality among critically ill patients in a single centre in Asia: comparison of artificial neural networks and logistic regression-based model
Dr. Brian Yu-chien Sung and his co-authors (Surgery) 宋昱謙醫生及其共同作者 (外科)	Changes in cardiovascular disease risk predicted by the Framingham risk model in the Hong Kong population between 2003-2005 and 2014-2015: data from Population Health Surveys

\* unable to join the ceremony

### 最佳原創論文獎

《香港醫學雜誌》編輯委員會設立最佳原創論文獎，旨在鼓勵醫生撰寫高質素原創論文。2024年的得獎作者及其團隊在儀式上接受嘉許：

### Prize for Best Original Research by Young Fellows (BORYF)

The Academy also presented the Prize for Best Original Research by Young Fellows to the awardees and their teams whose research works were considered excellent.

Medal 獎項	Awardee (Academy College) 得獎者 (分科學院)	Research Title 研究題目
Gold Medal 金獎	Dr. Jeremy Yuen-chun Teoh* and his team (Surgery) 張源津醫生及其團隊 (外科)	Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial
Silver Medal 銀獎	Prof. Jason Cheung and his team (Orthopaedic Surgery) 鍾培言教授及其團隊 (骨科)	Impaired Glycine Neurotransmission Causes Adolescent Idiopathic Scoliosis
Bronze Medal 銅獎	Dr. Louis Lau and his team (Medicine) 柳浩城醫生及其團隊 (內科)	Effect of Real-Time Computer-Aided Polyp Detection System (ENDO-AID) on Adenoma Detection in Endoscopists-in-Training: A Randomized Trial

\* unable to join the ceremony

### 最佳年青院士原創研究獎

醫專亦在儀式期間頒發最佳年青院士原創研究獎予在研究上表現傑出的得獎者及其團隊。

\* 未能出席儀式

## Prize for Best Original Research by Trainees (BORT)

Awardees of the Prize for Best Original Research by Trainees 2024 listed below received the honour in the ceremony. This prize aims to recognise excellence in research conducted by doctors during medical or dental specialist training.

## 最佳學員原創研究獎

最佳學員原創研究獎2024之得獎者在儀式上接受殊榮。此獎項旨在表揚醫生於接受醫學／牙科專科培訓期間在研究方面取得卓越成績。

Medal 獎項	Awardee (Academy College) 得獎者 (分科學院)	Research Title 研究題目
Gold Medal 金獎	Dr. Rex Wan-hin Hui (Medicine) 許允軒醫生 (內科)	Machine learning models for outcome prediction in chronic hepatitis B: Implications for clinical care
Silver Medal 銀獎	Dr. Long Chan (Radiology) 陳瓏醫生 (放射科)	Disappearance of Second Peak of Bimodal Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Curative Treatment in the Era of Antiviral Therapy
Bronze Medal 銅獎	Dr. Stanton King-dat Ho (Obstetrics and Gynecology) 何勁達醫生 (婦產科)	Comparative Analysis of HPV Detection in Clinician-Collected, Self-Collected, Urine, and Menstrual Blood Samples

## Certificate of Appreciation

Certificates of appreciation were also presented to five staff members of the Academy Secretariat in recognition of their dedication and contributions more than 15 years of service:

## 感謝狀

醫專亦頒發感謝狀予五位秘書處職員，以感謝他們服務醫專逾十五年：

Name 姓名	Title 職位
Ms. Camellia Chau 周穎芬女士	Chief Operations Officer served the Academy for 30 years 營運總監 已服務醫專三十年
Ms. Jessie Chow 周詠儀女士	Senior Executive Manager (Operations) served the Academy for 20 years 高級行政經理(營運) 已服務醫專二十年
Ms. Betty Lau 劉薇薇女士	Managing Editor served the Academy for 20 years 執行編輯 已服務醫專二十年
Mr. Warren Chan 陳俊華先生	Assistant Managing Editor served the Academy for 20 years 助理執行編輯 已服務醫專二十年
Ms. Jane Cheung 張玲玲女士	Clerical Officer (Education and Membership) 文書主任(教育及會籍) 已服務醫專十五年

## 2024 David Todd Oration

David Todd Oration, the most prestigious lecture paying tribute to the Founding President of the Academy Prof. Sir David Todd, was held in conjunction with the ceremony. Prof. Grace Wai-king Tang, Past President (2004-2008), Honorary Fellow of the Hong Kong Academy of Medicine and Chairman of the Medical Council of Hong Kong, was invited as the Orator, delivering an enlightening talk titled 'Changing Landscape of Medicine in Hong Kong'.



Prof. Grace Wai-king Tang, Orator of 2024 David Todd Oration  
2024年達安輝講座講者  
鄧惠瓊教授

## 2024達安輝講座

為向創院主席達安輝教授致以崇高敬意，醫專特設最負盛名的達安輝講座。醫專前主席、名譽院士及香港醫務委員會主席鄧惠瓊教授應邀出任2024年度的講者，發表以「Changing Landscape of Medicine in Hong Kong」為題的演講。



**Council and  
Committee Reports**  
院務委員會及  
其他委員會報告

# Council and Committee Reports

## 院務委員會及其他委員會報告

### Council

The Council comprises 27 members, including 6 Officers, 15 Ex Officio Members (President of each Academy College), 4 elected Council Members, 1 Co-opted Council Member and the Immediate Past President. The 2-year term of the 6 new Officers began on 6 December 2024. The work and recommendations from various committees were reported to Council for endorsement. Special items that concern the medical and dental profession as well as the health of the community were also brought to Council for deliberation or advice during the past year.

Number of Council meetings held :  
(09/2024-08/2025)

10

The Council also made submissions to the Government in response to the healthcare policies or public health concerns. Views from respective Academy Colleges were sought and scope for enhancement were identified.

### Projects Funding from the Hong Kong Jockey Club and Government

The Academy Council has solicited two sources of project funding from both Hong Kong Jockey Club Charities Trust and the Government. Under these two funding provisions, apart from those items already earmarked for specific purposes, certain funding items are available for utilization by both the Academy and different Colleges under the confined scope in respective designated areas for 3 to 5 years, such as review of training curricula, resources for promulgation and capacity building in medical professionalism & ethics, resources for addressing rapid development of artificial intelligence, and resources for on-going initiatives for promotion of doctors' well-being.

### 院務委員會

院務委員會由廿七名委員組成，其中包括六名幹事、十五名當然委員（各分科學院院長）、四名選任委員、一名增選委員、以及上屆主席。六名幹事的兩年任期於2024年12月6日展開。院務委員會處理並通過轄下各委員會提交的工作報告及建議，並就不同醫療政策事宜及公眾健康議題進行討論及提出建議。

院務委員會會議次數：  
(09/2024-08/2025)

10

院務委員會亦不時就香港特區政府倡議的醫療衛生政策及／或涉及公共衛生項目聽取分科學院的意見，並提出可予改善的範疇。

### 香港賽馬會及政府項目撥款

醫專院務委員會獲得香港賽馬會慈善信託基金及政府的兩項撥款。在這兩項撥款計劃下，除已指定用途的項目外，部分款項可供醫專及各分科學院在指定領域內使用，為期3至5年，涵蓋範疇包括：培訓課程檢討、醫學專業與道德倫理之推廣及能力建設、應對人工智能之快速發展，以及促進醫生身心健康的持續措施。

## Strategic Planning Retreat

A Strategic Planning Retreat was held on 1 March 2025 to review the Academy's goals, reaffirm the vision, and plan for the future. Key areas of focus included enhancing communication and engagement with specialist trainees and Fellows, supporting Colleges with shared resources and platforms, advancing training and continuing medical education, and strengthening collaboration with Chinese Mainland counterparts, as well as different partners regionally and internationally.

## 策略規劃集思會

2025年3月1日舉行了策略規劃集思會，審視醫專的目標、重申願景，並規劃未來發展。重點領域包括加強與專科培訓學員及院士的溝通和互動、為各分科學院提供共用資源與平台、推動培訓及延續醫學教育，並且強化與中國內地、區域及國際夥伴的合作。



The whole Academy Council, Education Committee and the Young Fellows Chapter participated in the Strategic Planning Retreat

院務委員會、教育委員會及年青院士分會代表等參與策略規劃退修會

## Establishment of Institute for Medical Advancement and Clinical Excellence (IMACE)

Following the announcement by the Chief Executive in his 2024 Policy Address that a professional platform should be established for developing evidence-based clinical guidelines and protocols as well as devising service quality and efficiency standards for the public and private healthcare sectors, the Academy was commissioned by the Government to assist in the setting up of the Institute for Medical Advancement and Clinical Excellence (IMACE). With funding support from the Government, the IMACE was officially inaugurated on 8 May 2025 with an office situated in Wong Chuk Hang, with a team of staff formed under the Academy's Secretariat. As an independent and professional-led platform comprising members from both the public and private healthcare sectors in Hong Kong, the seven Founding Members of the IMACE include the Academy, the Department of Health, the Hospital Authority, the Primary Healthcare Commission, the Faculty of Medicine of the Chinese University of Hong Kong, the LKS Faculty of Medicine of the University of Hong Kong, and the Hong Kong Private Hospitals Association.

## 成立醫學實證與臨床卓越研究所 (醫卓所)

根據行政長官在2024年《施政報告》中宣佈，提升醫療服務質素和效益，政府組織一個專業平台，以實證為本，制訂臨床指引，並研究建立公私營醫療服務質素及效益基準。政府委託醫專協助成立醫卓所，在政府資助下，醫卓所於2025年5月8日正式成立，辦事處設於黃竹坑，並由醫專秘書處組織團隊，負責醫卓所運作。醫卓所作為一個獨立且由專業主導的平台，成員橫跨香港公私營醫療界別，醫卓所有七個創始成員，包括醫專、衛生署、醫院管理局、基層醫療署、香港中文大學醫學院、香港大學李嘉誠醫學院，以及香港私家醫院聯會。



Representatives of the Academy, the Department of Health, the Hospital Authority, the Primary Healthcare Commission, the Faculty of Medicine of the Chinese University of Hong Kong, the LKS Faculty of Medicine of the University of Hong Kong, and the Hong Kong Private Hospitals Association at the Inaugural Meeting of IMACE  
醫專、衛生署、醫院管理局、基層醫療署、香港中文大學醫學院、香港大學李嘉誠醫學院，以及香港私家醫院聯會一眾代表出席醫卓所成立儀式

## Leadership Training Programme in Public Health for Chinese Mainland Counterparts

In collaboration with the Hong Kong Jockey Club, the Academy assisted the National Health Commission (NHC) of the People's Republic of China in taking forward the National Health Talent Capacity Building Programme which will commence in Hong Kong at the end of 2025. The programme aims to strengthen leadership capabilities of elite healthcare professionals in Chinese Mainland who would be equipped with enhanced knowledge and skills in prevention and control of communicable diseases, as well as management.

## Continuous Efforts in Cultivating Professionalism and Ethics in Clinical Practice

A set of Best Practice Guidelines (BPG) on Advance Medical Directives has recently been released by the Academy's Professional and Ethics Committee to provide necessary knowledge and relevant guidance to doctors and healthcare professionals, with a view to enhancing their professional capabilities in making informed, ethically sound decisions about life-sustaining treatments, while upholding patients' autonomy and complying with the legal framework of the Advance Decision on Life-sustaining Treatment Ordinance, which will come into effect in 2026. On 26 April 2025, a seminar was held on this subject, bringing together experts from various fields to discuss the legal, ethical, and medical considerations surrounding end-of-life care.

## 中國內地公共衛生領導力培訓計劃

醫專與香港賽馬會合作，協助中華人民共和國國家衛生健康委員會推進「國家衛生健康人才能力建設項目—第一類健康中國建設菁英賦能計劃」，計劃將於2025年底在香港開展。有關計劃旨在加強國家衛生健康委員會中國內地菁英醫療人員的領導能力，使其在傳染病防控與管理方面具備更高的知識與技能。

## 持續培養臨床執業的道德倫理及專業精神

醫專最近制訂並發佈了《預設醫療指示的良好作業指引》，旨在提升醫生及醫療人員於生命維持治療方面，作出知情及合乎倫理的決策能力，並確保他們在尊重病人自主權的同時，亦能遵守已落實於2026年生效的《維持生命治療的預作決定條例》。醫專於2025年4月26日舉辦了相關研討會，匯聚不同領域的專家探討臨終關懷的法律、倫理及醫療考量。



Seminar on Advance Medical Directives  
《預設醫療指示》相關研討會

The second edition of BPG for Expert Witnesses by the Academy's Professional and Ethics Committee has been released in August 2025. The updated guidelines aim to reflect the latest developments and feedback in the field, offering clearer and up-to-date guidance for medical professionals serving as expert witnesses in disciplinary and legal proceedings.

Following the promulgation of the BPG on Genetics and Genomics in 2023, the Academy has been in collaboration with the Hong Kong Genome Institute and established the HKAM-HKGI Research Excellence Grants in Genomic Medicine for Fellows and higher specialist trainees to apply. The grant aims to encourage and inspire research in genetics and genomics, and to fuel the talent pool for Hong Kong.

### Further Strengthening Ties and Collaborations with Regional and International Academic Counterparts

The Academy continues to strengthen collaborative efforts to elevate the standards of specialist training in the region. In March 2025, a delegation visited Beijing and met with leaders from the National Health Commission (NHC), Chinese Medical Association (CMA), and Chinese Medical Doctor Association (CMDA). The discussions focused on enhancing cooperation in specialist training, medical education, and cross-border healthcare development. The Academy also renewed Memorandums of Understanding (MOUs) with the NHC and CMA, reinforcing long-standing partnerships and paving the way for new collaborative initiatives. Also in March 2025, over 40 young specialist doctors from Hong Kong, Shenzhen, and Shanghai participated in the 'Hong Kong-Shenzhen-Shanghai Young Specialists' Study and Exchange Summit' held in Shanghai from 16 to 21 March. Jointly organised by the Academy, Shanghai Municipal Health Commission, Shenzhen Municipal Health Commission, Shanghai Medical Doctor Association, Shenzhen Medical Doctor Association, and the Shenzhen-Hong Kong Medical Specialist Training Centre, the programme served as a valuable platform for cross-regional dialogue and sharing of experiences in specialist training, medical innovation, and clinical practice. Furthermore, collaborations continue with different international medical organisations including the Academy of Medicine, Singapore, the Academy of Medicine of Malaysia, Korean Academy of Medical Sciences and the Macao Academy of Medicine.

醫專的專業及道德倫理委員會已於2025年8月發佈第二版的《專家證人的良好作業指引》。更新後的指引旨在反映該領域的最新發展與回饋，為在紀律及法律程序中擔任專家證人的醫療專業人士提供更清晰且與時俱進的指導。

隨着2023年發佈的《遺傳學及基因組學的良好作業指引》，醫專與香港基因組中心共同設立「基因組醫學卓越研究獎」，鼓勵有志於遺傳學和基因組學發展的院士及高級專科培訓學員進行相關研究，藉此推動科研，培育人才。

### 繼續加強與區域和國際教學夥伴的聯繫及協作

醫專繼續加強與不同學院協作，提升其在區域內的專科培訓水平。2025年3月，醫專代表團訪問北京，並與國家衛生健康委員會、中華醫學會及中國醫師協會的領導會面，討論加強專科培訓、醫學教育及跨境醫療發展方面的合作。醫專亦與國家衛生健康委員會及中華醫學會續簽合作備忘錄，鞏固長期夥伴關係，並奠定未來合作新項目的基礎。同年3月，超過40位來自香港、深圳及上海的年輕專科醫生參加了3月16日至21日在上海舉行的「港深滬年青專科醫生學習交流峰會」。該活動由醫專、上海市衛生健康委員會、深圳市衛生健康委員會、上海市醫師協會、深圳市醫師協會及深港醫學專科培訓中心共同主辦，為專科培訓、醫療創新及臨床實踐之跨區域交流及分享提供了寶貴平台。此外，醫專亦持續與多個海外醫學組織合作，包括新加坡醫學科學院、馬來西亞的醫學專科學院、韓國醫學科學院及澳門醫學專科學院。



The Academy delegation visited Beijing  
醫專代表團訪問北京

The SZ-HK Medical Specialist Training Centre (the Centre), one of the Academy's divisions, has been playing an advisory role in the development of structured specialist training programme in Shenzhen. This year, the Centre organised over 30 trainer courses covering teaching techniques, case-based learning, and exam question design, enhancing the instructional capabilities of trainers at pilot bases. Regular trainee training included over 60 theoretical and clinical sessions, ensuring internationally advanced training quality. The first cohort of specialist trainees will undergo their inaugural mid-term assessment at the end of 2025, with preparations progressing smoothly.

### Addressing on Diversity, Equity and Inclusivity in Medical and Dental Specialist Training

The Academy embraces a culture of inclusivity, providing equal opportunities for individuals who aspire to become professional medical and dental specialists, regardless of their gender, age, race, religion, sexual orientation, disability, and social or economic status. In 2024, the Council endorsed a set of Guidelines for Handling of Requests of Specialist Trainees with Disability or Special Educational Needs (SEN) aimed at promoting positive educational outcomes and meeting the objective of equal opportunities for specialist trainees with SEN, while maintaining professional standards required for training of medical / dental specialists in Hong Kong. The Academy has also issued a Positional Statement on Diversity, Equity and Inclusivity in Medical and Dental Training to reiterate its commitment and stance in November 2024.

醫專透過其支部深港醫學專科培訓中心（中心），以顧問角色在深圳推動專科培訓課程，支援當地發展醫學專科規範化培訓。本年度，中心組織超過30場導師培訓課程，內容涵蓋教學技巧、病例教學、試題編寫等方面，提升了各試點基地專科培訓導師的教學能力。同時，常態化開展學員培訓，組織理論及臨床培訓超過60場次，確保培訓質量達到國際先進水平。第一屆專科培訓學員將於2025年底進行首次中期考核，各項準備工作正在有序推進。

### 促進醫學專科及牙醫專科培訓的多元、平等及包容

醫專秉持共融文化，不論性別、年齡、種族、宗教、性取向、殘疾、以及社會或經濟狀況，皆為所有有志成為醫學專科及牙醫專科醫生的人士提供平等機會。醫專院務委員會於2024通過了一套《處理殘疾或有特殊教育需要的專科培訓學員之申請指引》，旨在促進有特殊教育需要的專科培訓學員取得積極教育成果和平等機會，同時維持培訓所需的專業標準。醫專還於2024年11月發佈了《醫學專科及牙醫專科培訓的多元、平等及包容的立場聲明》，重申其承諾及立場。

## Committees

### Education Committee

#### Continuing Medical Education (CME) / Continuous Professional Development (CPD)

The Academy has implemented mandatory CME for its Fellows since 1996. The 10<sup>th</sup> cycle started on 1 January 2023. According to the records of the 11 Academy Colleges using Academy's online membership management system, the International Network for Continuing Medical Education and Continuous Professional Development (iCMECPD), about 96% of Fellows have obtained at least 40 points, and about 74% have obtained 90 points or more, after the second year of the cycle.

Since 1 January 2008, all Academy Colleges have capped the passive CME / CPD points being allowed per cycle at 75 points or below. Fellows are strongly advised to maintain a balanced CME / CPD profile with a mix of different activities. At the end of the cycle, the Academy will provide the Medical Council / Dental Council of Hong Kong with information of Fellows who are on the Specialist Register and fulfil the CME / CPD requirements, as well as of those who are non-compliant and required to engage in remedial programme. In the 2023-2025 cycle, Academy Fellows can easily access different online resources on a new eHKAM Portal launched together with the eHKAM Learning Management System (eHKAM LMS). The current cycle will end on 31 December 2025 and the set of CME / CPD Guidelines for 2026-2028 has been updated.

#### CME Subcommittee

Since 2001, the Medical Council of Hong Kong has launched the 'CME Programme for Practising Doctors who are not taking CME Programme for Specialists'. The Academy has been appointed as Programme Accreditor, Administrator, and Provider of the Programme. The CME Subcommittee formed under the Education Committee oversees matters related to the Programme, vets and awards CME points for activities organised by CME providers. The Academy also plans and offers dedicated CME activities for Programme registrants every year with support from its Academy Colleges.

As of 31 August 2025, 595 doctors registered for the Academy's Programme through the Academy Colleges.

## 委員會

### 教育委員會

#### 延續醫學教育／持續專業發展

自1996年起，醫專為其院士推行強制性延續醫學教育。第十個週期已於2023年1月1日開始。根據十一個使用醫專網上會員管理系統iCMECPD的分科學院的紀錄，截至週期的第二年完結時，約百分之九十六的院士獲得最少四十個學分，約百分之七十四的院士取得九十個學分以上。

自2008年1月1日起，所有醫專分科學院就被動延續醫學教育分數增設上限為每個週期七十五分或以下。醫專積極建議院士進修不同類型的延續醫學教育／持續專業發展活動，平衡各方面的發展。週期完結時，醫專會向香港醫務委員會／香港牙醫管理委員會提交專科醫生名冊上已符合延續醫學教育／持續專業發展要求或仍未符合相關要求並須參與補修課程之院士名單及資料。2023-2025年週期間，醫專院士可以透過新推出的eHKAM Portal上的學習管理系統獲得各種線上醫學教育資源。現行週期將於2025年12月31日結束。2026-2028年週期的延續醫學教育／持續專業發展指引經已更新。

#### 延續醫學教育小組委員會

香港醫務委員會自2001年起推行普通科醫生自願延續醫學教育計劃。醫專獲香港醫務委員會委任為計劃下的評審單位、管理員及提供者。醫專教育委員會轄下的延續醫學教育小組委員會負責監管計劃之相關事項及審批延續醫學教育課程學分，並在醫專分科學院的支持下，每年為計劃登記者籌劃及提供延續醫學教育活動。

截至2025年8月31日，五百九十五名醫生透過分科學院向醫專登記參與此計劃。

The Academy has provided 3,253 hours of CME activities, including those delivered online and those organised by its Academy Colleges, for non-Fellows from 1 September 2024 to 31 August 2025. Details are as follows.

醫專在2024年9月1日至2025年8月31日期間，向非醫專院士提供合共三千二百五十三小時的延續醫學教育活動，當中包括網上教學活動及由其分科學院舉辦之課程，詳情如下：

Category 類別	Number of Activities 活動數目	CME Hours 延續醫學教育時數 (小時)
Conference / Lecture / Meeting / Seminar / Symposium 大會／演講／會議／研討會／座談會	1,549	2,588
Course 課程	118	504
Discussion 討論	6	6
Self-study 自修	30	38
Workshop 工作坊	37	117
<b>Total 總數</b>	<b>1,740</b>	<b>3,253</b>

### New Subspecialty

The Academy Council and Education Committee approved and recommended a new subspecialty 'Paediatric Cardiology' under Hong Kong College of Paediatricians. The recommendation was subsequently accepted by the Education and Accreditation Committee of the Medical Council of Hong Kong in March 2025 for inclusion in the Specialist Register.

### 新增設的亞專科

醫專院務委員會及教育委員會通過及建議為香港兒科醫學院新增設一門亞專科－「兒童心臟科」。此建議於2025年3月獲香港醫務委員會的教育及評審委員會接納，將上述亞專科列入專科醫生名冊之內。

### Progress on Credentialling

The document 'Guidelines on Credentialling for Endovascular Neurointerventional Procedures', which aims to set relevant standards of clinical practice of high-risk procedures involving multiple specialties, was formally issued in January 2022. During July 2024 to June 2025, the Academy has received a total of 11 applications, and 5 Fellows were credentialled for Category I – Endovascular Neurointerventional Procedures, while 2 Fellows was credentialled for Category II – Neurointerventional Procedures for Acute Ischaemic Stroke.

### 有關資歷認證的進度

《血管內神經介入技術程序資歷認證指引》於2022年1月推行，旨在為涉及不同專科範疇的高風險程序制訂標準，從而增加病人的保護和信心。2024年7月至2025年6月期間，醫專接獲並審核十一份「初始認證程序」申請。當中五位院士取得第一類別「血管內神經介入技術程序」資歷認證，兩位院士取得第二類別「急性缺血性中風介入技術程序」資歷認證。

The Academy has received 50 applications of continuous credentialling from the list of Fellows with “Exempted from Initial Credentialling Process” (grandfathering) whose validity period ended on 30 June 2025. 45 Fellows were endorsed for continuous credentialling for Category I – Endovascular Neurointerventional Procedures, while 5 Fellows were endorsed for continuous credentialling for Category II – Neurointerventional Procedures for Acute Ischaemic Stroke only.

To maintain continuous improvement, necessary updates have been made to the “Guidelines on Credentialling for Endovascular Neurointerventional Procedures”, and the latest version has been published in April 2025.

### **Certification for Specialist Registration (CSR) / Certification for Specialist Qualification (CSQ)**

According to the Medical Registration Ordinance and Dentists Registration Ordinance, any non-Academy Fellow doctor or dentist who wishes to have his / her name included in the Specialist Register of the Medical / Dental Council of Hong Kong must be certified by the Academy to have training and qualification comparable / equivalent to that required of a Fellow in the relevant specialty. An applicant for CSR is also required to submit evidence of his / her CME / CPD to the Academy for vetting.

After the Medical Registration (Amendment) Bill 2021 became effective on 29 October 2021, certain non-locally trained doctors wishing to practise in Hong Kong may apply for special registration as a stepping stone to ultimately obtain full registration in Hong Kong if they meet certain requirements under the Medical Registration Ordinance. In response to the introduction of this new pathway to full registration, the Academy has also introduced the Certification for Specialist Qualification (CSQ) in September 2022 to cater for the need of these applicants.

醫專接獲並審核50份來自「豁免初始認證程序」名單院士的「延續認證程序」申請。當中四十五位院士取得延續認證程序第一類別「血管內神經介入技術程序」資歷認證，五位院士取得延續認證程序第二類別「急性缺血性中風介入技術程序」資歷認證。

醫專亦就《血管內神經介入技術程序資歷認證指引》作出修訂，並於2025年4月發布。

### **非院士專科註冊資格審核／非院士專科資格審核**

根據《醫生註冊條例》和《牙醫註冊條例》，若非醫專院士的醫生或牙醫期望被列入香港醫務委員會／香港牙醫管理委員會之專科醫生名冊，必須經醫專證明其培訓和資格與相關專科之醫專院士的資歷相若或等同。申請專科註冊資格審核的醫生或牙醫亦須向醫專提交其延續醫學教育／持續專業發展活動的證明，以供審批。

《2021年醫生註冊(修訂)條例》於2021年10月29日生效後，非本地培訓醫生如符合相關條件，可申請循特別註冊途徑於本港擔任醫生工作，並獲得正式註冊資格，在港執業。醫專於2022年9月制訂了非院士專科資格審核機制以配合香港醫務委員會有關修訂。

After the Dentists Registration (Amendment) Ordinance 2024 has taken effect from 1 January 2025, certain non-locally trained dentists wishing to practise in Hong Kong may apply for limited registration or special registration as a stepping stone to ultimately obtain full registration in Hong Kong, if they meet certain requirements under Dental Registration Ordinance. The CSQ is also applicable to applicants for special registration who are not registered dentists in Hong Kong.

Based on the same vetting standards, both CSR and CSQ aim to assess and facilitate suitably qualified doctors or dentists (whether locally registered or not) who have received specialist training outside Hong Kong with professional standard comparable or equivalent to specialist qualifications recognised by the Academy to obtain applicable registration status and / or practise in Hong Kong.

From September 2024 to August 2025, a total of 5 applications for CSR / CSQ were successfully certified, 5 applications were considered unsuccessful, and 10 applications remained under vetting.

#### **Updates on Accreditation of Training Units, Training Documents, and CME / CPD Guidelines**

During the reporting period, the Committee endorsed updates submitted by Academy Colleges on their training units, training documents, and CME / CPD guidelines. In order to safeguard the standard of CME / CPD activities provided to Academy Fellows, the Academy has formulated a set of 'Guidelines for Handling Commercial Influence in CME Accreditation' as the guiding principles for organisers to ensure their CME activities are free of any commercial influence or bias. Colleges should also be prudent when considering CME accreditation for activities involving commercial elements, which are not prohibitive in general.

《2024年牙醫註冊(修訂)條例》於2025年1月1日生效後，非本地培訓牙醫如符合相關條件，可申請循有限度註冊或特別註冊途徑於本港擔任牙醫工作，並獲得正式註冊資格，在港執業。醫專亦因應制訂了非院士專科資格審核機制以配合香港牙醫管理委員會有關修訂。

非院士專科註冊資格審核／非院士專科資格審核均以相同的準則，審批非本地培訓醫生及牙醫（不論於本地註冊與否）的申請，並協助於香港以外已接受專科培訓，同時擁有與醫專認可的相若或等同資歷的醫生及牙醫取得註冊資格或在港執業。

2024年9月至2025年8月期間，共5份非院士專科註冊資格審核／非院士專科資格審核的申請成功獲批，5份申請被認為不成功，10份申請仍在審核中。

**有關培訓單位認證、培訓文件和延續醫學教育／持續專業發展指引的更新**  
報告期內，委員會通過了分科學院就其培訓單位、培訓文件和延續醫學教育／持續專業發展指引所提交的各項更新。為保障延續醫學教育／持續專業發展活動的水準，醫專制定認可有商業要素的延續醫學教育／持續專業發展活動的相關政策，以確保活動主辦機構所提供的活動內容不受商業因素影響。分科學院亦應謹慎地處理認可有商業要素的延續醫學教育／持續專業發展活動。

## Finance and Investment Committee

The Committee held two regular meetings during the year. It continued its role of monitoring and reviewing the Academy's financial status and cash position, as well as making recommendations to the Academy Council for long-term financial planning. The Committee would continue its role and make suggestions proactively to strive for financial sustainability of the Academy.

In the year, the Committee reviewed the existing investment strategy and devised a set of investment guidelines for the Academy, which reaffirmed that the importance of capital preservation, while achieving capital growth from investment is also aimed for. The Academy adopts a prudent and conservative approach in its investment strategy, with a limited appetite to take significant risks that may result in a loss of its capital.

With the low interest rates encountered during the year, a designated portion of the available funds was allocated in accordance with the guidelines for investment to equities expected to generate higher dividend yields and returns compared with fixed deposits.

The Committee will review and adjust the investment strategy in the future as appropriate.

## House Committee

### Human Resources

At an age when Artificial Intelligence is automating or taking over many tasks, the human workforce remains crucial for the Academy in supporting its Council and committees to carry out the statutory tasks, executing strategic plans to achieve objectives, organising educational activities for training and professional development, publication of journals and corporate materials, as well as managing events and facilities of the multi-purpose Academy building. Delivering all these requires more than just filling up posts and assigning roles, it calls for retaining dedicated people from different backgrounds with common values working in a concerted manner, empowering existing staff while bringing in new blood, and maintaining a positive environment where they can thrive.

## 財務委員會

委員會在年內召開了兩次定期會議，持續監察和審視醫專的財務及現金流狀況。委員會就醫專長遠的財務規劃向法院務委員會提出建議。委員會將繼續發揮其角色，積極提出意見，以維持醫專財務的可持續性。

年內，委員會檢視了現行的投資策略，並為醫學專科學院制訂了一套投資指引，重申資本保值的重要性，同時投資亦以實現資本增值為目標。醫專在投資策略上採取審慎及保守的態度，對於可能導致資本損失的重大風險承受能力有限。

由於年內利率偏低，醫專根據投資指引分配部分可用資金投資在預期可帶來較高股息回報及收益的股票，相比定期存款取得更佳回報。

委員會將適時檢討及調整投資策略，以確保策略持續適切。

## 內務委員會

### 人力資源

在人工智能逐漸自動化或逐步取代部分工作的趨勢下，人力資源對醫專仍然是十分重要。醫專秘書處在支援院務委員會及轄下委員會履行法定職能、推行策略計劃、籌辦培訓與專業發展活動、出版醫學期刊及機構刊物，以及管理醫專大樓的活動和設施方面，均肩負著重要角色。為實現使命，不僅是填補職位或分配工作，更是需要不同背景，擁有共同理念員工的齊心協力；既要鞏固現有團隊，也要吸納新成員，營造友善的工作環境，讓員工發揮所長和持續成長。

As of August 2025, there are around 70 staff members supporting the Academy's core functions and new projects. Over 10 colleagues were promoted to take up more senior roles or have an expanded scope of work for wider exposure since last October. Besides enhancing fringe benefits and implementing family-friendly policies, several initiatives for staff wellbeing and engagement have also been introduced, for example, "flexitime working hours", work-from-home arrangements, team building and social gatherings for all staff. 6 staff orientations were arranged to brief new recruits, and 6 social gatherings were organised for celebrating festivals together, staff wellness and building team spirit.

The Professional Qualifications and Standards Team has been strengthened to support the mandate given to the Academy by the Government to vet CSR and CSQ (Certification for Specialist Registration and Certification for Specialist Qualifications) in addition to the team's core responsibilities that included vetting fellowship nominations, accrediting CME / CPD activities and maintaining records for Fellows to ensure compliance with requirements to practise as specialists.

The Jockey Club Institute for Medical Education and Development, transformed from the previous Hong Kong Jockey Club Innovative Learning Centre for Medicine to become the Academy's execution arm in delivering educational activities for training and development, has been provided with additional manpower to help organise more courses, seminars and conferences under the expanded scope.

An External and Mainland Affairs Office was set up during the year to handle requests and enquiries from local, Chinese Mainland and overseas organisations for networking and collaboration opportunities. Around the same period, the Academy was entrusted by the Government to help set up an office to support and administer the operations of the newly established Institute for Medical Advancement and Clinical Excellence.

截至本年8月，醫專共有約七十名員工支援秘書處的工作。自去年10月起，超過十名員工獲得晉升，或擴展其工作範疇以累積更廣泛的經驗。除了完善員工福利及推行家庭友善政策外，醫專亦推出多項促進員工身心健康及提升員工參與度的措施，例如：彈性上班時間、在家工作安排、團隊凝聚活動及員工聯誼聚會。醫專於年內共舉辦六場新員工迎新簡介會，協助新同事適應工作環境；同時亦舉辦六次員工聚會，以慶祝節日、促進身心健康及加強團隊凝聚力。

為配合政府賦予學院的職能，醫專的專業資格及標準組進一步擴展工作範疇。除負責審核院士提名、認可延續醫學教育／持續專業發展活動，以及妥善保存紀錄，以確保院士符合專科執業要求外，亦負責進行非院士專科註冊資格審核及非院士專科資格審核等新職能，進一步強化整體審核及監管功能。

賽馬會醫學教育發展中心（前稱：香港賽馬會創新醫學模擬培訓中心），已成為醫專負責推行培訓與發展教育活動的執行部門。隨着職能範疇的擴展，教育發展中心已獲增聘人手，以協助籌辦更多課程、研討會及學術會議。

醫專在本年成立了對外及內地事務辦公室，專責處理本地、中國內地及海外機構有關聯繫及合作機會的查詢與相關事宜。與此同時，醫專亦獲政府委託，協助成立新設的醫學實證與臨床卓越研究所，並提供秘書處支援及管理其營運工作。

The Academy Secretariat has been promulgating 6 core values (Teamwork, Communication, Harmony, Inclusiveness, Integrity and Professionalism) among staff members. A motto (“Together, we work professionally in serving our Academy, with pride and integrity.”) has also been developed to enhance team spirit and staff morale as the Academy’s role and responsibilities expand and the scope of work continues to increase. Today, the 70 staff members work effectively together under different units and collaborate professionally in delivering various tasks, building up a reputation of reliability and quality services.

### Facilities and Building Management

During the reporting year, the Academy continued to enhance its facilities and promote sustainable development, ensuring a safe, comfortable, and environmentally responsible environment for Fellows, visitors, and event participants.

Increasingly frequent and intense summer rainfalls in recent years as well as natural wear and tear to the roof of the Run Run Shaw Hall have led to some water dripping issues. Comprehensive waterproofing works scheduled for the first quarter of this year were successfully completed. Additional waterproofing enhancements were carried out in various parts of the headquarters, including the G/F Exhibition Hall, 1/F foyer, and 5/F terrace, to ensure that events held in the Run Run Shaw Hall and other venues would be unaffected by adverse weather conditions.

To meet the growing demand for diverse events, the Academy undertook upgrades to its event venues and audio-visual systems during the year, including the refurbishment of chairs for events and the upgrade of laser projectors in the Council Chamber. The stage at the Run Run Shaw Hall was reinforced to accommodate the newly installed LED Wall. The new movable LED wall installation in the Run Run Shaw Hall, scheduled for completion in the fourth quarter of this year, is designed to provide an enhanced immersive experience for medical education conferences. The stage platform and stage staircases were also replaced to improve functionality and accessibility for guests.

醫專秘書處一直積極推廣和秉持六大核心價值（團隊合作、溝通、和諧、共融、誠信與專業精神），並訂立格言：「群策群力，以誠待人，服務醫專，樂業精神」，以進一步凝聚團隊精神，提升員工士氣。現時，醫專約有七十名員工分佈於不同部門，緊密協作、專業互助，致力提供可信賴及優質服務。

### 設施及大樓管理

在本年度，醫專持續優化設施管理，推動可持續發展，致力為院士、訪客及活動參加者提供更安全、舒適及環保的環境。

由於近年夏季降雨量顯著增加及邵逸夫堂頂部自然老化，導致邵逸夫堂出現滴水情況。為此，醫專已於本年第一季順利完成邵逸夫堂頂部的全面防水工程。此外，醫專亦於總部多個位置進行額外防水加固工程，包括地下展覽廳、一樓前廳及五樓平台等，以確保在極端天氣下，邵逸夫堂及其他活動場地的運作不受影響。

為配合日益多元的活動需求，醫專積極優化活動場地設施及視聽系統，包括翻新活動場地座椅及升級在院務會議廳內的激光投影機。邵逸夫堂的舞台亦已完成加固工程，以支援新添置的可移動LED屏幕牆。該屏幕牆預定於本年第四季完成安裝，旨在為醫學教育會議提供更佳的沉浸式視覺體驗。同時，邵逸夫堂內的舞台台板及樓梯亦已全面更新，旨在進一步提升場地的靈活性及賓客使用的便利性。

The Academy remains committed to environmental sustainability. Starting early this year, recycling bins have been placed on all office floors and in major event venues to encourage waste separation and recycling among staff and visitors. On 22 March, the Academy actively participated in the annual “Earth Hour” campaign to promote energy conservation. In support of low-carbon mobility, electric vehicle (EV) chargers were successfully installed this year for use by Fellows, visitors, and building users to reduce carbon emissions.

Looking ahead, the Academy plans to conduct an energy audit of the building and progressively replace existing lighting with more energy-efficient alternatives. The feasibility of installing infrared motion-sensor lighting in selected areas will also be explored to further optimize energy usage.

### Information Technology System

Since the launch of eHKAM in 2022, the platform’s Single Sign-On (SSO) functionality has reached two-thirds of Fellows and has been successfully extended to specialist trainees through integration with the membership management systems of individual Colleges. The Academy is currently developing a comprehensive event registration and attendance management platform, known as the “Attendance Management for Continuing Medical Education” (AMCME), within the eHKAM framework. AMCME enhances operational efficiency by streamlining accreditation application workflows and supporting digitalized attendance capture methods while integrating diverse College-specific requirements within a unified platform. The AMCME platform is scheduled for launch in the fourth quarter of 2025.

To strengthen cybersecurity posture and ensure system reliability, the Academy engaged a third-party information technology system audit firm to conduct comprehensive vulnerability assessments and penetration testing across all Internet-facing IT systems. All improvement recommendations from these assessments have been fully implemented. These security evaluations have been integrated into the Academy’s standard operational procedures to continuously maintain the reliability and security of information technology infrastructure.

醫專一直堅守環境可持續發展的承諾，於年初在大樓各辦公樓層及主要活動場地設置環保回收箱，鼓勵員工及訪客進行廢物分類及回收。醫專亦於本年3月22日積極參與「地球一小時」活動，推動節能意識。為支持低碳出行，醫專於本年度成功安裝電動車充電設施，供院士、訪客及大廈使用者使用，以減少碳排放。

展望未來，醫專計劃進行大樓的能源效益審核，並逐步以更高效節能的照明設備取代現有系統，以推動綠色營運。同時，醫專亦將研究於部分區域試行安裝紅外線感應照明燈的可行性，進一步提升能源使用效益。

### 資訊科技系統

自醫專於2022年底推出eHKAM以來，該平台的單一登入功能已覆蓋三分之二的院士，並已透過與各分科學院的會員管理系統整合，成功延伸至專科培訓學員。醫專現正於eHKAM框架內開發一個全面的活動登記及出席情況管理平台，名為「持續醫學教育出席情況管理系統」(AMCME)。AMCME透過簡化認證申請流程及支援數碼化點名方式，同時在統一平台架構內整合各分科學院的特定要求，以提升整體效率。AMCME平台預定於2025年第四季推出。

為加強網絡安全防護及確保系統穩定可靠，醫專聘請第三方資訊科技系統審計公司，對所有面向互聯網的資訊科技系統進行全面漏洞評估及滲透測試，所有改善建議已全面落實。此外，醫專亦已將相關安全評估納入標準營運程序，以持續維持資訊科技基建的可靠性及安全性。

In early 2025, the Academy completed upgrades to unified threat management devices at the Internet gateway to enhance network reliability and security. The implementation of next-generation protection technologies, including deep learning capabilities and intrusion prevention systems, ensures a secure and efficient digital working environment.

These technological advancements demonstrate the Academy's commitment to ensuring robust security measures in place and improving user experience across all educational and administrative platforms by maintaining state-of-the-art digital infrastructure.

### Membership Services and Benefits

The Academy has continued to foster social wellbeing and a sense of belonging among Fellows. In 2024-2025, the Social Subcommittee broadened its efforts to connect different generations of Fellows from various backgrounds through a lineup of activities. The tradition of the HKAM and Medical Alumni Golf Tournament, along with the ongoing hands-on gardening programme, continued to provide opportunities for active engagement and networking. This year's social activities also included a special fieldtrip to visit the Hong Kong Jockey Club's racecourse area to learn about turf management with demonstration by the experts. Social connections were further strengthened through regular Yum Cha gatherings, including special editions for Mother's Day and Father's Day, as well as a Senior Fellows sharing session with lunch gathering.

醫專於2025年初完成互聯網閘道的統一威脅管理設備升級，以進一步提升網絡可靠性及安全性。新一代防護技術的實施，包括深度學習功能及入侵防護系統，確保數碼工作環境既安全又高效。

這些技術提升展示了醫專致力建立健全穩固的保安措施，並透過維持最先進的數碼基建以改善所有教育和行政平台的用戶體驗。

### 會員服務及優惠

在2024至2025年度，醫專透過社交小組委員會，舉辦一系列內容豐富、形式多元的活動，進一步促進院士之間的聯繫與凝聚力。醫專延續高爾夫球賽的傳統及繼續推行園藝計劃，為院士提供了積極參與和交流的機會。今年的活動涵蓋身心健康與學習體驗，包括到香港賽馬會馬場參觀並由專家帶領進行草坪管理體驗。醫專亦繼續舉辦聚餐活動，包括母親節及父親節的慶祝茶敘，以及資深院士交流暨午餐聚會，促進院士之間的交流。



Field visit to the Hong Kong Jockey Club Racecourse and turf management practice  
香港賽馬會馬場參觀及草坪管理體驗



Senior Fellows Sharing session  
資深院士交流活動



Tea gatherings at the Academy  
醫專茶敘

The Academy's football team, AM F.C., has continued to show great dedication through its regular monthly practices and active participation in friendly matches with various groups, such as the Chinese International School Alumni teams and the Hong Kong Sports Institute staff team to strengthen the players' performance and team spirit. The AMFC has grown to a size with over 80 registered players and one of the most notable achievements of the team is winning the 2<sup>nd</sup> runner up at the Hong Kong Medical Association Football Day 2025.



AM F.C. at the Hong Kong Medical Association Football Day 2025  
「醫專足聯」參與香港醫學會2025足球日

The Academy has been soliciting a range of corporate offers for Fellows, including festive delicacies and dining services. Fellows' immediate family members holding Supplementary Cards may also use the Lounge facilities located on the third floor of the Academy Building.

### Advocating Doctors' Well-being

The well-being of doctors is closely linked to patient treatment outcomes. The Academy developed the "Well-being Charter" in 2021, dedicated to promoting and enhancing the well-being of Academy Fellows and specialist trainees. The Academy actively organizes activities advocating for doctors' well-being, striving to comprehensively improve overall wellness.

醫專一直為院士搜羅各式企業優惠，包括節日禮品及餐飲服務等。院士的直系親屬現亦可憑附屬卡使用三樓院士軒設施。

### 提倡醫生身心健康

醫生的福祉與病人治療成果息息相關。醫專在2021年推出了《身心健康約章》，致力促進及提升院士和專科培訓學員的身心健康。醫專積極舉辦提倡醫生身心健康的活動，致力於全面提升整體福祉。

The Academy has maintained a strong commitment to advancing doctors' well-being through a variety of focused initiatives. The Task Force on Well-being recently hosted a workshop entitled "Using Laughter to Improve Well-Being," which emphasized laughter as a powerful means to boost both physical and mental health. The session featured expert insights and interactive experience led by Dr. Carrie Horwitch, a dedicated advocate from the United States known for advocating the healing power of laughter to enhance physical and mental health. Additionally, the Academy has continued to offer the 'Mindfulness Induction Group' programme, marking its sixth mental health training led by Dr. Ling Chiu, a certified instructor of the Mindfulness-Based Stress Reduction (MBSR) programme. To further support wellness, the Academy revamped the well-being webpage (well-being.hkam.org.hk) to enhance usability and broaden its informational scope by incorporating new sections on Disability and Special Education Needs (SEN), as well as Social and Wellness Activities. Improvements were also made to the mobile version, alongside a refreshed visual identity for the 'ASAP approach'—Awareness, Self-care, Ask for Help, and Promotion of Well-being—through updated colour schemes and imagery.

醫專一向致力透過多項多元活動推動醫生的身心健康。身心健康專責小組舉辦了「以笑聲提倡身心健康」工作坊，強調笑聲作為促進身體與心理健康的有效方式。講座特別邀請了美國知名倡導笑聲療法促進身心健康的專家Dr. Carrie Horwitch分享寶貴意見及帶領現場互動環節。此外，醫專繼續舉辦由正念減壓療法課程認證導師趙玲醫生主持的「靜觀體驗小組」精神健康課程，並順利開展第六期培訓。醫專亦優化了身心健康網頁(well-being.hkam.org.hk)，提升使用體驗並擴充資訊內容，新增了殘疾及特殊教育需要(SEN)以及社交和健康活動等專欄。同時，手機版網頁也進行了優化。網頁採用全新色調與圖片設計，重新塑造了「ASAP」模式，即認知、關注、自助、求助及推廣身心健康的視覺形象。



Using Laughter to Improve Well-Being Workshop  
「以笑聲提倡身心健康」工作坊



The sixth mental health training 'Mindfulness Induction Group' programme  
第六期「靜觀體驗小組」精神健康培訓課程



Enhancement of the Well-being Website  
優化身心健康網頁

## Events

A new multi-purpose venue, The Sage, was built and introduced in 2025, offering our Fellows a versatile space for hosting banquets, lectures, and other significant events. The venue name “The Sage” was selected through a naming competition held in late 2024, with Dr. Benjamin Fenn from the College of Surgeons of Hong Kong as the winner. It represents a meeting place of wise, experienced, and sophisticated individuals for knowledge, fun, and friendship. This newly added venue which is located inside the Academy’s library, enhances Academy’s capacity to provide exceptional experiences, fostering both professional and social engagement in an elegant and unique setting.

On 15 February, the first of the Senior Fellows Series: Sharing Session & Lunch Gathering was held in the Sage, effectively showcasing the venue’s potential for impactful gatherings.

## 活動

全新的多功能場地「匯賢廳」在2025年建立及啟用，為院士提供一個靈活多變的空間，用以舉辦宴會、講座及各類重要活動。「匯賢廳」一名由2024年底舉辦的命名比賽中選出，由香港外科醫學院的範健醫生勝出。此名稱寓意為智慧與經驗兼備人士匯聚之所，象徵知識交流、友誼建立及社交互動的理想平台。「匯賢廳」位於圖書館內，它的落成進一步提升了醫專在專業及社交活動方面的接待能力，為專業及社交互動提供卓越體驗，並在雅緻獨特的環境中促進交流與合作。


於本年2月15日，資深院士交流暨午餐聚會在匯賢廳舉行，充分展示了其舉辦不同活動的潛力。



Senior Fellows Series:  
Sharing Session & Lunch  
Gathering held at The Sage.  
資深院士交流會暨午餐聚  
會在匯賢廳舉行。

Building on vibrant event calendar from previous years, the Event Team continued to provide professional services to support events and activities in 2025, reflecting a continued. The demand for venues and number of bookings have returned to pre-pandemic levels. A great variety of events were held in the building during the past year, from examinations to workshops and private gatherings to major conferences, with attendees and speakers representing diverse regions worldwide.

延續往年多姿多彩的活動日程，活動統籌部於2025年持續提供專業支援服務，協助籌辦各類活動，展現醫專在活動策劃方面的持續承擔。場地需求及預訂數量已恢復至疫情前水平。過去一年，大樓舉辦了多項類型豐富的活動，包括考試、工作坊、私人聚會及大型會議等，吸引來自世界各地的講者及與會者，促進國際交流與專業發展。



The Combined Asia Pacific Orthopaedic Association (APOA) Hand and Upper Limb Society (HULS) 2<sup>nd</sup> Meeting and 37<sup>th</sup> Hong Kong Society for Surgery of the Hand (HKSSH) Annual Congress held at the Academy Building.  
亞太骨科協會上肢分會第二次會議暨第37屆香港手外科醫學會年會在醫專大樓舉行。

Looking ahead, two LED walls will be in used at the 1/F Run Run Shaw Hall in the fourth quarter of 2025 to deliver stunning visual effects and enhanced interactivity, creating a more spectacular stage for various events. The installation of LED walls shows the Academy's commitment to support environmental sustainability by reducing waste through the elimination of physical banners and backdrops. Additionally, to further promote environmental protection, recycle bins have been added outside event venues to reduce waste. The catering service provider has also been requested to offer sustainable food options on menus for organisers to consider for their events. The Academy will continue to uphold high standards in venue management, ensuring a comfortable environment to accommodate an increasing growing number of events.

展望未來，2幅LED顯示牆將在2025年第四季度在一樓邵逸夫堂正式投入使用，預計能透過震撼的視覺效果提升互動體驗，為各類活動打造更具吸引力的舞台。使用LED顯示牆亦體現醫專對環境可持續發展的承擔，透過取代實體橫額及背景板，有效減少廢物產生。此外，為進一步推動環境保護理念，醫專已於主要活動場地外設置回收箱，以鼓勵廢物分類及回收。餐飲服務供應商亦應邀在餐單中加入可持續食材選項，供活動主辦單位考慮選用，共同推動綠色活動文化。醫專將持續致力於維持場地的高標準，確保舒適的環境，迎接更多類型的活動。

#### Number of Activities Held at the Academy Building 在醫專大樓舉辦的活動數目

Category 類別	Number of Activities 活動數目
Examinations 考試	110
Conference, Seminar, Workshops and Meeting 學術會議、研究會、工作坊及委員會會議	703
Banquet 宴會	43
Others 其他	31
Total 總數	887

## Membership Committee

The Academy received 219 nominations for Fellowship from the Academy Colleges between July and December 2024. All nominations were vetted by the Membership Committee and recommended to the Council for approval. Those new Fellows were formally admitted at the Annual General Meeting and conferred at the Ceremony on 6 December 2024.

From January to June 2025, 141 nominations for Fellowship were vetted by the Committee and were recommended to the Council for approval. The nominations were formally endorsed at the Extraordinary General Meeting held on 19 June 2025. The Fellowships will be conferred at the Annual Fellowship Conferment Ceremony in December 2025.

## Professionalism and Ethics Committee

The Professionalism and Ethics Committee (PEC) was established in March 2019 to further promote and enhance the standard and practice of medical professionalism and ethics among Academy Fellows and specialist trainees. During this term, PEC has published a set of Best Practice Guidelines on Advance Medical Directives (AMD), as a response to the introduction of the Advance Decision on Life-Sustaining Treatment Ordinance by the Government of the Hong Kong Special Administrative Region in November 2024. To keep up with the ever-changing social development, the Task Forces under PEC also continued to organise seminars and workshops on topics associated with medical professionalism and ethics, with a focus on enhancing Fellows' understanding of medico-legal issues and equipping Fellows and other healthcare professionals with the knowledge and skills to navigate relevant issues arising from the Ordinance before it comes into effect.

## 會籍委員會

2024年7月至12月期間，委員會共接獲及審核二百一十九份由分科學院提名的院士申請，並提交予院務委員會審批。該批新的院士申請已於2024年12月6日的周年全體大會上通過。新院士在同日舉行的頒授儀式上獲頒授有關資格。

2025年1月至6月期間，委員會共審核一百四十一份院士申請，並提交予院務委員會審批。有關提名已於2025年6月19日舉行之特別會員大會上正式通過。這批院士將於2025年12月舉行的院士頒授儀式上獲頒相關資格。

## 專業及道德倫理委員會

專業及道德倫理委員會於2019年3月成立，致力推廣及提升醫專院士和專科培訓學員在醫學專業及道德倫理方面的水準和實踐。在這個任期內，因應香港特別行政區政府於2024年11月就《維持生命治療的預作決定條例》刊憲，委員會發佈了一份《預設醫療指示的良好作業指引》以供參考。為配合不斷變化的社會發展，委員會轄下的專責小組繼續舉辦與醫療專業及道德倫理主題相關的研討會和工作坊，重點加深院士們對相關醫療法律的認知，以及讓院士和其他醫療人員在《條例》正式生效前加深對相關條例的認知及其實務操作，以協助他們應對相關事件。

## Task Force on Advance Medical Directives

### Best Practice Guidelines on Advance Medical Directives

The Task Force on Advance Medical Directives (AMDs) has developed a set of 'Best Practice Guidelines Advance Medical Directives', with the aim to equip Academy Fellows and healthcare professionals with the necessary knowledge to navigate the complex process of AMDs in the legal, ethical, and practical dimensions. The set of BPG was published in April 2025.

### Seminar on Advance Medical Directives: Best Practice Guidelines on Advance Medical Directives

A half-day seminar on Advance Medical Directives organised by the Task Force on Advance Medical Directives was successfully held on 26 April 2025. It focused on discussing the 'Best Practice Guidelines on Advance Medical Directives (AMD)' before its official release. Over 130 participants from various specialties attended. Positive feedback and useful suggestions were received. Two more seminars will be organised to better equip Academy Fellows and other healthcare professionals with the knowledge and skills to navigate relevant issues arising from the Advance Decision on Life-sustaining Treatment before it comes into effect in May 2026.

## 預設醫療指示專責小組

### 預設醫療指示的良好作業指引

委員會轄下的預設醫療指示專責小組制定了一套《預設醫療指示的良好作業指引》，在法律框架、標準表格等範疇，詳細闡釋條例的應用情況和實務操作，以協助院士和其他醫療人員在法律、道德和實務層面上應對複雜的預設醫療指示流程。該指引已於2025年4月發佈。

### 預設醫療指示的良好作業指引研討會

由委員會轄下的預設醫療指示專責小組主辦的為期半天的「預設醫療指示的良好作業指引」研討會於2025年4月26日成功舉行。該研討會旨在與相關醫療界別人士就《預設醫療指示的良好作業指引》進行討論及分享。活動當天有超過130位來自不同專科的參加者出席，並收到了正面的反饋和實用的建議。專責小組計劃在2026年5月《維持生命治療的預作決定條例》正式生效前舉辦另外兩場研討會，以協助院士和其他醫療人員更深入地了解及掌握《條例》的應用，以便應付相關事情。



Over 130 participants from various specialties attended the seminar on Advance Medical Directives. Over 130 participants from various specialties attended the seminar on Advance Medical Directives. Over 130 participants from various specialties attended the seminar on Advance Medical Directives. Over 130 participants from various specialties attended the seminar on Advance Medical Directives.

### Task Force on Artificial Intelligence

#### Launch of HKAM AI Portal

Led by the Task Force on Artificial Intelligence (AI), and with support from the Education Technology and Student in Medical and Health Sciences Education (EdTech & SIMHSE) team of the Hong Kong University (HKU) LKS Faculty of Medicine (HKUMed) and the Centre for Medical Ethics and Law (CMEL) of HKU in sharing the valuable resources, the HKAM AI Portal was successfully launched in October 2024 to share resources and training materials on developments, professionalism, ethical and legal aspects of Artificial Intelligence (AI) in healthcare. This portal aims to serve as a resource platform for use by Academy Fellows and other healthcare professionals. Multi-media content such as event recordings of AI-focused seminars and webinars organised by the Academy, AI-related reading materials, conference review, teaching materials and guidelines on AI etc. are available in the Portal.

### Task Force on Genetics and Genomics

#### HKAM-HKGI Research Excellence Grants in Genomic Medicine 2024

The HKAM-HKGI Research Excellence Grants in Genomic Medicine (the Grant) is jointly introduced by the Academy and Hong Kong Genome Institute (HKGI). It aims to encourage and support initiatives of research in the field of genetic and genomic medicine conducted by the Academy's young Fellows and higher specialist trainees. Further to the successful launch of the first round of the Grant in 2023, the second round of the Grant was opened in July 2024. Five applications were received by the deadline. After due assessment, three young Fellows were awarded the Grant. Details are as follows:

### 人工智能專責小組

#### 醫專人工智能平台

在香港大學李嘉誠醫學院教育科技團隊及香港大學醫學倫理與法律研究中心的支持下，委員會轄下的人工智能專責小組於2024年10月推出「醫專人工智能平台」，旨在分享人工智能在醫學領域的發展以及與醫學專業、道德倫理及法律相關的資源和培訓。作為專為人工智能而設的平台，院士們及其他醫療人員可以從此獲取多項有關的多媒體資源，包括醫專舉辦與人工智能相關研討會的錄影、人工智能相關文獻、研討會回顧、以及人工智能教材及指引等。

### 遺傳學及基因組學專責小組

#### 香港醫學專科學院－香港基因組中心 基因組醫學卓越研究獎2024

由醫專與香港基因組中心共同設立的香港醫學專科學院－香港基因組中心基因組醫學卓越研究獎旨在鼓勵和支持年青院士和高級專科培訓學員開展基因組醫學相關研究。首輪研究獎已於2023年頒發予三名得獎者。第二輪研究獎於2024年7月開放申請，截止日期前共收到五份申請。經評審後，三名年青院士獲得獎項。詳情如下：

Awardee (Specialty) 得獎者 (分科)	Project Title 項目標題
Prof. Chan Yu Hin (Paediatrics) 陳宇軒教授 (兒科)	Unraveling the disease pathogenesis of childhood steroid-resistant nephrotic syndrome through spatially resolved transcriptome signatures of kidney tissue
Dr. Wong Siu Him Janus (Orthopaedic Surgery) 黃兆謙醫生 (骨科)	Identification of genomic risk factors of atypical femoral fracture through whole genome sequencing and development of fracture risk assessment tool – a multicentre study
Dr. Ma Mingyao (Medicine) 馬銘遙醫生 (內科)	Personalize drug prescription in kidney transplant recipients utilizing pharmacogenetics panel – an exploratory prospective, randomized controlled clinical trial

## Task Force on Laws for Healthcare Practitioners

### Seminar on Medical Consent: Practical Implications for Hong Kong

Organised by Centre for Medical Ethics and Law, the University of Hong Kong and co-organised by the Academy, the hybrid seminar 'Medical Consent: Practical Implications for Hong Kong' was successfully held on 9 April 2025. This seminar explored the legal issues arising from consent to medical treatment, including important decisions from across common law and legislative interventions such as the Advance Decision on Life-Sustaining Treatment Ordinance, and examined the practical application and implications of these developments for medical practice in Hong Kong.

### Webinar on Clinical Negligence Update – An Update in UK Case Law and Expert Evidence

Jointly organised by the Task Force on Laws for Healthcare Practitioners and the Academy's Jockey Club Institute for Medical Education and Development, a webinar on Clinical Negligence Update – An Update in UK Case Law and Expert Evidence was successfully held on 29 May 2025. This webinar provided an update on UK case law and expert evidence in clinical negligence cases, and highlighted recent changes and challenges in handling medico-legal issues. Over 290 participants joined the webinar. Positive feedback and useful suggestions were received.

### Second Edition of Best Practice Guidelines for Expert Witnesses

The Task Force on Laws for Healthcare Practitioners published a set of 'Best Practice Guidelines for Expert Witnesses' in October 2023, with the aim to assist and prepare medical doctors and dentists who are partaking, or are considering to partake, in the role of an expert witness by setting out the relevant standards and regulations and offering practical advice. To maintain continuous improvement and reflect the latest developments in the field, necessary updates have been made to the Guidelines, and the Second Edition has been published in August 2025.

## 醫療人員相關法律專責小組

### 醫療同意原則：香港實況研討會

香港大學醫學倫理與法律研究中心及香港醫學專科學院於2025年4月9日聯合舉辦線上及線下研討會，討論醫療同意原則在香港的實際應用及影響。該研討會探討了就醫療程序徵求同意所衍生的法律問題，包括其對普通法及《維持生命治療的預作決定條例》等立法律程序內的重要決定的影響，並檢視了這些醫療發展於香港執業環境下的實際應用和意義。

### 線上研討會－從英國判例法的最新發展及專家證據看醫療疏忽

醫療人員相關法律專責小組及賽馬會醫學教育發展中心於2025年5月29日聯合舉辦醫療疏忽線上研討會，從英國判例法的角度出發，探討法例的最新發展以及相關醫療疏忽案件中的專家證據。該研討會亦重點討論了近年在處理醫療法律問題上面對的變化和挑戰。當天共有超過290位參加者參與線上研討會，並收到了正面的反饋和實用的建議。

### 專家證人的良好作業指引第二版

委員會轄下的醫療人員相關法律專責小組於2023年10月發布了一套《專家證人的良好作業指引》，旨在透過制定相關標準和規定並提供實用建議，以協助正在擔任專家證人或考慮擔任專家證人的醫生和牙醫為相關工作做好準備。為持續改進並反映有關領域的最新發展，專責小組修訂《指引》後於2025年8月發布第二版以供參考。

### Workshop on Expert Witness Report Writing

The first workshop on Expert Witness Report Writing organised by the Task Force on Laws for Healthcare Practitioners was successfully held on 9 March 2024. By popular demand, the second workshop was organised on 23 August 2025, with over 30 participants attended. The workshop aimed to provide the participants with the opportunity to apply the knowledge gained in the 'HKAM Online Training Course for Expert Witnesses' to hone their report writing skills. Ten experienced medico-legal lawyers and medical expert witnesses were invited to act as coaches to share their insights and experience. Participants were actively engaged and returned positive feedback.

### 專家證人報告撰寫工作坊

由醫療人員相關法律專責小組主辦的首個撰寫專家證人報告工作坊於2024年3月9日成功舉行。因應院士們對此類型工作坊的需求，第二個工作坊於2025年8月23日舉行，共有超過30名參加者出席。該工作坊旨在為參加者提供實踐機會以運用在「香港醫學專科學院之專家證人線上培訓課程」中獲得的知識以磨練他們撰寫報告的技巧。十位經驗豐富的醫療法律律師和醫學界專家證人受邀出席作為教練並分享他們的真知灼見和經驗。參加者積極參與並給予正面的反饋。



The Convenor of the Task Force, coaches and participants at the workshop  
專責小組召集人、工作坊導師和參加者

## Task Force on Sports and Exercise Medicine

In response to the growing demand for the advancement of sports medicine, the Task Force on Sports and Exercise Medicine (SEM) was established in 2024. Its mandate was to drive the development of SEM and to design a comprehensive framework for related training programmes from a multidisciplinary perspective. It had also engaged relevant stakeholders such as the Hong Kong Sports Institute and offers professional opinions and suggestions for advocacy of the importance of SEM. Following the Government's 2024 Policy Address, which emphasized the importance of sports medicine development, the Academy formalized its collaboration with the Hong Kong Sports Institute through a Memorandum of Understanding to strengthen the partnership and enhance joint initiatives. Furthermore, a major milestone was the successful Sports and Exercise Medicine Summit held on 15 December 2024, featuring distinguished speakers and guests who engaged in vibrant discussions and idea exchanges. Work continues in 2025 with ongoing discussions on formulating Sports and Exercise Medicine training courses for healthcare professionals.

## Task Force on Organ Donation

To advance the promotion and awareness of organ donation, the Task Force on Organ Donation was established with its inaugural meeting held on 12 May 2025. In addition to representatives from various Colleges, the Task Force included members from the Hong Kong Society of Transplantation and experts in related fields. The Task Force had reviewed global and local trends with statistics in organ donation, and discussed on potential initiatives and work plans. To move these efforts forward, several subgroups were created to develop frameworks for incorporating organ donation into specialist training curricula; devise promotional strategies aimed at the public through social media campaigns, community events, and school-based education; and prepare a position statement on education and training in organ donation at a later stage. The Academy is committed to furthering education and advocacy on this vital societal issue, with the goal of enhancing the knowledge and skills of Academy Fellows and specialist trainees regarding organ donation, and raising awareness among healthcare professionals and the general public.

## 運動及體育醫學專責小組

為應對運動醫學發展日益增長的需求，醫專的運動及體育醫學專責小組於2024年成立，旨在推動運動及體育醫學的發展，並從跨學科的角度設計相關培訓課程的全面框架。專責小組亦聯繫香港體育學院等相關持份者參與，提供專業意見及建議，以倡導運動及體育醫學的重要性。隨著政府在2024年施政報告中強調發展運動醫學的重要性，醫專與香港體育學院簽署合作備忘錄，雙方合作正式建立，藉此加強夥伴關係並推動聯合項目。此外，醫專於2024年12月15日成功舉辦了運動及體育醫學論壇，標誌着一個重要里程碑，多位傑出講者及嘉賓獲邀參與，展開熱烈討論與交流。專責小組2025年的工作仍持續進行，目前正就為醫療專業人員制定運動及體育醫學培訓課程展開深入討論。

## 器官捐贈專責小組

為推進器官捐贈的宣傳及意識，器官捐贈專責小組已成立，並於2025年5月12日舉行首次會議。除了來自各學院的代表外，小組成員還包括香港移植學會的成員及相關領域的專家。專責小組已審視全球及本地器官捐贈的趨勢與統計數據，並就潛在的倡議和工作計劃進行了討論。為推動相關工作，小組成立了多個分組，設立框架以將器官捐贈納入專科培訓課程；通過社交媒體活動、社區活動和校本教育，制定面向公眾的宣傳策略；以及在後期階段準備有關器官捐贈教育與培訓的立場聲明。醫專致力於促進這項重要社會議題的教育與倡導工作，目標是提升醫專院士及專科培訓學員在器官捐贈方面的知識與技能，並提高醫療人員及公眾的意識。

## Young Fellows Chapter

The Academy established the Young Fellows Chapter (YFC) in 2017, comprising representatives from 15 Academy Colleges who have been conferred Academy Fellowship within the past 10 years. The aim of YFC is to nurture future healthcare leaders by engaging young Fellows in various activities and affairs of the Academy, enabling them to better understand the Academy's objectives and work. The 8<sup>th</sup> term of the Young Fellows Chapter commenced on 1 July 2024.

Members of the YFC have consistently supported the work of the Academy Council and actively participated in discussions across various committees on professional training and educational matters. They are also dedicated to coordinating activities that foster connections among Academy Fellows from different specialties, thereby building relationships and strengthening bonds. The new Governing Council of YFC is devoted to assisting the Academy in promoting medical professionalism.

There were several initiatives and activities organized by the YFC during the year.

1. An immersive workshop was held in November 2024, designed to foster connections among Fellows across Colleges through interactive milk tea and egg tart making. The event also aimed to promote work-life balance in the medical profession. The workshop was successfully completed with enthusiastic participation and received positive feedback.

## 年青院士分會

醫專於2017年成立年青院士分會，分會成員包括來自十五間分科學院的代表，他們均在過去十年內獲頒授學院院士資格。年青院士分會旨在鼓勵年青院士參與醫專活動和事務以了解醫專的宗旨及工作，從而培育出未來醫學領袖。第八屆年青院士分會於2024年7月1日履新。

年青院士分會成員熱衷參與醫專各委員會的事務，就專業培訓及學術事宜進行討論和交流。分會成員亦積極參與籌備多項聯誼活動，藉以加強醫專院士們的聯繫，提高凝聚力。新一屆年青院士分會致力協助醫專提升醫療人員專業水平。

報告年內，年青院士分會舉辦了多項新項目和活動。

1. 年青院士分會於2024年11月舉辦互動式工作坊，旨在透過製作奶茶和蛋撻體驗將各學院的年青院士聯繫起來，同時推廣醫學專業的工作與生活平衡。工作坊在熱烈的參與和正面的回饋中圓滿結束。



An interactive milk tea and egg tart making workshop was arranged by YFC  
年青院士分會舉辦製作奶茶和蛋撻體驗互動式工作坊

2. In December 2024, YFC co-organised the 'Sports and Exercise Medicine Summit' in collaboration with the Jockey Club Institute for Medical Education and Development (JCIMED). The summit convened over 90 healthcare professionals and sports and exercise medicine experts to highlight the importance of promoting healthy lifestyles. It also reinforced the collaboration with the Hong Kong Sports Institute (HKSI), following the signing of a Memorandum of Understanding (MOU) between the Academy and the HKSI to advance the development of sports and exercise medicine.
2. 於2024年12月，年青院士分會與賽馬會醫學教育發展中心(JCIMED)聯合舉辦主題為「運動及體育醫學」的論壇。是次論壇吸引了超過90名醫生及運動醫學專家參加，強調推廣全民健康生活方式的重要性。此外，醫專與香港體育學院(HKSI)亦簽署合作備忘錄，攜手發展運動及體育醫學。
3. Another joint symposium was co-organised by the YFC and the JCIMED in June 2025, titled 'Medial-Legal Symposium on Social Media and Medical Promotion'. Aimed to educating medical practitioners and dentists about the legal and ethical challenges associated with medical advertising and social media use, the symposium was successfully completed and received positive feedback.
3. 年青院士分會於2025年6月與賽馬會醫學教育發展中心(JCIMED)聯合舉辦另一個研討會，主題為「社交媒體與醫療推廣－醫學法律研討會」。是次研討會旨在教育醫療從業員及牙醫有關醫療廣告及社交媒體應用的法律與倫理挑戰，活動順利完成並獲與會者正面評價。



Joint symposium 'Medial-Legal Symposium on Social Media and Medical Promotion' was co-organised by the YFC and the JCIMED  
 年青院士分會與賽馬會醫學教育發展中心合辦「社交媒體與醫療推廣－醫學法律研討會」

4. The 'Hong Kong-Shenzhen-Shanghai Young Specialists' Study and Exchange Summit', jointly organised by the Academy, Shanghai Municipal Health Commission, Shenzhen Municipal Health Commission, Shanghai Medical Doctor Association, Shenzhen Medical Doctor Association and the SZ-HK Medical Specialist Training Centre, was successfully held in Shanghai in March 2025. This exchange provided an excellent opportunity to strengthen collaboration, emphasising the vital role of young physicians in shaping a sustainable and globally-connected healthcare future.

4. 與醫專、上海市衛生健康委員會、深圳市衛生健康委員會、上海市醫師協會、深圳市醫師協會和深港醫學專科培訓中心聯合舉辦的「港深滬年青專科醫生學習交流峰會」於2025年3月在上海成功舉行。這次交流機會加強了雙方的合作，突顯了年青醫生在塑造一個可持續發展、與全球聯繫的醫療未來中所扮演的角色。



'Hong Kong-Shenzhen-Shanghai Young Specialists' Study and Exchange Summit' held in March 2025  
「港深滬年青專科醫生學習交流峰會」盛況

5. YFC members served as Masters of Ceremonies in various important Academy events, including the Medical Education Conference and the HKAM Council Dinner with Distinguished Young Fellows, both held in September 2024.

5. 年青院士分會成員曾擔任多個醫專重要活動的司儀，如2024年9月舉辦的醫學教育會議及醫專院務委員會與傑出年青院士晚宴。



YFC members served as Masters of Ceremonies in various important Academy events  
年青院士分會成員擔任多個醫專重要活動的司儀

6. YFC has established and managed Instagram and Facebook accounts to keep Fellows informed about the upcoming activities and to foster connections, even in the absence of physical meet-up, thereby strengthening the community.

6. 年青院士分會還設立及管理Instagram及Facebook專頁，為院士提供最新的活動資訊及在實體活動以外聯繫院士，共同建構更強大的院士網絡。

## Election

Pursuant to the Hong Kong Academy of Medicine Ordinance, an election has been conducted for five Council members. The election notice and nomination form were sent to all Fellows on 20 June 2025. Five nominations were received by the deadline of 22 August 2025 and checked to be in order. The particulars of the nominated Fellows are as follows:

## 選舉

醫專根據《香港醫學專科學院條例》指引，五名選任委員須由選舉產生。醫專於2025年6月20日向所有院士發出選舉通知書及提名表格，提名期至2025年8月22日結束。秘書處共收到五份有效提名表格，獲提名院士的資料如下：

Nominees 獲提名院士	Colleges to which the nominee belongs 所屬分科學院
Dr. Benny Chun-pong Cheng 鄭振邦醫生	Anaesthesiologists 麻醉科
Dr. Christina Man-tung Cheung 張敏彤醫生	Physicians 內科
Prof. Simon Hung-san Lam 林鴻生教授	Paediatricians 兒科
Dr. Sut-yee Tse 謝雪兒醫生	Family Medicine 家庭醫學
Dr. Emily Fung-yee Yeung 楊鳳儀醫生	Ophthalmologists 眼科

Dr. Wing-cheong Leung  
Honorary Secretary

梁永昌醫生  
名譽秘書



The Academy's Divisions /  
Initiatives  
醫專支部／項目

# The Academy's Divisions / Initiatives

## 醫專支部／項目



香港醫學專科學院出版社  
HONG KONG ACADEMY OF MEDICINE PRESS

### Hong Kong Academy of Medicine Press

The Hong Kong Academy of Medicine Press (Academy Press) was established in October 2002. As an integral part of the Academy, Academy Press publishes medical journals, newsletters, monographs, and congress packages for various Colleges and societies.

#### Publications

The Academy Press currently publishes 6 periodical journals, including the flagship publication, the Hong Kong Medical Journal (HKMJ); the Asian Journal of Gerontology & Geriatrics; the East Asian Archives of Psychiatry; the Hong Kong Journal of Gynaecology, Obstetrics and Midwifery; the Hong Kong Journal of Ophthalmology; and the Hong Kong Journal of Radiology; as well as 2 newsletters: Academy Focus and Eye Opener.

### Hong Kong Medical Journal (HKMJ)

It has been another productive and rewarding year for the Hong Kong Medical Journal (HKMJ), with the key highlights summarised below.

#### Circulation

As of 31 August 2025, around 1,100 Fellows receive the print copies of HKMJ. Together with about 540 members of the Hong Kong Medical Association and other individuals who subscribe to the printed edition, the total circulation is around 1,700.

#### Online Access

All Fellows are enrolled in the e-Alert service (unless they have opted out) and receive an email with the table of contents when each new issue is available online. In the past reporting year, the HKMJ website received an average of 22,000 visitors each month.

### 香港醫學專科學院出版社

香港醫學專科學院出版社(醫專出版社)於2002年10月成立。作為醫專的一部分，醫專出版社為轄下分科學院及其他醫學組織出版醫學期刊、會員通訊、專題著作及會議刊物等。

#### 出版刊物

醫專出版社目前出版六本醫學期刊，包括旗艦刊物《香港醫學雜誌》(雜誌)、《亞洲老年學及醫學雜誌》、《東亞精神科學誌》、《香港婦產助產科雜誌》、《香港眼科學刊》及《香港放射科醫學雜誌》；此外，亦出版兩本會員通訊：Academy Focus和《眼界》。

### 《香港醫學雜誌》

對《香港醫學雜誌》而言，本年度是繁忙而豐盛的一年，其重點發展概述如下。

#### 印刷數量

截至2025年8月31日，約有一千一百名院士訂閱雜誌的印刷版。連同約五百四十名香港醫學會會員及個人訂戶訂閱印刷版，《香港醫學雜誌》每期印刷數量約為一千七百本。

#### 在線閱覽

院士可透過電子提示服務，定時經電子郵箱收取新一期《香港醫學雜誌》目錄(取消接收通知的院士除外)。報告年內，《香港醫學雜誌》網站的每月平均訪客人數約為二萬二千名。

## Editorial Board

As of August 2025, the HKMJ Editorial Board comprises 7 Senior Editors and 48 Editors and Advisors. Each Senior Editor is responsible for coordinating one of the various sections of the Journal. The Editors nominate reviewers and make recommendations regarding submitted papers. The Advisors lend their professional expertise to provide statistical or methodological guidance for submitted papers or support other aspects of journal management. Under the leadership of the Editor-in-Chief, the Editorial Board establishes and defines the Journal's policies; makes editorial decisions; and formulates clear guidelines for authors, reviewers, and the editorial office to ensure smooth journal operations. The Editorial Board members are committed to enhancing the quality and relevance of the Journal by expediting articles on current hot topics and applying rigorous methodological review of submitted articles.

## Impact Factor

The Hong Kong Academy of Medicine Press is delighted that the 2024 Journal Impact Factor of the HKMJ is 2.6 (Clarivate, 2025), maintaining its position in Quartile 1 in the "Medicine, General and Internal" category of the Journal Citation Reports. Appreciation goes to all Editorial Board members, authors, and reviewers for their continued dedication and support.

## Prize for Best Original Paper Award (BOPA)

The award, presented by the Editorial Board of the Hong Kong Medical Journal, encourages high-quality original writing by doctors. The winners of the 2024 Prize for Best Original Paper Award were: Dr. Pauline Ng and her team's research 'Ten-year territory-wide trends in the utilisation and clinical outcomes of extracorporeal membrane oxygenation in Hong Kong'; Dr. Swan Lau and her team's research 'Prediction of hospital mortality among critically ill patients in a single centre in Asia: comparison of artificial neural networks and logistic regression-based model'; and Dr. Brian Sung and his team's research 'Changes in cardiovascular disease risk predicted by the Framingham risk model in the Hong Kong population between 2003-2005 and 2014-2015: data from Population Health Surveys'.

## 編輯委員會

目前，編輯委員會（編委會）包括七位高級編輯和四十八位編輯及顧問。高級編輯各自統籌不同類型的醫學論文工作，編輯則負責提名同行評審人並對已提交的論文作出建議，而顧問主要就論文的統計學或研究方法，以及管理期刊等事宜提供專業意見。在總編輯領導下，編委會為雜誌制定政策，決定送審或退稿，以及為作者、同行評審人和編輯部人員制定清晰明確的指引，確保雜誌順利運作。編委會致力提高雜誌的質量和相關性，包括加快處理當前熱門話題的文章和嚴謹審查已提交文章的研究方法。

## 學術影響力

2025年科睿唯安期刊引證報告顯示，2024年《香港醫學雜誌》的影響指數為2.6，在Medicine, General and Internal領域中繼續維持在Q1區。謹此感謝編委會、作者和同行評審人的積極參與和支持。

## 《最佳原創論文獎》

《香港醫學雜誌》編輯委員會設立最佳原創論文獎，旨在鼓勵醫生撰寫高質素的原創文章。2024年得獎者包括吳楊珮寧醫生及其團隊，研究題目為「香港體外膜氧合使用和臨床結果的十年趨勢」、劉詩韻醫生及其團隊，研究題目為「亞洲單一中心重症患者住院死亡率預測：人工神經網絡與邏輯迴歸模型的比較」，以及宋昱謙醫生及其團隊，研究題目為「弗雷明翰風險模型評估的2003至2005年及2014至2015年間香港人口心血管疾病風險變化：人口健康調查數據」。

## Prize for Best Original Research by Young Fellows (BORYF)

The Prize for Best Original Research by Young Fellows was successfully launched in 2019, with an aim to recognise excellence in outstanding research conducted and led by young Fellows. The submissions were assessed by an Evaluation Panel, and the highest-rated abstracts were selected as finalists. Esteemed invited Final Judges assessed the full papers of the five finalists and chose the three final winners. The winners of the 2024 Prize for Best Original Research by Young Fellows were: Dr. Jeremy Teoh (from The College of Surgeons of Hong Kong) who won the gold medal for his team's research 'Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial'; Prof. Jason Cheung (from The Hong Kong College of Orthopaedic Surgeons) who won the silver medal for his team's study 'Impaired glycine neurotransmission causes adolescent idiopathic scoliosis'; and Dr. Louis Lau (from Hong Kong College of Physicians) who won the bronze medal for his team's research 'Effect of real-time computer-aided polyp detection system (ENDO-AID) on adenoma detection in endoscopists-in-training: a randomized trial'.

## 《最佳年青院士原創研究獎》

《最佳年青院士原創研究獎》設立於2019年，旨在表揚年青院士的卓越學術研究成就。初審小組選出評分最高的五篇文章摘要，繼而由總評審團評審文章全文並選出三名得獎者。2024年得獎者包括（金獎）香港外科醫學院張源津醫生及其團隊，研究題目為Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial、（銀獎）香港骨科醫學院鍾培言醫生及其團隊，研究題目為Impaired glycine neurotransmission causes adolescent idiopathic scoliosis，以及（銅獎）香港內科醫學院柳浩城醫生及其團隊，研究題目為Effect of real-time computer-aided polyp detection system (ENDO-AID) on adenoma detection in endoscopists-in-training: a randomized trial。

## Enhancing Professional Research Skills: Training Workshop for Medical Practitioners in Hong Kong

Medical research knowledge and skills are essential for the professional advancement of medical practitioners and dentists. Although undergraduate and postgraduate training comprehensively covers the required knowledge and skills for clinical consultation, the Academy takes a leading role in enhancing research capacity and organizing training workshops. Funded by the Professional Services Advancement Support Scheme (PASS) of the Government of the Hong Kong Special Administrative Region, four identical workshops titled “Enhancing Professional Research Skills: Training Workshops for Medical Practitioners in Hong Kong” were conducted via Zoom in 2021-2022, and were well received by doctors from different specialties. In response to doctors’ demand for research training and with funding support from PASS, the Academy organized the research workshop in physical format in Q2 2025. The workshop, titled “Enhancing Professional Research Skills: Training Workshops for Medical Practitioners in Hong Kong”, comprised four modules: Introduction to research; Performance of research in clinical practice; Conducting Research Studies and Generating Evidence; and Dissemination of research findings. This four-module workshop aims to provide medical and dental specialists with more in-depth knowledge and skills required for medical research. A total of 27 doctors and dentists attended and benefited from this workshop, the majority of whom were from the public sector. We are very grateful to all the speakers and attendees for their support and positive feedback.

## 提升醫學專業研究技能培訓工作坊

醫學研究知識和技能對醫生和牙醫的專業發展至關重要。醫專明白本科及研究生的培訓已全面涵蓋臨床諮詢所需的知識和技能，故在提升醫生和牙醫研究能力的範疇中擔任主導角色，積極籌組培訓工作坊。在「專業服務協進支援計劃」的資助下，醫專於2021年9月至2022年6月期間以「提升醫學專業研究技能培訓」為題，以網上形式共舉辦四場工作坊，並廣受參加者讚譽。為回應醫生和牙醫對研究培訓的需求，醫專在支援計劃的資助下於2025第二季以實體形式舉辦此工作坊。是次工作坊一共涵蓋四個單元，主題包括研究導論、研究於臨床實踐中的功能、開展研究和產出證據，以及研究結果的發布。工作坊共有二十七名醫生和牙醫出席，大部分來自公立醫院及醫療機構。我們非常感謝所有講者及參與者對工作坊的支持和積極回應。



## Jockey Club Institute for Medical Education and Development (Formerly known as Hong Kong Jockey Club Innovative Learning Centre for Medicine)

Hong Kong Jockey Club Innovative Learning Centre for Medicine (HKJC ILCM) was inaugurated in December 2013 to promote innovative learning and research among healthcare professionals for safe and quality patient care. In November 2024, HKJC ILCM was formally upgraded and transformed into Jockey Club Institute for Medical Education and Development (JCIMED). This transformation aims to enhance medical education and specialist training standards in Hong Kong, focusing on capacity building and quality improvement in medical education.

Between September 2024 and August 2025, JCIMED organized and hosted various training programmes and activities, either independently or in collaboration with partners like Hospital Authority, Academy Colleges, and local universities. Participants in these programmes included Academy Fellows, specialist trainees, nurses, medical students, allied healthcare and paramedical professionals.

### Inauguration Ceremony of the Establishment for Jockey Club Institute for Medical Education and Development

With the generous support from the Hong Kong Jockey Club Charities Trust, Academy established the Jockey Club Institute for Medical Education and Development (JCIMED). The inauguration ceremony was held on 27 November 2024. The ceremony was graced by distinguished guests, including Ms. Imelda Chan, Head of Charities (Positive Ageing & Elderly Care, and Healthy Community) of The Hong Kong Jockey Club, Immediate Past President of the Academy, Prof. Gilberto Leung, President of the Academy, Prof. Philip Li, Vice-President (Education and Examinations) of the Academy, and Dr. Benny Cheng, Honorary Director of JCIMED.

## 賽馬會醫學教育發展中心 (前稱香港賽馬會創新醫學模擬培訓中心)

香港賽馬會創新醫學模擬培訓中心 (模擬培訓中心) 於2013年12月成立，旨在促進醫療專業人員的創新學習和研究，以實現安全和優質的患者護理。2024年11月，模擬培訓中心正式升格並轉型為賽馬會醫學教育發展中心 (教育發展中心)，這一轉變旨在提升香港醫學教育和專科培訓的標準，著重於醫學教育的能力建設和質量提升。

在2024年9月至2025年8月期間，教育發展中心籌組及主辦，或與多個合作夥伴舉辦了各種培訓課程及活動。合作夥伴包括醫院管理局，醫專分科學院及本地大學。課程的主要對象為醫專院士、專科培訓學員、護士、醫科學生、其他專職醫療人員和輔助醫療人員。

### 賽馬會醫學教育發展中心成立典禮

在香港賽馬會慈善信託基金的慷慨支持下，醫專成立了賽馬會醫學教育發展中心 (教育發展中心)。中心成立典禮於2024年11月27日舉行。香港賽馬會慈善事務部主管 (豐盛耆年及長者服務、健康社區) 陳載英女士、香港醫學專科學院上屆主席梁嘉傑教授、香港醫學專科學院主席李錦滔教授，以及教育發展中心榮譽總監鄭振邦醫生等嘉賓出席了成立典禮。

JCIMED is dedicated to innovation in medical education, integrating extended reality, artificial intelligence, and other advanced technologies into teaching. It develops comprehensive curricula, including competency-based medical education, faculty training, and modern CME / CPD methods. Additionally, it strengthens research and development in medical education, promotes innovation in teaching methods, and implements a robust quality assurance system to maintain high standards of medical education. JCIMED is equipped with upgraded facilities and equipment, including state-of-the-art simulation technology and extended reality equipment. With its broad mission, enhanced technological capabilities, and comprehensive approach, JCIMED is elevating the level of postgraduate medical education.

教育發展中心致力於醫學教育的創新，將擴展實境、人工智能和其他先進技術融入教學。中心開發全面課程，包括能力為本醫學教育、師資培訓和現代延續醫學教育／持續專業發展方法。此外，中心加強醫學教育的研究與開發，促進教學方法創新，並實施健全的質量保證系統，維持高標準的醫學教育。中心配備升級的設施及設備，包括最先進的模擬技術和擴展實境設備。憑藉其廣泛的使命、強化的技術能力及全面的方法，教育發展中心正在提升大學本科以上程度的醫學教育水平。



Distinguished guests attended the inauguration ceremony of the establishment for JCIMED.


一眾嘉賓出席慶祝賽馬會醫學教育發展中心成立典禮。

### Learning Online Educator Course

Amid the continuing demand for online learning driven by the COVID-19 pandemic, the Learning Online (LOL) Educator Course remains committed to equipping educators with both theoretical knowledge and practical technical skills to deliver effective online teaching through virtual education platforms and modalities. Throughout the course, participants had the opportunity to develop a concise training module to enhance their teaching skills and apply what they have learned in a practical setting. Since its inception in 2021, a total of 8 LOL Educator Courses have been conducted, with the accumulated participants of 204 from 15 Academy Colleges.

### 學習在線教育課程

網上學習的需求在疫情後穩步增加，學習在線教育課程致力於為教育者提供理論知識與實踐技術，幫助他們善用虛擬教育平台及模式，提升在線教學效果。課程期間，參與者可設計一個簡短培訓單元，藉此鍛煉教學技巧並實踐所學。自2021年開課以來，合共舉辦了8期課程，累計有來自15醫專分科學院的204名參與者。



Trainers and participants of the Learning Online Educator Course  
學習在線教育課程導師與學員

### Air Crew Resuscitation Simulation Course

Co-organised by JCIMED and the Hong Kong College of Anaesthesiologists, the Air Crew Resuscitation Simulation Course continues to strengthen the clinical and resuscitation competencies of the Government Flying Service's aircrew through realistic simulation-based training. From 2022 to 2025, 6 courses were successfully conducted, including 2 sessions held between September 2024 and August 2025, further enhancing participants' readiness for medical emergency.

### Comprehensive Simulation Educator Course

The Comprehensive Simulation Educator Course (CSEC) is a flagship faculty development programme aimed at equipping healthcare professionals and educators with the essential skills to design, deliver, and evaluate simulation-based learning. The course provides comprehensive training in scenario development, facilitation of simulation activities, effective debriefing techniques, and learner-centred education approaches. Since its launch in 2016, the course has been developed and delivered by local faculty and has constantly received positive feedback from participants. It has also been endorsed by the Centre for Medical Simulation (CMS) in Boston since 2018, reflecting its international recognition. Between September 2024 and August 2025, 5 sessions were successfully conducted. The programme will continue to be offered regularly to support the ongoing advancement of simulation-based teaching in healthcare.

### 空勤人員模擬拯救訓練課程

教育發展中心與香港麻醉科醫學院持續合作，透過貼近實境的模擬訓練，提升政府飛行服務隊空勤人員的臨床及復甦方面的知識與能力。自2022年至2025年間，已成功合辦6次課程，其中包括在2024年9月至2025年8月期間舉行的2次課程，進一步強化參加者應對緊急醫療情況的準備。

### 綜合模擬教育導師課程

綜合模擬教育導師課程是教育發展中心的重點導師發展課程，旨在提升醫療專業人員及教育工作者在設計、推行及評估模擬教學方面的能力。課程內容涵蓋模擬情境設計、模擬活動的引導與執行、有效的復盤技巧，以及以學習者為中心的教學理念。自2016年起，課程由本地師資團隊籌劃及授課，並持續獲得學員的高度評價。自2018年起，課程獲美國波士頓的模擬醫學中心認可，彰顯其國際水平。教育發展中心於2024年9月至2025年8月期間，共成功舉辦5期課程。此課程將持續定期舉辦，以推動模擬教學在醫療教育中的發展。



JCIMED conducts the Comprehensive Simulation Educator Course.  
教育發展中心舉辦綜合模擬教育導師課程。

### Debriefing Skills for Simulation Instructors Course

The Debriefing Skills for Simulation Instructor (DSSI) Course aims to provide the essential knowledge and skills to enhance learners' competence in debriefing methods commonly used in simulation training. The participants learnt the basic concepts of experiential and learner-centred education, as well as developed skills in a structured approach to debriefing. Upon completion of the course, the learner was capable of facilitating a simulated scenario and applying adult learning theories in the teaching activity. A total of 118 participants completed 5 courses held throughout the year. Since the programme's inception in 2018, 569 participants from diverse healthcare disciplines, including those affiliated with Hospital Authority, universities in Hong Kong, private hospitals, and Academy Colleges, have completed the programme and been certified as simulation-based learning trainers.

### 模擬訓練導師復盤技巧課程

模擬訓練導師復盤技巧課程旨在為參加者提供相關的知識及技能，以提升學員在模擬訓練中常用的復盤方法。參加者從課程中學習以「體驗為主」、「學員為本」的教學基本概念，並提升結構性復盤及回饋的技巧。完成課程後，參加者具備帶領模擬訓練的能力，並在教學活動中應用成人學習理論。本年度教育發展中心共舉辦5次課程，合共118位學員完成培訓。自2018年課程推出以來，已有569位來自不同醫療專業的參加者完成課程並獲得模擬訓練導師認證，當中包括來自醫院管理局轄下不同醫護專科、本港多間大學、私立醫院和醫專分科學院的醫療人員。



Debriefing Skills for Simulation Instructors Course is one of the JCIMED's signature courses.

模擬訓練導師復盤技巧課程是教育發展中心的重點課程之一。

### Advanced Simulation Training in Mechanical Ventilation Course

JCIMED developed a one-day Advanced Simulation Training in Mechanical Ventilation Course (ASTiM), in collaboration with the Hong Kong Society of Critical Care Medicine and the Hong Kong College of Critical Care Nursing, aiming at enhancing participants' knowledge and skills in mechanical ventilation through interactive learning activities and hands-on simulation training workshops with cross-specialty experts. Participants include healthcare professionals who need to use advanced ventilators in their posts. The 8<sup>th</sup> ASTiM was conducted in January 2025, and the 9<sup>th</sup> ASTiM will be held in January 2026.

### 呼吸機模擬培訓進階課程

教育發展中心與香港危重病學會和香港危重病護理學院合作，舉辦呼吸機模擬培訓進階課程。課程為期一天，通過互動學習活動和跨專科專家教授、着重實踐操作的模擬培訓工作坊，旨在提升參加者使用呼吸機的知識和技巧。課程的對象為需要利用呼吸機照顧病人的醫療人員，第8班已於2025年1月舉行，而第9班將於2026年1月舉行。



The ASTiM course is a specialised course developed by the JCIMED. 呼吸機模擬培訓進階課程是教育發展中心編製的專項技術課程。

### Workplace-based Assessment Workshop

The Workplace-based Assessment (WBA) Workshop aims to share the principles behind performance review and workplace-based assessment, as well as the applications of different methods of feedback and debriefing. A total of 9 WBA workshops were held between September 2024 and August 2025. JCIMED would continue to run the WBA workshops with different Academy Colleges.

### 工作間進行評估工作坊

工作間進行評估工作坊旨在分享績效評估與工作間進行評估的原則，以及各種反饋和復盤方法的應用。教育發展中心於2024年9月至2025年8月期間共九次舉辦此工作坊，並將會繼續與醫專各分科學院合辦工作間進行評估工作坊。

Date (MM/YY) 日期 (月／年)	Workshop 工作坊	Co-organising Division / College 合辦支部／分科學院
09/2024	3 <sup>rd</sup> WBA Workshop (Trainer & Trainee) 第三次工作間進行評估工作坊 (導師及專科培訓員)	The Hong Kong College of Otorhinolaryngologists 香港耳鼻喉科醫學院
11/2024	7 <sup>th</sup> Intensive Care Medicine WBA Trainee Workshop 第七次危重病醫學工作間進行評估專 科培訓員工作坊	The Hong Kong College of Anaesthesiologists and Hong Kong College of Physicians 香港麻醉科醫學院及香港內科醫學院
03/2025	2 <sup>nd</sup> WBA Workshop (Trainer & Trainee) (HKJC-funded) 第二次工作間進行評估工作坊 (導師及專科培訓員) (香港賽馬會資助)	Hong Kong College of Radiologists 香港放射科醫學院
	3 <sup>rd</sup> WBA Workshop (Trainer & Trainee) (HKJC-funded) 第三次工作間進行評估工作坊 (導師及專科培訓員) (香港賽馬會資助)	Hong Kong College of Radiologists 香港放射科醫學院
05/2025	1 <sup>st</sup> WBA Trainer Workshop (HKJC-funded) 第一次工作間進行評估導師工作坊 (香港賽馬會資助)	Hong Kong College of Paediatricians 香港兒科醫學院
07/2025	3 <sup>rd</sup> WBA Trainer Workshop 第三次工作間進行評估導師工作坊	Shenzhen-Hong Kong Medical Specialist Training Centre and the Hong Kong College of Anaesthesiologists 深港醫學專科培訓中心及香港麻醉科 醫學院
	8 <sup>th</sup> WBA Trainee Workshop (HKJC-funded) 第八次工作間進行評估專科培訓員工 作坊 (香港賽馬會資助)	The Hong Kong College of Orthopaedic Surgeons 香港骨科醫學院
08/2025	2 <sup>nd</sup> WBA Trainee Workshop (HKJC-funded) 第二次工作間進行評估專科培訓員工 作坊 (香港賽馬會資助)	The Hong Kong College of Anaesthesiologists 香港麻醉科醫學院
	8 <sup>th</sup> Intensive Care Medicine WBA Workshop (Trainer and Trainee) 第八次危重病醫學工作間進行評估工 作坊 (導師及專科培訓員)	The Hong Kong College of Anaesthesiologists and Hong Kong College of Physicians 香港麻醉科醫學院及香港內科醫學院



Collaboration with different Academy Colleges on Workplace-based Assessment Workshops.  
教育發展中心與不同醫專分科學院合辦工作間進行評估工作坊。

### Basic Medical Education Course

JCIMED has developed the Basic Medical Education Course (BMEC) to support the strategy of the Academy in promoting further education of our medical Fellows. Based on discussions held at the Strategic Planning Retreat on Education and Training 2023 and the decisions of the Faculty Development Working Group, the BMEC serves as the primary course for faculty development at the Academy. BMEC is a generic clinical education course for all clinical specialties, aiming to cover the most practical topics in clinical education for postgraduate settings, and the mode of delivery can be modified according to learners' needs. The course is delivered through a combination of online and in-person sessions. 2 courses were held by JCIMED between September 2024 and August 2025 and 15 Academy Colleges and Hospital Authority were invited to nominate doctors and healthcare professionals to participate in the course.

### 基礎醫學教育課程

教育發展中心開發了基礎醫學教育課程，以支援醫專促進醫學院士繼續深造的策略。根據2023年教育與培訓策略規劃集思會的討論和導師發展工作組的決定，基礎醫學教育課程是醫專導師發展的基本課程。基礎醫學教育課程是一門針對所有臨床專業的通用臨床教育課程，旨在涵蓋大學本科以上環境中臨床教育中最實用的主題，並且授課方式可以根據學習者的需求進行修改。該課程通過在線和面對面課程相結合的方式進行。教育發展中心在2024年9月至2025年8月期間共舉辦了2次課程，15所醫專分科學院及醫院管理局獲邀提名醫生和醫療專業人員參加課程。



Fellows were nominated by different Academy Colleges to join BMEC. 不同醫專分科學院提名院士參加基礎醫學教育課程。

### Sports and Exercise Medicine Summit

The Summit successfully concluded on 15 December 2024, gathering over 90 healthcare professionals and experts to explore the latest advancements in the field. Topics included an introduction to sports and exercise medicine, management of sports injuries, evidence-based approaches to exercise prescription, and community exercise promotion. The event featured engaging panel discussions and sharing sessions with elite athletes, culminating in enthusiastic feedback from the audience.

### 運動及體育醫學論壇

論壇於2024年12月15日順利結束，聚集了90多位醫療專業人員和專家，共同探討該領域的最新進展。討論主題包括運動及體育醫學的介紹、運動損傷的管理、以證據為基礎應對運動處方以及全民運動推廣。活動中安排了精彩的專題討論和與精英運動員的分享環節，最終獲得了觀眾的熱烈回饋。



Sports and Exercise  
Medicine Summit  
運動及體育醫學論壇



### Seminar on Advance Medical Directives: Best Practice Guidelines on Advance Medical Directives

A half-day seminar on Advance Medical Directives (AMD): Best Practice Guidelines on Advance Medical Directives organized by the Task Force on AMD under the Professionalism and Ethics Committee and JCIMED was successfully held on 26 April 2025. As Hong Kong moves toward the implementation of the Advance Decision on Life-sustaining Treatment Ordinance in May 2026, this timely event brings together distinguished healthcare and legal professionals to address critical developments in medical decision making. Dr. Libby Lee, the former Under Secretary for Health and Prof. Philip Li, President of the Academy delivered the welcoming and opening remarks, and the seminar features presentations by a group of distinguished speakers. This seminar represents a significant milestone in advancing healthcare professionals' capacity to make informed, ethically sound decisions about life-sustaining treatments, ultimately enhancing patient autonomy and medical care standards. Around 120 participants attended the seminar.

### 預設醫療指示研討會：預設醫療指示的良好作業指引

由專業及道德倫理委員會轄下的預設醫療指示專責小組和教育發展中心主辦的《預設醫療指示的良好作業指引》半日研討會已於2025年4月26日圓滿舉行。隨著《維持生命治療的預作決定條例》將於2026年5月在香港正式實施，是次研討會適時匯聚多位醫療及法律界的專業人士，共同探討醫療決策方面的重要發展。時任醫務衛生局副局長李夏茵醫生及醫專主席李錦滔教授分別致歡迎及開幕辭，研討會亦邀請多位專家作專題分享。這場研討會在提升醫療專業人員於生命維持治療方面，作出知情及合乎倫理的決策能力方面具重要意義，有助促進病人自主，並推動醫療服務質素的提升。是次研討會約有120名參加者出席。



Seminar on Advance Medical Directives: Best Practice Guidelines on Advance Medical Directives  
預設醫療指示研討會：預設醫療指示的良好作業指引

### Webinar on Clinical Negligence Update – An Update in UK Case Law and Expert Evidence (29 May 2025)

This webinar was jointly organized by The Task Force on Laws for Healthcare Practitioners, under the Academy's Professionalism and Ethics Committee, and the JCIMED, with support from Kennedys. Featuring Mr. Christopher Malla from Kennedys, the webinar provided an essential update on recent developments in UK case law and the evolving role of expert evidence in clinical negligence. It also explored how these changes impact court cases and disciplinary inquiries in Hong Kong, offering valuable insights for medical professionals. Around 300 participants attended the webinar.

### 有關臨床過失的更新網上研討會－英國判例法和專家證據的最新發展／動態 (2025年5月29日)

是次網絡研討會由醫專專業及道德倫理委員會轄下的醫護人員法律專責小組，以及教育發展中心合辦，並得到肯尼狄律師行支援。網絡研討會邀請了Christopher Malla先生，提供了關於英國案例法最新發展，以及專家證據在臨床過失中不斷演變的角色。它還探討了這些變化如何影響香港的法庭案件和紀律調查，為醫療專業人員提供了寶貴的見解。是次網絡研討會約有300名參加者出席。



Webinar on Clinical Negligence Update – An Update in UK Case Law and Expert Evidence  
有關臨床過失的更新網上研討會－英國判例法和專家證據的最新發展／動態

### Medico-legal Symposium on the use of Social Media and Medical Promotion (7 June 2025)

This symposium was organized in collaboration with the JCIMED, with funding support from the Hong Kong Jockey Club Charities Trust. The symposium brought together experts and participants to examine the legal and ethical challenges associated with medical advertising and social media use. It offered valuable insights and practical guidance to support professional standards in an increasingly digital landscape. Around 100 participants from various specialties attended with positive feedback.

### 關於使用社交媒體和醫療推廣的醫療法律研討會 (2025年6月7日)

是次研討會由香港賽馬會慈善信託基金資助，與教育發展中心合辦。研討會彙集了一眾專家和參與者，探討了與醫療推廣和社交媒體使用相關的法律和道德挑戰。它提供了寶貴的真知灼見和實務指導，以支援日益數位化環境中的專業標準。大約100位來自不同專科的參加者出席當天活動，並獲得了積極的反饋。




Medico-legal Symposium on the use of Social Media and Medical Promotion  
關於使用社交媒體和醫療推廣的醫療法律研討會

## eHKAM Learning Management System (eHKAM LMS)

As of August 2025, the eHKAM Learning Management System (LMS) marks its fourth year of implementation, establishing itself as a platform for online education and CME / CPD activities across Academy Colleges and the Academy. Over the past years, there has been a steady growth in participation rates, notably with an increasing number of specialist trainees leveraging the platform for online learning.

To facilitate users in using the LMS, the Academy has provided interactive training sessions for College administrative staff and trainers, supplemented by self-paced, online resources, ensuring accessibility whenever guidance is required. The "Introduction to eHKAM LMS (for trainers)" online course has been published in October 2024. By integrating step-by-step videos, interactive questions, and course quiz, this course enables participants to master fundamental LMS skills like uploading course content and creating assessment through online quizzes. Participants who successfully complete this online course not only strengthen their capabilities but also earn CME / CPD points.



Since its launch in 2021, the eHKAM LMS Task Force has been integral in guiding the development and implementation of LMS. Following the establishment of JCIMED in November 2024, the Task Force was transformed to the eLearning and Technology Subcommittee under JCIMED to ensure ongoing guidance in e-Learning and technology-based initiatives.

## 醫專學習管理系統

截至2025年8月，醫專學習管理系統 (eHKAM LMS)已啟用四年，穩步發展成為醫專及其各分科學院推行網上教育及延續醫學教育／持續專業發展活動的重要平台。系統於過去一年的使用率持續穩步上升，尤其見於越來越多專科培訓學員積極利用該平台進行網上學習。

為協助用戶更有效地使用LMS，醫專為各分科學院的行政人員及培訓導師安排了互動式培訓環節，並提供自主學習的線上資源，確保使用者在需要時可隨時獲得支援。其中，Introduction to eHKAM LMS (for trainers)網上課程已於2024年10月正式發布。該課程結合步驟示範影片、互動式問題及課程測驗，協助參與者掌握上載課程內容、建立評核測驗等基本LMS操作技能。成功完成課程的參與者，不僅能提升網上教學能力，亦可獲得相應的延續醫學教育／持續專業發展學分。

Introduction to eHKAM LMS (for Trainers) featuring interactive elements designed to enhance learner engagement and knowledge retention.

Introduction to eHKAM LMS (for Trainers)網上課程利用互動元素提升學習成效及鞏固已獲得的知識。

學習管理系統專責小組自2021年成立以來，一直主導學習管理系統的發展與推行工作。教育發展中心於2024年11月成立後，工作小組正式轉型為醫學教育發展中心轄下的線上學習與技術小組委員會，以繼續帶領醫專在電子學習及科技應用範疇的發展。

In 2024, the eHKAM LMS Task Force conducted surveys and focus groups to collect user feedbacks and suggestions of using the LMS. The evaluation covers key areas of activity such as needs analysis to assess technological and educational needs, usability testing including pilot testing of the Learning On-Line (LOL) Educator Course, assessment of participant experience and satisfaction, evaluation of learning outcomes, and estimation of cost, reusability, and sustainability. The analysis report highlights the significant progress made in e-learning implementation at the Academy. It also suggests continuous refinement of system usability, faculty engagement strategies, and administrative processes, so as to enhance user experience and most importantly postgraduate medical education.

2024年間，學習管理系統專責小組透過問卷調查及焦點小組討論，廣泛收集用戶對學習管理系統使用的意見與建議。評估範圍涵蓋多個關鍵層面，包括需求分析（評估技術與教學需求）、可用性測試（如Learning On-Line Educator Course課程的試行測試）、參與者體驗與滿意度、學習成效評估，以及成本效益、資源重用性與可持續性等。分析報告充分肯定了醫專在推動電子學習方面所取得的顯著進展，同時建議持續優化系統的使用者介面、提升教學人員的參與度，並改善行政流程，以進一步提升整體使用體驗，並最終促進專科培訓及醫學教育的質素。



With the conclusion of the three-year funded LMS project, the Academy remains steadfast in its dedication to supporting and enhancing online learning for more efficient and effective postgraduate medical training and CME / CPD.

隨著為期三年的LMS項目圓滿結束，醫專依然堅定致力於支援並持續提升網上學習的發展及優化，以推動更高效、更優質的專科醫學培訓及延續醫學教育／持續專業發展活動，迎接未來醫療教育的需求及挑戰。



深港医学专科培训中心  
SZ-HK Medical Specialist Training Centre

## SZ-HK Medical Specialist Training Centre

The year 2025 represented a significant chapter of strategic advancement and reinforced collaboration for the SZ-HK Medical Specialist Training Centre (hereinafter referred to as “the Centre”). Operating under the esteemed guidance and unwavering support of the Hong Kong Academy of Medicine (HKAM), the Centre has not only built upon the solid foundation laid in previous years but has also accelerated its pivotal role in shaping a high-calibre, internationally-aligned specialist medical workforce for Shenzhen and the Greater Bay Area.

### Broadening the Scope of Specialist Training

Under the guidance of the Academy, the Centre has continued to be the cornerstone of specialist medical training in Shenzhen. In 2025, we successfully expanded our training programmes into additional key medical specialties, moving beyond the initial pilot disciplines. This expansion was facilitated through strengthened collaborations with the respective constituent Colleges of the Academy, ensuring that each new specialty's curriculum and assessment standards meet rigorous international benchmarks. The meticulous process of base accreditation, leveraging the expertise of both Hong Kong and Shenzhen assessors, continues to ensure that all training sites provide an environment conducive to excellence in clinical education and practice.

### Improved Training System Development

With the support of the Academy, the Centre has organized over 30 trainer courses covering teaching techniques, case-based learning, and design of examination question, enhancing the instructional capabilities of trainers at pilot bases. Regular trainees training included over 60 theoretical and clinical sessions, ensuring a training quality that meets advanced international training quality. The first cohort of specialist trainees will undergo their inaugural mid-term assessment at the end of 2025, with preparations progressing smoothly.

## 深港醫學專科培訓中心

2025年，對深港醫學專科培訓中心（以下簡稱「中心」）而言，是戰略性邁進與協作關係深化的重要一年。在香港醫學專科學院（醫專）的卓越指導和堅定支持下，中心不僅鞏固了往年打下的堅實基礎，更在為深圳及粵港澳大灣區培養高水準、與國際接軌的專科醫療人才方面，加速發揮其關鍵作用。

### 拓展專科培訓

在醫專的指導下，中心持續作為深圳市專科醫師培訓的基石。2025年，我們成功將培訓計劃擴展至更多專科，超越了最初的試點學科。透過與分科學院更深入的合作，確保每個新增專科的課程和考核標準均符合嚴格的國際標準。憑藉深港兩地專家的專業知識，我們持續進行嚴謹的試點基地評審，確保所有培訓基地均能提供有利於卓越臨床教育與實踐的環境。

### 完善培訓建設體系

在醫專的支持下，中心在本年度組織超過30場導師培訓課程，內容涵蓋教學技巧、病例教學、試題編寫等方面，提升了各個試點基地專科培訓導師的教學能力。同時，中心亦恆常性舉辦學員培訓，累計舉辦超過60場理論及臨床課程，確保培訓質量達到國際水平標準。第一屆專科培訓學員將於2025年底進行首次中期考核，各項準備工作正在有序展開。

## Fostering High-Level Regional Exchange and Collaboration

A landmark achievement of 2025 was the hosting of the “Hong Kong-Shenzhen-Shanghai Young Specialists’ Study and Exchange Summit”. Prof. Philip Li, President of the Academy, led a delegation of approximately 50 young specialists from Shenzhen and Hong Kong to Shanghai. Focused on “Young Specialist Training Systems”, the summit facilitated in-depth exchanges on training models, with visits to top institutions like Ruijin Hospital and Fudan Zhongshan Hospital to learn about precision medicine and smart ward innovations. This summit underscored the Centre’s growing influence as a regional hub for medical education. The event provided a unique platform for nearly 50 young specialists from Shenzhen and Hong Kong to engage in profound dialogues with their Shanghai counterparts, sharing best practices and innovative approaches to specialist training. This exchange significantly broadened perspectives and fostered a strong community of future medical leaders across the region.

## 促進高層次區域交流與協作

2025年的一項標誌性成就是舉辦了「港深滬年青專科醫生學習交流峰會」。香港醫學專科學院主席李錦滔教授帶領團率隊，深港約50名年青專科醫生共同前往上海參與研討會。高峰會以「年輕專科醫師培養體系」為核心，深入交流滬港深三地培訓模式，活動包括參觀上海交通大學醫學院附屬瑞金醫院、復旦大學附屬中山醫院等頂尖機構，學習精準醫療、智慧病房等先進設備。此次高峰會彰顯了中心作為醫學教育區域樞紐日益增長的影響力。活動為近50名來自深圳和香港的年青專科醫生提供了一個獨特的平台，與上海的醫生進行深入對話，分享專科培訓的最佳實踐與創新方法。這次交流深入拓展了參與者的視野，並在區域內培育了一個充滿潛力的未來醫療領袖社群。



Shanghai – Hong Kong – Shenzhen Young Specialists’ Study and Exchange Summit  
港深滬年青專科醫生學習交流峰會

## Enhancing International Alignment and Training Quality

The Centre’s commitment to international standards remained a top priority. Our collaborations with prestigious international bodies, including UK Royal Colleges, intensified. These partnerships facilitated advanced train-the-trainer programmes, curriculum development workshops, and quality assurance visits, directly enhancing the pedagogical skills of our faculty and the overall quality of the training experience. Furthermore, the Centre maintained its rigorous schedule of theoretical and clinical training for all enrolled trainees, implementing a robust monitoring system to ensure the consistent delivery of high-standard education across all affiliated training bases.

## 提升國際接軌與培訓質量

接軌國際標準的承諾仍然是中心的首要任務。我們與英國皇家醫學院等知名國際機構的合作持續深化，推動了高階導師培訓計劃、課程開發工作坊及質量督導訪問，直接提升了師資的教學能力及培訓體驗的整體質量。此外，中心為所有學員持續提供嚴謹的理論和臨床培訓，並實施完善的監管機制，確保在所有協作培訓基地均能持續提供高標準的教育。

## Future Outlook

The SZ-HK Medical Specialist Training Centre's achievements in 2025 have solidified its reputation as an indispensable engine for medical talent development. Through strategic expansion, deepened international and regional collaborations, and a steadfast focus on quality, the Centre is exceptionally well-positioned to continue its vital contribution to healthcare in Shenzhen and the Greater Bay Area, under the continued esteemed guidance of the Academy. The SZ-HK Medical Specialist Training Centre's achievements in 2025 have solidified its reputation as an indispensable engine for medical talent development. Through strategic expansion, deepened international and regional collaborations, and a steadfast focus on quality, the Centre is exceptionally well-positioned to continue its vital contribution to healthcare in Shenzhen and the Greater Bay Area, under the continued esteemed guidance of the Academy.

## 未來展望

深港醫學專科培訓中心在2025年取得的成就，鞏固了其作為醫療人才培養不可或缺的地位，深化國際與區域合作。在醫專的指導下，中心會繼續推動深圳及粵港澳大灣區的醫療衛生的發展。深港醫學專科培訓中心在2025年取得的成就，鞏固了其作為醫療人才培養不可或缺的地位，深化國際與區域合作。在醫專的指導下，中心會繼續推動深圳及粵港澳大灣區的醫療衛生的發展。



Honorary  
Treasurer's Report  
名譽司庫報告

## Honorary Treasurer's Report

### 名譽司庫報告

A deficit of around HKD \$3.1M was recorded for the year ended 31 December 2024, which included depreciation expenses of around HKD \$5.7M. If adding back the depreciation, an operating surplus of HKD \$2.6M was found in 2024. The Council and its Finance and Investment Committee would continue to review and impose appropriate measures to ensure the Academy's financial sustainability.

At the time of writing the report, the Academy and Hong Kong Academy of Medicine Foundation Fund held a total of cash or its equivalents around HKD \$130M.

On behalf of the Academy, I would like to thank members of the Finance and Investment Committee for their time and effort to help the Academy keep a healthy and sustainable position in its finance.

醫專在2024年度錄得約三百一十萬港元的赤字，當中包括約五百七十萬港元的折舊開支。若撇除折舊開支，則錄得營運盈餘約二百六十萬港元。院務委員會及財務委員會將繼續檢視及採取適當的措施，以確保醫專財政的可持續性。

撰寫報告時，醫專及香港醫學專科學院基金會所持的現金或現金等價物共值約為一億三千萬港元。

本人謹代表醫專，衷心感謝財務委員會各委員付出寶貴的時間和努力，協助處理財務及投資事項，讓醫專保持穩健而可持續的財政狀況。

Prof. Eric Wai-choi Tse  
Honorary Treasurer

謝偉財教授  
名譽司庫



Independent  
Auditor's Report and  
Financial Statements  
獨立核數師報告及  
財務報表

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**REPORTS AND CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

---

<b>CONTENTS</b>	<b>Pages</b>
INDEPENDENT AUDITOR'S REPORT .....	1 to 3
CONSOLIDATED STATEMENT OF INCOME AND EXPENDITURE .....	4
CONSOLIDATED STATEMENT OF INCOME AND EXPENDITURE AND OTHER COMPREHENSIVE INCOME .....	5
CONSOLIDATED STATEMENT OF FINANCIAL POSITION .....	6
CONSOLIDATED STATEMENT OF CHANGES IN RESERVE AND FUNDS .....	7
CONSOLIDATED STATEMENT OF CASH FLOWS .....	8
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS .....	9 to 34

**INDEPENDENT AUDITOR'S REPORT TO THE COUNCIL OF  
HONG KONG ACADEMY OF MEDICINE**

香港醫學專科學院

(Established in Hong Kong)

## Opinion

We have audited the consolidated financial statements of Hong Kong Academy of Medicine ("the Academy") and its structured entity, The Hong Kong Academy of Medicine Foundation Fund (collectively "the Group") set out on pages 4 to 34, which comprise the consolidated statement of financial position as at 31 December 2024, the consolidated statement of income and expenditure, the consolidated statement of income and expenditure and other comprehensive income, the consolidated statement of changes in reserve and funds and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2024, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with HKFRS Accounting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the Hong Kong Academy of Medicine Ordinance.

## Basis for opinion

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Other information

The council members of the Academy are responsible for the other information. The other information comprises all the information included in the annual report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**INDEPENDENT AUDITOR'S REPORT TO THE COUNCIL OF  
HONG KONG ACADEMY OF MEDICINE**

香港醫學專科學院

(Established in Hong Kong)

---

(Continued)

**Responsibilities of the council members for the consolidated financial statements**

The council members of the Academy are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and section 14 of Hong Kong Academy of Medicine Ordinance, and for such internal control as the council members determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the council members are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the council members either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the consolidated financial statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. This report is made solely to you, as a body, in accordance with section 14 of the Hong Kong Academy of Medicine Ordinance, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the council members.

**INDEPENDENT AUDITOR'S REPORT TO THE COUNCIL OF  
HONG KONG ACADEMY OF MEDICINE**

香港醫學專科學院

(Established in Hong Kong)

---

(Continued)

**Auditor's responsibilities for the audit of the consolidated financial statements (Continued)**

- Conclude on the appropriateness of the council members' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the group financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the council members regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*Crowe (HK) CPA Limited*

Crowe (HK) CPA Limited  
Certified Public Accountants  
Hong Kong, 17 July 2025

Poon Cheuk Ngai  
Practising Certificate Number P06711

HCH1010-2024

**HONG KONG ACADEMY OF MEDICINE****香港醫學專科學院****CONSOLIDATED STATEMENT OF INCOME AND EXPENDITURE  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	<u>Note</u>	<u>2024</u> HK\$	<u>2023</u> HK\$
Subscriptions and fees	4	37,002,450	33,016,100
Other revenue	5	<u>16,851,512</u>	<u>17,490,981</u>
Total revenue		53,853,962	50,507,081
Other income and other net gain	6	16,060,679	32,446,262
Depreciation	9	(5,717,884)	(5,579,105)
Staff costs	7	(30,261,054)	(27,961,192)
Other operating expenses		<u>(37,082,860)</u>	<u>(38,750,726)</u>
(Deficit)/surplus for the year	7	<u>(3,147,157)</u>	<u>10,662,320</u>

The accompanying notes form an integral part of these consolidated financial statements.

**HONG KONG ACADEMY OF MEDICINE****香港醫學專科學院****CONSOLIDATED STATEMENT OF INCOME AND EXPENDITURE AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>(Deficit)/surplus for the year</b>	(3,147,157)	10,662,320
<b>Other comprehensive (loss)/income for the year, net of nil income tax</b>		
Items that will not be reclassified subsequently to income and expenditure:		
Change in fair value of investments in equity instruments designated at fair value through other comprehensive income	<u>1,629,564</u>	<u>(221,160)</u>
<b>Total comprehensive (loss)/income for the year</b>	<u>(1,517,593)</u>	<u>10,441,160</u>

The accompanying notes form an integral part of these consolidated financial statements.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**  
**AT 31 DECEMBER 2024**

	<u>Note</u>	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>Non-current assets</b>			
Property, plant and equipment	9	12,016,205	13,612,382
Investments in equity instruments designated at fair value through other comprehensive income	11	5,891,406	4,261,842
		17,907,611	17,874,224
<b>Current assets</b>			
Inventories - general merchandise		344,344	389,367
Prepayments, deposits and other receivables	12	10,844,677	9,378,447
Time deposits with original maturity over three months	13	31,706,871	58,790,707
Cash and cash equivalents	13	78,515,323	29,034,267
		121,411,215	97,592,788
<b>Current liabilities</b>			
Deferred income	15	(28,680,031)	(3,223,902)
Accruals and other payables	14	(11,515,647)	(10,981,738)
		(40,195,678)	(14,205,640)
<b>Net current assets</b>		<u>81,215,537</u>	<u>83,387,148</u>
<b>Non-current liabilities</b>			
Deferred income	15	(1,256,001)	(1,876,632)
<b>Net assets</b>		<u>97,867,147</u>	<u>99,384,740</u>
<b>Reserve and funds</b>	16		
Fair value reserve		(816,672)	(2,446,236)
Foundation fund		37,936,231	37,936,231
General fund		60,747,588	63,894,745
		<u>97,867,147</u>	<u>99,384,740</u>

Approved and authorised for issue by the Council on 17 July 2025.

On behalf of the Council



Prof. Philip Kam-tao Li  
President



Prof. Eric Wai-choi Tse  
Honorary Treasurer

The accompanying notes form an integral part of these consolidated financial statements.

**HONG KONG ACADEMY OF MEDICINE**

香港醫學專科學院

**CONSOLIDATED STATEMENT OF CHANGES IN RESERVE AND FUNDS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Fair value reserve HK\$	Foundation fund HK\$	General fund HK\$	Total HK\$
<b>At 1 January 2023</b>	(2,225,076)	37,936,231	53,232,425	88,943,580
Surplus for the year	-	-	10,662,320	10,662,320
Other comprehensive loss				
Investments in equity instruments designated at fair value through other comprehensive income:				
Changes in fair value	(221,160)	-	-	(221,160)
Total comprehensive income/(loss) for the year	(221,160)	-	10,662,320	10,441,160
<b>At 31 December 2023 and 1 January 2024</b>	(2,446,236)	37,936,231	63,894,745	99,384,740
Deficit for the year	-	-	(3,147,157)	(3,147,157)
Other comprehensive income				
Investments in equity instruments designated at fair value through other comprehensive income:				
Changes in fair value	1,629,564	-	-	1,629,564
Total comprehensive (loss)/income for the year	1,629,564	-	(3,147,157)	(1,517,593)
<b>At 31 December 2024</b>	(816,672)	37,936,231	60,747,588	97,867,147

The accompanying notes form an integral part of these consolidated financial statements.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

	<u>Note</u>	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>Operating activities</b>			
(Deficit)/surplus for the year		(3,147,157)	10,662,320
Adjustments for:			
Depreciation		5,717,884	5,579,105
Interest income		(3,009,688)	(2,631,995)
Dividend income from other financial assets		(352,372)	(432,577)
<b>Operating cash flows before changes in working capital</b>		(791,333)	13,176,853
Decrease/(increase) in inventories		45,023	(207,957)
(Increase)/decrease in prepayments, deposits and other receivables		(1,466,230)	1,120,919
Increase/(decrease) in deferred income		24,835,498	(485,902)
Increase in accruals and other payables		533,909	3,475,313
<b>Net cash generated from operating activities</b>		<u>23,156,867</u>	<u>17,079,226</u>
<b>Investing activities</b>			
Purchase of property, plant and equipment		(4,121,707)	(914,253)
Withdrawal/(placement) of time deposits with original maturity over three months		27,083,836	(35,028,630)
Interest received		3,009,688	2,631,995
Dividend received from other financial assets		352,372	432,577
<b>Net cash generated from/(used in) investing activities</b>		<u>26,324,189</u>	<u>(32,878,311)</u>
<b>Net increase/(decrease) in cash and cash equivalents</b>		49,481,056	(15,799,085)
<b>Cash and cash equivalents at 1 January</b>		<u>29,034,267</u>	<u>44,833,352</u>
<b>Cash and cash equivalents at 31 December</b>	13	<u>78,515,323</u>	<u>29,034,267</u>

The accompanying notes form an integral part of these consolidated financial statements.

**1. STATUS OF THE ACADEMY**

The Academy was established as a body corporate under the Hong Kong Academy of Medicine Ordinance on 1 August 1992. The principal activities of the Academy are to promote and advance the science of medicine by education and exchange of information as well as to improve the standard of local health care. The Academy has its registered office and principal place of business at 99 Wong Chuk Hang Road, Aberdeen, Hong Kong.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION**

**a) Statement of compliance**

These financial statements have been prepared in accordance with all applicable HKFRS Accounting Standards ("HKFRSs"), which collective term includes all applicable Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and accounting principles generally accepted in Hong Kong. Material accounting policy information adopted by the Academy and its structured entity (together referred to as the Group) is set out below.

The HKICPA has issued certain amendments to HKFRSs which are mandatorily effective or available for early adoption for the current accounting period of the Group. Note 4 provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current accounting period reflected in these consolidated financial statements.

**b) Basis of preparation of the financial statements**

The consolidated financial statements for the year ended 31 December 2024 comprise the Academy and The Hong Kong Academy of Medicine Foundation Fund which is a structured entity of the Academy.

The measurement basis used in the preparation of the consolidated financial statements is the historical cost basis except that the following assets are stated at their fair value as explained in the accounting policies set out below:

- financial instruments classified as investments in equity instruments designated at fair value through other comprehensive income (see note 2(h));

The preparation of consolidated financial statements in conformity with HKFRSs requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**b) Basis of preparation of the financial statements (Continued)**

Judgements made by management in the application of HKFRSs that have significant effect on the consolidated financial statements and major sources of estimation uncertainty are discussed in note 20.

**c) Basis of consolidation**

The consolidated financial statements incorporate the financial statements of the Academy and the structured entity controlled by the Academy. Control is achieved when the Academy:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- has the ability to use its power to affect its returns.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

When the Group has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Group considers all relevant facts and circumstances in assessing whether or not the Group's voting rights in an investee are sufficient to give it power, including:

- the size of the Group's holding of voting rights relative to the size and dispersion of holdings of the other vote holders;
- potential voting rights held by the Group, other vote holders or other parties;
- rights arising from other contractual arrangements; and
- any additional facts and circumstances that indicate that the Group has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous members' meetings.

Consolidation of a structured entity begins when the Group obtains control over the structured entity and ceases when the Group loses control of the structured entity. Specifically, income and expenses of a structured entity acquired or disposed of during the year are included in the consolidated statement of profit or loss from the date the Group gains control until the date when the Group ceases to control the structured entity.

When necessary, adjustments are made to the consolidated financial statements of structured entity to bring its accounting policies in line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

## **2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

### **d) Property, plant and equipment**

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses (see note 2(g)).

- right-of-use assets arising from leases over freehold or leasehold properties where the Group is not the registered owner of the property interest; and
- items of plant and equipment, including right-of-use assets arising from leases of underlying plant and equipment (see note 2(e)).

Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are recognised in profit or loss during the financial period in which they are incurred.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Depreciation is calculated to write off the cost of items of property, plant and equipment using the straight line method over their estimated useful lives as follows:

Leasehold land and buildings classified as held under finance leases are depreciated over the shorter of the useful life of the buildings or the unexpired terms of the land leases using the straight line method.

Leasehold land and building	25 years
Computer equipment	5 years
Furnitures and fixtures	5 years
Training & office equipment	5 years
Leasehold improvements	5 years

Where parts of an item of property, plant and equipment have different useful lives, the cost of the item is allocated on a reasonable basis between the parts and each part is depreciated separately. Both the useful life of an asset and its residual value, if any, are reviewed annually.

Gains or losses arising from the retirement or disposal of an item of property, plant and equipment are determined as the difference between the net disposal proceeds and the carrying amount of the item and are recognised in the income and expenditure account on the date of retirement or disposal.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**d) Property, plant and equipment (Continued)**

Construction in progress include property, plant and equipment in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Cost includes professional fees and, for qualifying assets, borrowing costs capitalised in accordance with the Academy's accounting policy. Such properties, plant and equipment are classified to the appropriate categories of property, plant and equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

**e) Leases**

At inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is conveyed where the customer has both the right to direct the use of the identified asset and to obtain substantially all of the economic benefits from that use.

As a lessor

When the Group acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to the ownership of an underlying assets to the lessee. If this is not the case, the lease is classified as an operating lease. When a contract contains lease and non-lease components, the Group allocates the consideration in the contract to each component on a relative stand-alone selling price basis. The rental income from operating leases is recognised in accordance with note 2(n). When the Group is an intermediate lessor, the sub-leases are classified as a finance lease or as an operating lease with reference to the right-of-use asset arising from the head lease. If the head lease is a short-term lease to which the Group applies the exemption, then the Group classifies the sub-lease as an operating lease.

**f) Inventories**

Inventories are carried at the lower of cost and net recognised value. Cost is calculated using the weighted average method.

Net recognised value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net recognised value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**g) Credit losses and impairment of assets**

**(i) Credit losses from financial instruments**

The Group recognises a loss allowance for expected credit losses (“ECLs”) on the financial assets measured at amortised cost (including cash and cash equivalents and other receivables).

**Measurement of ECLs**

ECLs are a probability-weighted estimate of credit losses over the expected life of the financial instrument. Credit losses are measured as the present value of all expected cash shortfalls (i.e. the difference between the cash flows due to the Group in accordance with the contract and the cash flows that the Group expects to receive).

The expected cash shortfalls are discounted using the following discount rates where the effect of discounting is material:

- fixed-rate financial assets: effective interest rate determined at initial recognition or an approximation thereof;
- variable-rate financial assets: current effective interest rate;

The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

In measuring ECLs, the Group takes into account reasonable and supportable information that is available without undue cost or effort. This includes information about past events, current conditions and forecasts of future economic conditions.

ECLs are measured on either of the following bases:

- 12-month ECLs: these are losses that are expected to result from possible default events within the 12 months after the reporting date; and
- lifetime ECLs: these are losses that are expected to result from all possible default events over the expected life of a financial instrument.

The Group applies a simplified approach to measure ECL on time deposits, cash and cash equivalents, other receivables and amounts due from group entities. Under the simplified approach, the Group measures the loss based on lifetime ECL.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**g) Credit losses and impairment of assets (Continued)**

**(i) Credit losses from financial instruments (Continued)**

Significant increases in credit risk

In assessing whether the credit risk of a financial instrument has increased significantly since initial recognition, the Group compares the risk of default occurring on the financial instrument assessed at the reporting date with that assessed at the date of initial recognition. In making this reassessment, the Group considers that a default event occurs when (i) the debtor is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realising security (if any is held); or (ii) the financial asset is 90 days past due. The Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly since initial recognition:

- failure to make payments of principal or interest on their contractually due dates;
- an actual or expected significant deterioration in a financial instrument's external or internal credit rating (if available);
- an actual or expected significant deterioration in the operating results of the debtor;
- existing or forecast changes in the technological, market, economic or legal environment that have a significant adverse effect on the debtor's ability to meet its obligation to the Academy;
- an actual or expected internal credit rating downgrade for the debtor;
- an actual or expected significant change in the operating results of the debtor;
- significant changes in the expected performance and behaviour of the debtor.

Depending on the nature of the financial instruments, the assessment of a significant increase in credit risk is performed on either an individual basis or a collective basis. When the assessment is performed on a collective basis, the financial instruments are grouped based on shared credit risk characteristics, such as past due status and credit risk ratings.

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risks of default occurring as the weights. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**g) Credit losses and impairment of assets (Continued)**

**(i) Credit losses from financial instruments (Continued)**

Significant increases in credit risk (Continued)

ECLs are remeasured at each reporting date to reflect changes in the financial instrument's credit risk since initial recognition. Any change in the ECL amount is recognised as an impairment gain or loss in profit or loss. The Group recognises an impairment gain or loss for all financial instruments with a corresponding adjustment to their carrying amount through a loss allowance account, except for investments in financial assets that are measured at FVOCI (recycling), for which the loss allowance is recognised in other comprehensive income and shall not reduce the carrying amount of the financial asset in the statement of financial position.

Basis of calculation of interest income

Interest income recognised in accordance with note 2(n) is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit-impaired, in which case interest income is calculated based on the amortised cost (i.e. the gross carrying amount less loss allowance) of the financial asset.

At each reporting date, the Group assesses whether a financial asset is credit-impaired. A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable events:

- significant financial difficulties of the debtor;
- a breach of contract, such as a default or delinquency in interest or principal payments;
- it becoming probable that the debtor will enter into bankruptcy or other financial reorganisation;
- significant changes in the technological, market, economic or legal environment that have an adverse effect on the debtor; or
- the disappearance of an active market for a security because of financial difficulties of the issuer.

Write-off policy

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Group determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. Financial assets written off may still be subject to enforcement activities under the Group's recovery procedures, taking into account legal advice where appropriate.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**g) Credit losses and impairment of assets (Continued)**

**(i) Credit losses from financial instruments (Continued)**

**Write-off policy (Continued)**

Subsequent recoveries of an asset that was previously written off are recognised as a reversal of impairment in profit or loss in the period in which the recovery occurs.

**(ii) Impairment of other non-current assets**

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Internal and external sources of information are reviewed at the end of each reporting period to identify indications that plant and equipment including right-of-use assets may be impaired or, an impairment loss previously recognised no longer exists or may have decreased.

If any such indication exists, the asset's recoverable amount is estimated:

– **Calculation of recoverable amount**

The recoverable amount of an asset is the greater of its fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Where an asset does not generate cash inflows largely independent of those from other assets, the recoverable amount is determined for the smallest group of assets that generates cash inflows independently (i.e. a cash-generating unit).

– **Recognition of impairment losses**

An impairment loss is recognised in profit or loss if the carrying amount of an asset, or the cash-generating unit to which it belongs, exceeds its recoverable amount. Impairment losses recognised in respect of cash-generating units are allocated to reduce the carrying amount of the assets in the unit (or group of units) on a pro rata basis, except that the carrying value of an asset will not be reduced below its individual fair value less costs of disposal (if measurable) or value in use (if determinable).

– **Reversals of impairment losses**

An impairment loss is reversed if there has been a favourable change in the estimates used to determine the recoverable amount.

A reversal of an impairment loss is limited to the asset's carrying amount that would have been determined had no impairment loss been recognised in prior years. Reversals of impairment losses are credited to profit or loss in the year in which the reversals are recognised.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**h) Other financial assets**

Investments other than equity investments

Non-equity investments held by the Academy are classified as fair value through profit or loss (FVTPL) when the contractual cash flows of the investment do not represent solely payments of principal and interest. Changes in the fair value of the investment (including interest) are recognised in profit or loss.

Equity investments

An investment in equity securities is classified as financial assets at FVTPL unless the equity investment is not held for trading purposes and on initial recognition of the investment the Academy makes an irrevocable election to designate the investment at fair value through other comprehensive income (FVTOCI) (non-recycling) such that subsequent changes in fair value are recognised in other comprehensive income. Such elections are made on an instrument-by-instrument basis, but may only be made if the investment meets the definition of equity from the issuer's perspective. Where such an election is made, the amount accumulated in other comprehensive income remains in the fair value reserve (non-recycling) until the investment is disposed of. At the time of disposal, the attributable amount accumulated in the fair value reserve (non-recycling) is transferred to general fund. It is not recycled through profit or loss.

Dividends from an investment in equity securities, irrespective of whether classified as at FVTPL or FVTOCI, are recognised in profit or loss as other income in accordance with the policy set out in note 2(n).

**i) Receivables**

Receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less allowance for impairment of doubtful debts (see note 2(g)(i)), except where the receivables are interest-free loans made to related parties without any fixed repayment terms or the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less allowance for impairment of doubtful debts.

Receivables are stated at amortised cost using the effective interest method less allowance for credit losses (see note 2(g)).

**j) Payables**

Payables are initially recognised at fair value and thereafter stated at amortised cost unless the effect of discounting would be immaterial, in which case they are stated at cost.

**k) Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other financial institutions, and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value, having been within three months of maturity at a acquisition.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**k) Cash and cash equivalents (Continued)**

Cash and cash equivalents are assessed for expected credit losses (ECL) in accordance with the policy set out in note 2(g).

**l) Funds managed by the Group**

**i) Foundation fund**

Funds received which is used exclusively for the establishment and use of the Academy at such time as the Academy shall direct are accounted for as Foundation fund.

**ii) General fund**

The fund balance represents the accumulated surplus of the Foundation after deducting the amounts transferred to the Academy and is used to finance the general operations of the Group.

**m) Provisions and contingent liabilities**

Provisions are recognised for liabilities of uncertain timing or amount when the Group has a present legal or constructive obligation arising as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made. Where the time value of money is material, provisions are stated at the present value of the expenditure expected to settle the obligation.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. Possible obligations, whose existence will only be confirmed by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group are also disclosed as contingent liabilities unless the probability of outflow of economic benefits is remote.

**n) Revenue recognition**

**Revenue from contracts with customers**

The recognition of revenue from contracts with customers is based on the performance obligations identified in the contracts. Revenue is recognised when (or as) the Group satisfies as a performance obligation by transferring a promised good or service (i.e. an asset) to a customer who obtains the control of the assets:

**i) Provision of services**

Revenue from provision of services is recognised when the services are rendered.

**ii) Entrance fees and subscription fees**

Entrance fees are recognised at a point in time, i.e. when the cash is received. Subscription fees are recognised on an accrual basis and over time.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**n) Revenue recognition (Continued)**

**Revenue from contracts with customers (Continued)**

iii) Income from international congress and various functions

Income from international congress and various functions is recognised on an accrual basis and point in time.

**Revenue from other source**

i) Donations and grants

Donations income are recognised upon receipt of cash.

Designated grant are recognised on a systematic basis in the same periods in which the expenses are incurred.

Conditional donation, government grant and sponsorship grant income is recognised in the statement of financial position as deferred income initially and recognised in income and expenditure in the period when the conditions are fulfilled.

ii) Interest income

Interest income is recognised as it accrues using the effective interest method.

iii) Dividends

Dividend income is recognised when the shareholders' right to receive payment has been established.

iv) Rental income

Rental income is recognised in profit or loss in equal instalments over the period covered by the lease term.

**o) Related parties**

a) A person, or a close member of that person's family, is related to the Academy if that person:

- i) has control or joint control over the Academy;
- ii) has significant influence over the Academy; or
- iii) is a member of the key management personnel of the Academy or the Academy's parent.

**2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

**o) Related parties (Continued)**

- b) An entity is related to the Academy if any of the following conditions applies:
- i) The entity and the Academy are members of the same Academy (which means that each parent, subsidiary and fellow subsidiary is related to the others).
  - ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
  - iii) Both the entity and the Group are joint ventures of the same third party.
  - iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity.
  - v) The entity is a post-employment benefit plan for the benefit of employees of either the company or an entity related to the Academy.
  - vi) The entity is controlled or jointly controlled by a person identified in (a).
  - vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity).
  - viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the Group's parent.

Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity.

**p) Employee benefits**

- i) Short term employee benefits and contributions to defined contribution retirement plans
- Salaries, annual bonuses, paid annual leave, contributions to defined contribution plans and the cost of non-monetary benefits are accrued in the year in which the associated services are rendered by employees. Where payment or settlement is deferred and the effect would be material, these amounts are stated at their present values.
- Contributions to the Mandatory Provident Funds as required under the Hong Kong Mandatory Provident Fund Schemes Ordinance are charged to the income and expenditure account.
- ii) Termination benefits
- Termination benefits are recognised when, and only when, the Group demonstrably commits itself to terminate employment or to provide benefits as a result of voluntary redundancy by having a detailed formal plan which is without realistic possibility of withdrawal.

## **2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICY INFORMATION (Continued)**

### **q) Translation of foreign currencies**

Foreign currency transactions during the year are translated at the foreign exchange rates ruling at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated at the foreign exchange rates ruling at the end of the reporting period. Exchange gains and losses are recognised in profit or loss, except those arising from foreign currency borrowings used as effective hedge a net investment in a foreign operation which are recognised in other comprehensive income.

Non-monetary assets and liabilities measured in terms of historical cost in a foreign currency are translated using the foreign exchange rates ruling at the transaction dates. Non-monetary assets and liabilities denominated in foreign currencies stated at fair value are translated using the foreign exchange rates ruling at the dates the fair value was measured.

The functional and presentation currency of the Academy is Hong Kong dollars.

### **r) Government grants**

A government grant is recognised when there is reasonable assurance that it will be received and that the Group will comply with the conditions attached to it. Grants that compensate the Group for expenses or losses already incurred are recognised as other operating income on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the acquisition of an asset are presented by deducting them from the acquisition cost of the related asset.

## **3. CHANGES IN ACCOUNTING POLICIES**

The Academy has applied the following new and amendments to HKFRSs issued by the HKICPA to these consolidated financial statements for the first time, which are mandatorily effective for the Group's financial annual period beginning on or after 1 January 2024:

Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 and Non-current Liabilities with Covenants
Amendments to HKAS 7 and HKFRS 7	Supplier Finance Arrangements
Amendments to HKFRS 16	Lease Liability in a Sale and Leaseback

The application of the amendments to HKFRSs in the current year has had no material effect on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**4. SUBSCRIPTIONS AND FEES**

This represents the entrance fees and subscription fees received from fellows and members, and is analysed as follows:

	<u>2024</u> HK\$	<u>2023</u> HK\$
Entrance fees	8,686,600	7,530,000
Subscription fees	<u>28,315,850</u>	<u>25,486,100</u>
	<u>37,002,450</u>	<u>33,016,100</u>

**5. OTHER REVENUE**

	<u>2024</u> HK\$	<u>2023</u> HK\$
Income from various functions	11,535,867	12,119,496
Income from specialist certification	577,100	494,100
Training registration fee	<u>4,738,545</u>	<u>4,877,385</u>
	<u>16,851,512</u>	<u>17,490,981</u>

**6. OTHER INCOME AND OTHER NET GAIN**

	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>Other income</b>		
Advertising fee	119,640	328,870
Bank interest income *	3,009,688	2,631,995
Rental income	4,772,590	4,623,248
Subscriptions - journal	1,990,445	2,105,769
Donation income from The Hong Kong Jockey Club Charities Trust	-	15,744,275
Grant received from government	2,460,514	2,512,544
Grant received for research in genomic medicine	323,913	250,000
Grant received from Health Bureau	730,065	-
Grant received from JCIMED	552,701	-
Training income	-	1,625,463
Others	<u>1,748,751</u>	<u>2,204,009</u>
	15,708,307	32,026,173
<b>Other net gain</b>		
Dividend income from other financial assets	352,372	432,577
Exchange gain	<u>-</u>	<u>(12,488)</u>
	<u>352,372</u>	<u>420,089</u>
	<u>16,060,679</u>	<u>32,446,262</u>

\* The bank interest income was generated from financial assets at amortised cost.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**7. (DEFICIT)/SURPLUS FOR THE YEAR**

(Deficit)/surplus for the year is arrived at after charging:

	2024 HK\$	2023 HK\$
<b>a) Staff costs</b>		
Contributions to defined contribution retirement plans	1,917,544	1,780,786
Salaries, wages and other benefits	<u>28,343,510</u>	<u>26,180,406</u>
	<u>30,261,054</u>	<u>27,961,192</u>
<b>b) Other items</b>		
Auditor's remuneration	193,500	176,000
Depreciation	5,717,884	5,579,105
Net foreign exchange (loss)/gain	<u>(39,576)</u>	<u>12,488</u>

**8. TAXATION**

No provision has been made for Hong Kong Profits Tax as the Group is exempted from taxation under the provision of section 88 of the Hong Kong Inland Revenue Ordinance.

**9. PROPERTY, PLANT AND EQUIPMENT**

	Computer equipment HK\$	Furniture and fixtures HK\$	Training & office equipment HK\$	Leasehold improvements HK\$	Leasehold land and buildings HK\$	Construction in progress HK\$	Total HK\$
<b>Cost</b>							
At 1 January 2023	5,246,297	14,624,410	31,140,478	103,977,795	3,335,832	-	158,324,812
Additions	273,530	18,000	296,073	326,650	-	-	914,253
Disposals	<u>(24,995)</u>	<u>-</u>	<u>(154,622)</u>	<u>(755,147)</u>	<u>-</u>	<u>-</u>	<u>(934,764)</u>
At 31 December 2023 and 1 January 2024	5,494,832	14,642,410	31,281,929	103,549,298	3,335,832	-	158,304,301
Additions	525,482	1,517,705	538,420	-	-	1,540,100	4,121,707
Disposals	<u>(870,497)</u>	<u>(17,822)</u>	<u>(3,879,966)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(4,768,285)</u>
At 31 December 2024	<u>5,149,817</u>	<u>16,142,293</u>	<u>27,940,383</u>	<u>103,549,298</u>	<u>3,335,832</u>	<u>1,540,100</u>	<u>157,657,723</u>
<b>Accumulated depreciation</b>							
At 1 January 2023	4,415,330	14,585,387	28,787,827	89,986,689	2,272,345	-	140,047,578
Charge for the year	304,747	23,072	712,620	4,403,233	135,433	-	5,579,105
Write back on disposals	<u>(24,995)</u>	<u>-</u>	<u>(154,622)</u>	<u>(755,147)</u>	<u>-</u>	<u>-</u>	<u>(934,764)</u>
At 31 December 2023 and 1 January 2024	4,695,082	14,608,459	29,345,825	93,634,775	2,407,778	-	144,691,919
Charge for the year	304,926	90,314	791,354	4,397,857	133,433	-	5,717,884
Write back on disposals	<u>(870,497)</u>	<u>(17,822)</u>	<u>(3,879,966)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(4,768,285)</u>
At 31 December 2024	<u>4,129,511</u>	<u>14,680,951</u>	<u>26,257,213</u>	<u>98,032,632</u>	<u>2,541,211</u>	<u>-</u>	<u>145,641,518</u>
<b>Carrying amount</b>							
At 31 December 2024	<u>1,020,306</u>	<u>1,461,342</u>	<u>1,683,170</u>	<u>5,516,666</u>	<u>794,621</u>	<u>1,540,100</u>	<u>12,016,205</u>
At 31 December 2023	<u>799,750</u>	<u>33,951</u>	<u>1,936,104</u>	<u>9,914,523</u>	<u>928,054</u>	<u>-</u>	<u>13,612,382</u>

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**9. PROPERTY, PLANT AND EQUIPMENT (Continued)**

The Academy entered into an agreement with the Hong Kong Special Administrative Region Government for grant by Private Treaty of Aberdeen Inland Lot No. 414 for a term of 50 years less 3 days with effect from 1 July 1997 and on which the headquarters of the Academy were built. The Academy is required to pay an amount equal to 3% of the rateable value per annum, which has been charged to the income and expenditure account.

**10. INTEREST IN A SPECIAL PURPOSE ENTITY**

Details of the special purpose entity are as follows:

<u>Name of the special purpose entity</u>	<u>Form of business structure</u>	<u>Place of incorporation and operation</u>	<u>Principal activity</u>	<u>Proportion of ownership interest held by Academy</u>
The Hong Kong Academy of Medicine Foundation Fund	Incorporated	Hong Kong	Fund raising and investment management	100%

**11. INVESTMENTS IN EQUITY INSTRUMENTS DESIGNATED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME**

	<u>2024</u> HK\$	<u>2023</u> HK\$
Investments designated at FVTOCI:		
- Equity securities listed in Hong Kong	<u>5,891,406</u>	<u>4,261,842</u>

At 31 December 2024, the amounts comprise equity securities listed in Hong Kong of HK\$5,891,406 (2023: HK\$4,261,842) that are carried at fair value. These investments are not held for trading, instead, they are held for long-term strategic purposes. The council members have elected to designate these investments in equity instruments as at FVTOCI as they believe that recognising short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Academy's strategy of holding these investments for long-term purposes and realising their performance potential in the long run.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**12. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES**

	<u>2024</u> HK\$	<u>2023</u> HK\$
Bank interest receivables	1,019,590	1,066,190
Deposits	71,603	56,603
Deposit paid to building management company	700,000	700,000
Function fee receivable	6,971,820	5,031,091
Prepaid expenses	1,057,948	1,323,699
Receivable from associations, government authorities and independent third parties arising from academic functions	<u>1,023,716</u>	<u>1,200,864</u>
	<u>10,844,677</u>	<u>9,378,447</u>

All of the prepayments, deposits and other receivables are expected to be recovered within one year.

The Group's credit policy is set out in note 19(a).

**13. TIME DEPOSITS AND CASH AND CASH EQUIVALENTS**

	<u>2024</u> HK\$	<u>2023</u> HK\$
Time deposits with original maturity of three months or less	66,796,900	13,147,800
Cash at bank and on hand	<u>11,718,423</u>	<u>15,886,467</u>
	<u>78,515,323</u>	<u>29,034,267</u>
Time deposits with original maturity over three months	<u>31,706,871</u>	<u>58,790,707</u>

Included in cash and cash equivalents are the following amounts denominated in a currency other than the functional currency of the entity to which they relate:

	<u>2024</u>	<u>2023</u>
United States Dollars	538,687	513,204
Renminbi	<u>305,108</u>	<u>304,172</u>

**14. ACCRUALS AND OTHER PAYABLES**

	<u>2024</u> HK\$	<u>2023</u> HK\$
Accrued expenses payable to building management company	(2,671,678)	(2,089,729)
Other accrued expenses	<u>(8,843,969)</u>	<u>(8,892,009)</u>
	<u>(11,515,647)</u>	<u>(10,981,738)</u>

All accruals and other payables are expected to be settled within one year or are repayable on demand.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**15. DEFERRED INCOME**

	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>Current</b>		
Grant received from government	25,192,554	2,661,160
Grant received for research in genomic medicine	847,253	473,912
Others	<u>2,640,224</u>	<u>88,830</u>
	28,680,031	3,223,902
<b>Non-current</b>		
Grant received for research in genomic medicine	<u>1,256,001</u>	<u>1,876,632</u>
	<u>29,936,032</u>	<u>5,100,534</u>

**16. RESERVE AND FUNDS**

**Movements in components of reserve and funds**

The reconciliation between the opening and closing balances of each component of the Group's consolidated reserve and funds is set out in the consolidated statement of changes in reserve and funds. Details of the changes in the Academy's individual components of reserve and funds between the beginning and the end of the year are set out below:

**The Academy**

	<u>Fair value reserve</u> HK\$	<u>General fund</u> HK\$	<u>Total</u> HK\$
At 1 January 2023	(2,225,076)	76,112,577	73,887,501
Surplus for the year	-	10,030,485	10,030,485
Other comprehensive loss			
Investments in equity instruments designated at fair value through other comprehensive income:			
Changes in fair value	(221,160)	-	(221,160)
Total comprehensive income/(loss) for the year	<u>(221,160)</u>	<u>10,030,485</u>	<u>9,809,325</u>
At 31 December 2023 and 1 January 2024	(2,446,236)	86,143,062	83,696,826
Deficit for the year	-	(3,783,569)	(3,783,569)
Other comprehensive income			
Investments in equity instruments designated at fair value through other comprehensive income:			
Changes in fair value	1,629,564	-	1,629,564
Total comprehensive (loss)/income for the year	<u>1,629,564</u>	<u>(3,783,569)</u>	<u>(2,154,005)</u>
At 31 December 2024	<u>(816,672)</u>	<u>82,359,493</u>	<u>81,542,821</u>

## 16. RESERVE AND FUNDS (Continued)

### The Academy (Continued)

Fair value reserve comprises the cumulative net change in the fair value of equity instruments designated at FVTOCI held at the end of the reporting period and is dealt with in accordance with the accounting policy in note 2(h). Funds received are accounted for in the Foundation fund which is used exclusively for the establishment and use of the Academy at such time as the Academy shall direct. General fund represents the cumulative surplus of the Academy.

## 17. CAPITAL MANAGEMENT

The Group defined all components of reserve and funds as "capital". On this basis, the amount of capital employed at 31 December 2024 was HK\$97,867,147 (2023: HK\$99,384,740).

The Group's primary objectives when managing capital are to safeguard the Group's ability to continue as a going concern.

The Group's capital structure is regularly reviewed and managed. Adjustments are made to the capital structure in light of changes in economic conditions affecting the Group, to the extent that these do not conflict with the Council's fiduciary duties towards the Group or the requirements of the Hong Kong Academy of Medicine Ordinance.

The Group was not subject to externally imposed capital requirements in either the current or prior year.

## 18. COMMITMENTS

### Lease commitment

#### The Academy as lessor

Undiscounted lease payments under non-cancellable operating leases in place at the reporting date will be receivable by the Academy in future periods as follows:

	<u>2024</u> HK\$	<u>2023</u> HK\$
Within 1 year	391,500	378,000
After 1 year but within 5 years	<u>216,000</u>	<u>67,500</u>
	<u>607,500</u>	<u>445,500</u>

The Academy leases out certain areas of its headquarter under operating leases. None of the leases includes contingent rentals.

## 19. FINANCIAL INSTRUMENTS

The Group's major financial instruments include investments in equity instruments designated at FVTOCI, receivables, time deposits, cash and cash equivalents and accruals and other payables. Details of the financial instruments are disclosed in the respective notes. The risk associated with these financial instruments include credit risk, liquidity risk, currency risk, interest rate risk and price risk. The policies on how to mitigate these risks are set out below. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

### a) Credit risk

The Group's credit risk is primarily attributable to receivables, time deposits and cash and cash equivalents. Management has a credit policy in place and the exposures to these credit risks are monitored on an ongoing basis.

- i) In respect of the receivables, in order to minimize risk, the management has a credit policy in place and the exposures to these credit risks are monitored on an ongoing basis. Credit evaluations of its debtor's financial position and condition is performed on each and every major debtor periodically. These evaluations focus on the debtor's past history of making payments when due and current ability to pay, and take into account information specific to the debtor. The Group does not require collateral in respect of its financial assets. The Group also takes into account the economic environment in which the debtor operates.
- ii) The investments in equity instruments designated at FVTOCI are liquid securities listed on the recognised stock exchanges. Given their high credit standing, management does not expect any investment counterparty to fail to meet its obligations.
- iii) The credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit - rating agencies.
- iv) The Group does not provide any guarantees which would expose the Group to the credit risk.

### b) Liquidity risk

The Group's policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash and readily realisable marketable securities and/or from other groups to meet its liquidity requirements in the short and longer term.

The following liquidity tables show the remaining contractual maturities at the end of reporting period of the Group's non-derivative financial liabilities, which are based on contractual undiscounted cash flows and the earliest date the Group can be required to pay.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**19. FINANCIAL INSTRUMENTS (Continued)**

**b) Liquidity risk (Continued)**

	Contractual undiscounted cash outflow		Carrying amount at 31 <u>December</u> HK\$
	Within 1 year or <u>on demand</u> HK\$	Total contractual undiscounted <u>cash flow</u> HK\$	
<b>As at 31 December 2024</b>			
Non-derivative financial liabilities			
Accruals and other payables	<u>11,515,647</u>	<u>11,515,647</u>	<u>11,515,647</u>
<b>As at 31 December 2023</b>			
Non-derivative financial liabilities			
Accruals and other payables	10,981,738	10,981,738	10,981,738

**c) Interest rate risk**

The Group is exposed to interest rate risk only to the extent that it earns bank interest on cash and deposits.

The effective interest rates per annum relating to cash at bank and time deposits at the end of the reporting period ranges from 0.01% to 4.24% (2023: 0.01% to 5.19%) for the Group.

**Sensitivity analysis**

At 31 December 2024, it is estimated that a general increase/decrease of 100 basis points in interest rates, with all other variables held constant, would increase/decrease the Group's surplus for the year and increase/decrease the Group's general fund by approximately HK\$1,102,000 (2023: HK\$835,000). Other components of equity would not be affected (2023: HK\$Nil) by the changes in interest rates.

The sensitivity analysis above has been determined assuming that the change in interest rates had occurred at the end of the reporting period and had been applied to the exposure to interest rate risk for financial instruments in existence at that date. The 100 basis point increase represents management's assessment of a reasonably possible change in interest rates over the period until the end of next reporting period. The analysis is performed on the same basis for 2023.

## 19. FINANCIAL INSTRUMENTS (Continued)

### d) Currency risk

The Group's functional currency is Hong Kong dollars. The Group is exposed to currency risk through cash and bank balances denominated in Renminbi ("RMB") and United States dollars ("USD"). As the Hong Kong dollar ("HKD") is pegged to the USD, the Group does not expect any significant movements in the USD/HKD exchange rate. At 31 December 2024, it is estimated that a general increase or decrease in 5% of exchange rates, with all variables held constant, would increase/decrease the Group's surplus for the year and increase/decrease the Group's general fund by approximately HK\$16,000 (2023: HK\$17,000).

### e) Fair values measurement

Fair value hierarchy

The following table presents the fair value of the Group's financial instruments measured at the end of the reporting period on a recurring basis, categorised into the three-level fair value hierarchy as defined in HKFRS 13, Fair value measurement. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available.
- Level 3 valuations: Fair value measured using significant unobservable inputs.

	Fair value as at			Valuation	Significant
	31 December	31 December	Fair value	techniques and	unobservable
<u>Financial assets</u>	<u>2024</u>	<u>2023</u>	<u>hierarchy</u>	<u>key inputs</u>	<u>inputs</u>
	HK\$	HK\$			
<b>Investments in equity instruments designated at FVTOCI</b>					
Listed equity securities	5,891,406	4,261,842	Level 1	Quoted bid prices in an active market	N/A

At 31 December 2024 and 2023, all financial instruments measured at fair value fall into level 1 of the fair value hierarchy described above.

### f) Price risk

The Group is exposed to equity price changes arising from listed equity investments. The Group's listed investments are listed on recognised stock exchange. Listed investments held in the investments in equity instruments designated at FVOCI have been chosen based on their longer term growth potential and are monitored regularly for performance against expectations.

**19. FINANCIAL INSTRUMENTS (Continued)**

**f) Price risk (Continued)**

The Council monitors the market price risk of the investments individually and estimated that a 5% increase/decrease in market prices of equity securities at 31 December 2024, with all other variables held constant, would increase/decrease the Group's fair value reserve and capital by HK\$295,000 (HK\$213,000).

**20. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS**

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

**a) Useful lives of property, plant and equipment**

The Group determines the estimated useful lives and related depreciation charges for its items of property, plant and equipment. This estimate is based on the historical experience of the actual useful lives of items of property, plant and equipment of similar nature and functions. Management will revise the depreciation charge where useful lives are different to the ones previously estimated, and it will write-off or write-down technically obsolete or non-strategic assets that have been abandoned or sold.

**b) Measurement of the ECLs for receivables**

The measurement of the expected loss allowance for receivables is an area that requires the use of complex models and significant assumptions about future economic conditions and credit behavior (the likelihood of debtors defaulting and the resulting losses). Further details are set out in note 19(a) Credit Risk.

**21. RELATED PARTY TRANSACTIONS**

In addition to the transactions and balances disclosed elsewhere in these financial statements, the Group entered into the following material related party transaction:

Transactions with key management personnel

All members of key management personnel are the council members of the Academy, and no remuneration was paid to the council members during the years ended 31 December 2024 and 2023.

**HONG KONG ACADEMY OF MEDICINE**  
**香港醫學專科學院**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**22. ACADEMY'S STATEMENT OF FINANCIAL POSITION**

	<u>Note</u>	<u>2024</u> HK\$	<u>2023</u> HK\$
<b>Non-current assets</b>			
Property, plant and equipment		12,016,205	13,612,382
Investments in equity instruments designated at fair value through other comprehensive income		5,891,406	4,261,842
		17,907,611	17,874,224
<b>Current assets</b>			
Inventories – general merchandise		344,344	389,367
Prepayments, deposits and other receivables		10,743,320	9,170,932
Amount due from a special purpose entity		19,200	19,010
Time deposits		31,706,871	44,000,000
Cash and cash equivalents		62,255,156	28,308,065
		105,068,891	81,887,374
<b>Current liabilities</b>			
Deferred income		28,680,031	3,223,902
Accruals and other payables		11,497,649	10,964,238
		(40,177,680)	(14,188,140)
<b>Net current assets</b>		64,891,211	67,699,234
<b>Non current liabilities</b>			
Deferred income		(1,256,001)	(1,876,632)
<b>Net assets</b>		81,542,821	83,696,826
<b>Reserve and funds</b>			
Fair value reserve	16	(816,672)	(2,446,236)
General fund		82,359,493	86,143,062
		81,542,821	83,696,826

Approved and authorised for issue by the Council on 17 July 2025.

On behalf of the Council



Prof. Philip Kam-tao Li  
President



Prof. Eric Wai-Choi Tse  
Honorary Treasurer

**23. POSSIBLE IMPACT OF NEW AND AMENDMENTS TO HKFRSs ISSUED BUT NOT YET EFFECTIVE FOR THE YEAR ENDED 31 DECEMBER 2024**

Up to the date of approval for issue of these consolidated financial statements, the HKICPA has issued a number of new and amendments to HKFRS which are not yet effective for the year ended 31 December 2024 and which have not been adopted in these consolidated financial statements, as follows:

Amendments to HKAS 21	Lack of Exchangeability <sup>1</sup>
Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments <sup>2</sup>
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity <sup>2</sup>
Annual Improvements to HKFRS Accounting Standards 2024	Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7 <sup>2</sup>
HKFRS 18 and consequential amendments to other HKFRSs	Presentation and Disclosure in Financial Statements <sup>3</sup>
HKFRS 19	Subsidiaries without Public Accountability: Disclosures <sup>3</sup>
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture <sup>4</sup>

<sup>1</sup> Effective for annual periods beginning on or after 1 January 2025

<sup>2</sup> Effective for annual periods beginning on or after 1 January 2026

<sup>3</sup> Effective for annual periods beginning on or after 1 January 2027

<sup>4</sup> Effective for annual periods beginning on or after a date to be determined

The Academy is in the process of making an assessment of what the impact of these developments is expected to be in the period of initial application. Except as described below, the council members anticipate that the application of the new and amendments or interpretations will have no material impact on the results and the financial position of the Academy.

**HKFRS 18 Presentation and Disclosure in Financial Statements and consequential amendments to other HKFRSs**

HKFRS 18 replaces HKAS 1 Presentation of Financial Statements ("HKAS 1"). It carries forward many requirements from HKAS 1 unchanged. HKFRS 18 brings major changes to the statement of profit or loss and notes to the financial statements as follows:

(a) HKFRS 18 requires an entity:

- (i) to classify income and expenses into operating, investing and financing categories in the statement of profit or loss, plus income taxes and discontinued operations;
- (ii) to present two new defined subtotals, namely, operating profit or loss and profit or loss before financing and income taxes.

**23. POSSIBLE IMPACT OF NEW AND AMENDMENTS TO HKFRSs ISSUED BUT NOT YET EFFECTIVE FOR THE YEAR ENDED 31 DECEMBER 2024 (Continued)**

**HKFRS 18 Presentation and Disclosure in Financial Statements and consequential amendments to other HKFRSs (Continued)**

- (b) It requires an entity to disclose management-defined performance measures (“MPM”) and reconciliations between MPM and subtotals listed in HKFRS 18 or totals or subtotals required by HKFRSs.
- (c) It sets out requirements to help an entity determine whether information about items should be in the primary financial statements or in the notes and provides principles for determining the level of detail needed for the information.

HKFRS 18 also set out classification requirements for foreign exchange differences, the gain or loss on the net monetary position, and gains and losses on derivatives and designated hedging instruments.

In addition, some paragraphs in HKAS 1 have been moved to HKAS 8 Basis of Preparation of Financial Statements and HKFRS 7. Minor amendments to HKAS 7 Statement of Cash Flows and HKAS 33 Earnings per Share are also made.

HKFRS 18 and consequential amendments to other HKFRSs are effective for annual reporting periods beginning on or after 1 January 2027, with early application permitted. The application of the new standard is expected to affect the presentation of the consolidated statement of profit or loss and disclosures in the future consolidated financial statements. The Academy is in the process of assessing the detailed impact on the consolidated financial statements.



Appendices  
附錄

# Appendix 1

## 附錄一

### Membership of the Academy's Committees and Subcommittees

#### 醫專轄下各委員會及小組委員會的成員名單

(as of August 2025 截至2025年8月)

#### Hong Kong Academy of Medicine 香港醫學專科學院

##### Appeals Committee 上訴委員會

<b>Chairman</b> 主席	Dr. David Fang 方津生醫生
<b>Panel Members</b> 成員	To be appointed by the Academy Council 將由醫專院務委員會委任

##### Credentialling for Endovascular Neurointerventional Procedures Committees

##### 血管內神經介入技術程序資歷認證委員會

##### Category I: Endovascular Neurointerventional Procedures

##### 第一類別：血管內神經介入技術程序

<b>Chairman</b> 主席	Dr. Kai-yuen Pang 彭佳源醫生		
<b>Vice-Chairman</b> 副主席	Dr. Wai-lun Poon 潘偉麟醫生		
<b>Members</b> 委員	Dr. Chui-kwan Kan 簡聚坤醫生	Dr. Ming-hei Lai 賴銘曦醫生	Dr. Kwong-yui Yam 任廣銳醫生

##### Category II: Neurointerventional Procedures for Acute Ischaemic Stroke

##### 第二類別：急性缺血性中風介入技術程序

<b>Chairman</b> 主席	Dr. Wai-man Lui 呂偉文醫生		
<b>Vice-Chairman</b> 副主席	Dr. Richard Li 李梓強醫生		
<b>Members</b> 委員	Dr. Kwong-yau Chan 陳廣有醫生	Dr. Chui-kwan Kan 簡聚坤醫生	Dr. Ming-hei Lai 賴銘曦醫生
	Prof. Thomas Wai-hong Leung 梁慧康教授	Dr. Wai-lun Poon 潘偉麟醫生	

## Education Committee 教育委員會

<b>Chairman 主席</b>	Prof. Clement Chee-yung Tham 譚智勇教授		
<b>Members 委員</b>	Dr. Albert Kam-ming Chan 陳錦明醫生	Dr. Johnny Wai-man Chan 陳偉文醫生	Dr. Catherine Shiu-yin Chong 莊紹賢醫生
	Dr. Sau-kwan Chu 朱秀群醫生	Dr. Thomas Wai-hung Chung 鍾偉雄醫生	Dr. Jerome Yu 虞積龍醫生
	Prof. Ivan Fan-ngai Hung 孔繁毅教授	Prof. Carmen Kar-mun Chan 陳嘉敏教授	Dr. Daniel Wong 黃祈恩醫生
	Dr. Kin-man Lee 李健民醫生	Dr. Jackie Ching-kan Leung 梁靜勤醫生	Dr. Rock Yuk-yan Leung 梁毓恩醫生
	Prof. Albert Martin Li 李民瞻教授	Dr. Chun-tat Lui 雷俊達醫生	Dr. Flora Yi-man Mo 巫綺文醫生
	Dr. Wai-lun Poon 潘偉麟醫生	Prof. Grace Wai-king Tang 鄧惠瓊教授	Dr. Michael Tim-yun Ong 王添欣醫生
	Prof. Samuel Yeung-shan Wong 黃仰山教授	Dr. Wai-yeung Wong 王維揚醫生	Dr. Frankie Wai-tsoi Cheng 鄭偉才醫生
<b>Co-opted Member 增選委員</b>	Dr. Benny Chun-pong Cheng 鄭振邦醫生		

## CME Subcommittee 延續醫學教育小組委員會

<b>Chairman 主席</b>	Dr. David Vai-kiong Chao 周偉強醫生		
<b>Members 委員</b>	Dr. Chi-lap Au 區志立醫生	Dr. Billy Chi-fai Chiu 趙志輝醫生	Dr. Se-fong Hung 熊思方醫生
	Dr. Mary Bi-lok Kwong 鄺碧綠醫生	Prof. Cindy Lo-kuen Lam 林露娟教授	Dr. Yim-chu Li 李艷珠醫生
	Dr. Lorna Ventura Ng 吳蓮蓮醫生	Dr. Gene Wai-wang Tsoi 蔡惠宏醫生	Prof. Clement Chee-yung Tham 譚智勇教授

## Finance and Investment Committee 財務委員會

<b>Chairman 主席</b>	Mrs. Vivian Chan 陳盧鳳儀女士		
<b>Members 委員</b>	Dr. Yu-fat Chow 周雨發醫生	Dr. David Fang 方津生醫生	Dr. Julian Chun-yan Fong 方俊仁醫生
	Dr. Stephen Kam-so Foo* 傅鑑蘇醫生	Dr. Adrian Chi-heng Fung 馮智衡醫生	Mr. Paul Kai-lung Go 吳繼龍先生
	Dr. Eric Hui-lun Lau^ 劉珣綸醫生	Prof. Eric Wai-choi Tse 謝偉財教授	
<b>Ex-Officio Member 當然委員</b>	Prof. Philip Kam-tao Li 李錦滔教授		

(\*Until November 2024 直至2024年11月)

(^From December 2024 to June 2025 由2024年12月至2025年6月)

## House Committee 內務委員會

<b>Chairman</b> 主席	Dr. Wing-cheong Leung 梁永昌醫生		
<b>Members</b> 委員	Prof. Henry Lik-yuen Chan 陳力元教授	Dr. Alexander Chiu 邱家駿醫生	Dr. Stephen Kam-so Foo* 傅鑑蘇醫生
	Ms. Julie Shuk-nei Li 李淑妮女士	Dr. Raymond Yun-lok Mak 麥潤樂醫生	Dr. Kathleen Pik-han So 蘇碧嫻醫生
	Dr. Sut-yee Tse 謝雪兒醫生	Prof. Eric Wai-choi Tse 謝偉財教授	Dr. Clara Wing-yee Wu 胡詠儀醫生
<b>Ex-Officio Member</b> 當然委員	Prof. Gilberto Ka-kit Leung^ 梁嘉傑教授	Prof. Philip Kam-tao Li 李錦滔教授	
<b>Advisor (Catering)</b> 顧問 (餐飲)	Mr. Pierre Wai-ping Lau 劉惠平先生		

(\*Until November 2024 直至2024年11月)

(^Until December 2024 直至2024年12月)

## Human Resources Subcommittee 人力資源小組委員會

<b>Chairman</b> 主席	Dr. Wing-cheong Leung 梁永昌醫生		
<b>Members</b> 委員	Prof. Henry Lik-yuen Chan 陳力元教授	Dr. Alexander Chiu 邱家駿醫生	Ms. Katherine Ka-wan Shiu 蕭嘉韻女士
	Dr. Yu-fat Chow 周雨發醫生	Prof. Gilberto Ka-kit Leung* 梁嘉傑教授	Prof. Philip Kam-tao Li 李錦滔教授
<b>Ex-Officio Members</b> 當然委員	Prof. Clement Chee-yung Tham 譚智勇教授	Prof. Eric Wai-choi Tse 謝偉財教授	Prof. Martin Chi-sang Wong 黃至生教授

(\*Until December 2024 直至2024年12月)

## IT Subcommittee 資訊科技小組委員會

<b>Chairman</b> 主席	Dr. Alexander Chiu 邱家駿醫生		
<b>Members</b> 委員	Dr. Marvin Man-ting Chung 鍾汶庭醫生	Mr. Alex Kin-ming Lee 李健明先生	Ms. Julie Shuk-nei Li 李淑妮女士
	Dr. Ada Wing-ting Tse 謝穎婷醫生	Dr. Kaye Wing-sze Wong* 王詠詩醫生	Dr. Dennis King-hang Yee* 余敬行醫生

(\*Until June 2025 直至2025年6月)

### Social Subcommittee 社交小組委員會

<b>Co-Chairmen</b> 聯合主席	Dr. Joseph Chun-kit Chung 鍾駿傑醫生	Dr. Clara Wing-yee Wu 胡詠儀醫生	
<b>Members</b> 委員	Dr. Fiona Yuet-yan Chan 陳悅欣醫生	Dr. Loretta Wing-yan Chan 陳穎欣醫生	Dr. Amy Yim-ling Cheung 張炎鈴醫生
	Dr. Yat Chow 周一醫生	Dr. Annabel Kai-tung Choy 蔡啟彤醫生	Dr. Julian Chun-yan Fong 方俊仁醫生
	Dr. Jacky Chiu-leung Ho 何昭良醫生	Dr. Tom Fu-tak Ho 何富德醫生	Dr. Eric Hui-lun Lau* 劉珣綸醫生
	Dr. Yolanda Yee-hung Law 羅綺紅醫生	Dr. Julianna Cho-hwei Liew 劉卓慧醫生	Dr. Johann Lok 駱宇漢醫生
	Dr. Hung-to Luk 陸洪滔醫生	Dr. Aldo Chiu-lun Wong 王昭麟醫生	Dr. Zion Wing-hei To* 杜永禧醫生
	Dr. Stephanie Nga-sze Wong 黃雅詩醫生	Dr. Frankie Sze-hoi Yeung 楊思凱醫生	

(\*Until June 2025 直至2025年6月)

### Task Force on Well-Being 身心健康專責小組

<b>Chairman</b> 主席	Dr. Wing-cheong Leung 梁永昌醫生		
<b>Members</b> 委員	Dr. Adrian Wai Chan 陳偉醫生	Dr. Albert Kam-ming Chan 陳錦明醫生	Dr. Chloe Lam Chan^ 陳琳醫生
	Dr. Ivy Shui-ying Cheng 鄭慧凝醫生	Dr. Siu-ning Chiu 趙少寧醫生	Dr. Annabel Kai-tung Choy 蔡啟彤醫生
	Dr. Jacky Chiu-leung Ho 何昭良醫生	Prof. Gilberto Ka-kit Leung* 梁嘉傑教授	Prof. Philip Kam-tao Li 李錦滔教授
	Dr. Johann Lok 駱宇漢醫生	Dr. Hung-to Luk 陸洪滔醫生	Dr. Jerome Lok-tsun So^ 蘇樂進醫生
	Dr. Kelvin Lap-kiu Tsoi 蔡立喬醫生	Dr. Violet Yee-kei Tsoi 蔡綺琪醫生	Dr. Aldo Chiu-lun Wong 王昭麟醫生
	Dr. Clara Wing-yee Wu 胡詠儀醫生	Dr. Stephen Ho-chun Wu^ 胡浩晉醫生	
<b>Honorary Advisors</b> 名譽顧問	Dr. Ling Chiu 趙玲醫生	Dr. Rosalie Suk-yee Lo 羅淑兒博士	

(\*Until December 2024 直至2024年12月)

(^Until June 2025 直至2025年6月)

## Membership Committee 會籍委員會

<b>Chairman</b> 主席	Dr. Hung-to Luk 陸洪滔醫生		
<b>Members</b> 委員	Prof. Tai-kwong Chan 陳棣光教授	Prof. Leung-kim Hung 熊良儉教授	Dr. Wing-cheong Leung 梁永昌醫生
	Prof. Chi-kong Li 李志光教授	Dr. Julianna Cho-hwei Liew 劉卓慧醫生	

## Professionalism and Ethics Committee 專業及道德倫理委員會

<b>Co-Chairmen</b> 聯席主席	Dr. James Shing-ping Chiu 趙承平醫生	Prof. Gilberto Ka-kit Leung 梁嘉傑教授	
<b>Members</b> 委員	Dr. Victor Abdullah 石偉棠醫生	Dr. Chi-wing Chan 陳智榮醫生	Dr. Ying-kei Chan 陳英琪醫生
	Prof. Annie Nga-yin Cheung 張雅賢教授	Dr. Chin-pang Cheung 張展鵬醫生	Dr. Wing-wa Go 吳榮華醫生
	Prof. Chi-tim Hung 熊志添教授	Prof. Gavin Matthew Joynt 喬伊諾教授	Dr. Mary Bi-lok Kwong 鄺碧綠醫生
	Dr. Chun-hung Lai 賴俊雄醫生	Dr. Billy Ming-hei Lai 賴銘曦醫生	Dr. Yolanda Yee-hung Law 羅綺紅醫生
	Dr. Jenny Yin-yan Leung 梁彥欣醫生	Prof. Chi-kong Li 李志光教授	Dr. Eric Wai-ching Yan 甄偉政醫生
	Dr. Jacqueline Kwan-yuk Yuen 阮君毓醫生	Dr. Nancy Shi-yin Yuen 袁淑賢醫生	

## Task Force on Advance Medical Directives 預設醫療指示專責小組

<b>Convener</b> 召集人	Dr. Doris Man-wah Tse 謝文華醫生		
<b>Members</b> 委員	Dr. Philip Swan-lip Beh (term expired in July 2025) 馬宣立醫生	Prof. Gavin Matthew Joynt 喬伊諾教授	Dr. Mary Bi-lok Kwong 鄺碧綠醫生
	Prof. Linda Chiu-wa Lam 林翠華教授	Dr. Oi-fung Wong 黃凱峯醫生	Dr. Jacqueline Kwan-yuk Yuen 阮君毓醫生

## Task Force on Artificial Intelligence 人工智能專責小組

<b>Convener</b> 召集人	Dr. Neeraj Ramesh Mahboobani 馬承志醫生		
<b>Members</b> 委員	Dr. Rex Kwok-him Au-Yeung 歐陽覺謙醫生	Dr. Suet-ming Chau 周雪明醫生	Prof. Yiu-fai Cheung 張耀輝教授
	Dr. Chun-tat Lui 雷俊達醫生	Dr. Matthew Man-hei Luk 陸文熹醫生	Dr. Michael Tim-yun Ong 王添欣醫生
	Dr. Daniel Wong 黃祈恩醫生	Dr. Hon-wah Yung 容瀚華醫生	

### *Task Force on Disclosure, Apology and Alternative Dispute Resolutions* 披露、道歉及非訴訟解紛專責小組

<b>Convener</b> 召集人	Prof. Gavin Matthew Joynt 喬伊諾教授		
<b>Members</b> 委員	Dr. Ping-tak Chan 陳平德醫生	Dr. James Shing-ping Chiu 趙承平醫生	Dr. Wing-wa Go 吳榮華醫生
	Dr. Eric Ming-tung Hui 許明通醫生	Dr. Chun-hung Lai 賴俊雄醫生	Dr. Yolanda Yee-hung Law 羅綺紅醫生
	Prof. Gilberto Ka-kit Leung 梁嘉傑教授	Dr. Amy Ching-yung Liu 廖清蓉醫生	Dr. Hing-yu So 蘇慶餘醫生
	Dr. Alan King-woon So 蘇景桓醫生	Dr. Nancy Shi-yin Yuen 袁淑賢醫生	

### *Task Force on Genetics and Genomics* 遺傳學及基因組學專責小組

<b>Convener</b> 召集人	Prof. Gilberto Ka-kit Leung 梁嘉傑教授		
<b>Members</b> 委員	Prof. Annie Nga-yin Cheung 張雅賢教授	Dr. Calvin Yeow-kuan Chong 張耀君醫生	Dr. Wing-cheong Leung 梁永昌醫生
	Dr. Ho-ming Luk 陸浩明醫生	Prof. Pak-chung Sham 沈伯松教授	Prof. William Chi-wai Wong 黃志威教授
	Dr. Raymond Siu-ming Wong 王紹明醫生		

### *Task Force on Laws for Healthcare Practitioners* 醫療人員相關法律專責小組

<b>Convener</b> 召集人	Dr. James Shing-ping Chiu 趙承平醫生		
<b>Members</b> 委員	Dr. Ping-tak Chan 陳平德醫生	Dr. James Wesley Ching-hei Cheng 鄭正禧醫生	Dr. Wing-kit Choi 蔡永傑醫生
	Dr. Calvin Yeow-kuan Chong 張耀君醫生	Dr. Thomas Man-chi Dao 陶敏之醫生	Dr. Chun-hung Lai 賴俊雄醫生
	Dr. Yolanda Yee-hung Law 羅綺紅醫生	Prof. Sydney Chi-wai Tang 鄧智偉教授	Dr. Barbara Sau-man Tam 譚秀雯醫生
	Dr. Steven Ho-shan Wong 黃河山醫生	Dr. Eddie Cheuk-pun Yuen 袁卓斌醫生	

### Task Force on Social Media 社交媒體專責小組

<b>Convener</b> 召集人	Prof. Chi-tim Hung 熊志添教授		
<b>Members</b> 委員	Dr. Kai-tai Chan 陳啟泰醫生	Dr. Calvin Yeow-kuan Chong 張耀君醫生	Dr. Ken Ka-ming Ho 何家銘醫生
	Dr. Gary Kui-kai Lau 劉巨基醫生	Dr. Julianna Cho-hwei Liew 劉卓慧醫生	Dr. Lilian Hiu-lei Wong 王曉莉醫生

### Task Force on Sports and Exercise Medicine 運動及體育醫學專責小組

<b>Convener</b> 召集人	Prof. Philip Kam-tao Li 李錦滔教授		
<b>Members</b> 委員	Dr. Dorothy Fung-ying Chan 陳鳳英醫生	Dr. Timmy Chi-wing Chan 陳智榮醫生	Dr. Tze-wang Chan 陳子弘醫生
	Dr. Ying-kei Chan 陳英琪醫生	Dr. Kelvin Kam-lung Chong 莊金隆醫生	Dr. Boris Chun-kei Chow 鄒雋基醫生
	Dr. Raymond Chi-yan Fung 馮子恩醫生	Dr. Tony King-hang Ha 夏敬恒醫生	Dr. Eric Hui-lun Lau 劉珣綸醫生
	Prof. Gilberto Ka-kit Leung 梁嘉傑教授	Dr. Julianna Cho-hwei Liew 劉卓慧醫生	Dr. Calvin Hoi-kwan Mak 麥凱鈞醫生
	Dr. Keith Nin-yuan Pan 潘寧遠醫生	Dr. Godfrey Kwok-fai Tam 譚國輝醫生	Prof. Clement Chee-yung Tham 譚智勇教授
	Dr. Matthew Sik-hon Tsui 徐錫漢醫生	Dr. Esther Yee-tak Yu 余懿德醫生	Prof. Patrick Shu-hang Yung 容樹恒教授

### Task Force on Organ Donation 器官捐贈專責小組

<b>Convenor</b> 召集人	Prof. Philip Kam-tao Li 李錦滔教授		
<b>Members</b> 委員	Dr. Derrick Kit-sing Au 區結成醫生	Dr. David Vai-kiong Chao 周偉強醫生	Dr. Calvin Pak-wing Cheng 鄭柏榮醫生
	Dr. Ivy Shui-ying Cheng 鄭慧凝醫生	Dr. Simon Chi-yuen Cheung 張志遠醫生	Dr. Kai-ming Chow 周啟明醫生
	Dr. Vanessa Wing-see Chow 周穎思醫生	Dr. Adrian Chi-heng Fung 馮智衡醫生	Dr. James Yan-yue Fung 馮恩裕醫生
	Dr. Grace Ho 何潔明醫生	Dr. Carmen Ka-man Lam 林嘉雯醫生	Dr. Raymond Wai-man Leung 梁偉民醫生
	Dr. Alison Lap-tak Ma 馬立德醫生	Dr. Alexander Ng 吳文達醫生	Prof. Chi-fai Ng 吳志輝教授
	Dr. Wesley Ng 吳偉涯醫生	Dr. Gary Cheuk-hang So 蘇卓恒醫生	Prof. Clement Chee-yung Tham 譚智勇教授
	Dr. Matthew Sik-hon Tsui 徐錫漢醫生	Dr. Jerry On-yat Wong 黃安溢醫生	Prof. Martin Chi-sang Wong 黃至生教授
	Dr. Wai-tat Wong 黃維達醫生		

## Young Fellows Chapter 年青院士分會

<b>Chairman</b> 主席	Dr. Adrian Chi-heng Fung 馮智衡醫生		
<b>Vice-Chairman</b> 副主席	Dr. Phoebe Pui-ying Lam 林珮盈醫生		
<b>College Representatives</b> 分科學院代表			
<b>Anaesthesiologists</b> 麻醉科	Dr. Emmanuel Hei-lok Cheung 張熙諾醫生	<b>Otorhinolaryngologists</b> 耳鼻喉科	Dr. Courtney Oi-yee Chan 陳靄怡醫生
	Dr. Janice Ho-ting Leung 梁皓婷醫生		Dr. Wilson Wai-shun Ng 吳偉迅醫生
<b>Community Medicine</b> 社會醫學	Dr. Jianchao Quan 全劍超醫生	<b>Paediatricians</b> 兒科	Dr. Francis Ling-yee Chan 陳令貽醫生
	Dr. Jess Wing-lam Yim 嚴穎琳醫生		Dr. Enoch Chi-tak So 蘇智德醫生
<b>Dental Surgeons</b> 牙科	Dr. Phoebe Pui-ying Lam 林珮盈醫生	<b>Pathologists</b> 病理科	Dr. Crystal Ki Lam 林琪醫生
	Dr. Kaye Wing-sze Wong 王詠詩醫生		Dr. Johann Lok 駱宇漢醫生
<b>Emergency Medicine</b> 急症科	Dr. Ying Cheung 張盈醫生	<b>Physicians</b> 內科	Dr. Annabel Kai-tung Choy 蔡啟彤醫生
	Dr. Hinson Hin-son Li 李軒迅醫生		Dr. Jacky Chiu-leung Ho 何昭良醫生
<b>Family Physicians</b> 家庭醫學	Dr. Cheryl Yuen-ching Chan 陳婉晴醫生	<b>Psychiatrists</b> 精神科	Dr. Adelina Sze-hang Tsoi 蔡思衡醫生
	Dr. Aldo Chiu-lun Wong 王昭麟醫生		
<b>Obstetricians and Gynaecologists</b> 婦產科	Dr. Karen Ng 吳嘉詠醫生	<b>Radiologists</b> 放射科	Dr. Boris Chun-kei Chow 鄒雋基醫生
	Dr. Ada Wing-ting Tse 謝穎婷醫生		Dr. Carol Wing-kei Ng 吳穎琦醫生
<b>Ophthalmologists</b> 眼科	Dr. Sunny Chi-lik Au 區自力醫生	<b>Surgeons</b> 外科	Dr. Adrian Chi-heng Fung 馮智衡醫生
	Dr. Simon Ka-ho Szeto 司徒家浩醫生		Dr. Jason Yu-yin Li 李宇彥醫生
<b>Orthopaedic Surgeons</b> 骨科	Dr. Tze-wang Chan 陳子弘醫生		
	Dr. Marvin Man-ting Chung 鍾汶庭醫生		

## Panels of Judges for Academy's Prizes 醫專獎項評審團

### HKAM-HKGI Research Excellence Grants in Genomic Medicine Vetting Panel

#### 香港醫專－香港基因組中心基因組醫學卓越研究獎評審小組

<b>Chairman</b> 主席	Prof. Philip Kam-tao Li 李錦滔教授		
<b>Members</b> 委員	Dr. Calvin Yeow-kuan Chong 張耀君醫生	Dr. Su-vui Lo 羅思偉醫生	Prof. Clement Chee-yung Tham 譚智勇教授

### Prize for Best Original Research by Young Fellows (BORYF) 最佳年青院士原創研究獎

(Until 31 December 2024 直至2024年12月31日)

<b>Chairman</b> 主席	Prof. Martin Chi-sang Wong 黃至生教授		
<b>Final Judges</b> 總評審團	Dr. David Vai-kiong Chao 周偉強醫生	Prof. Wai-keung Leung 梁惠強教授	Dr. Thomas Ho-fai Tsang 曾浩輝醫生
	Prof. Samuel Yeung-shan Wong 黃仰山教授	Prof. Benny Chung-ying Zee 徐仲鏌教授	
<b>Evaluation Panel</b> 評審小組	Dr. Ben Yuk-fai Fong 方玉輝醫生	Dr. Eddy Kwok-fai Lam 林國輝博士	Dr. Kwok-yin Leung 梁國賢醫生
	Prof. Anthony Chi-fai Ng 吳志輝教授	Prof. Harry Hao-xiang Wang 王皓翔教授	Dr. Ian Yat-hin Wong 王逸軒醫生

### Prize for Best Original Research by Trainees (BORT) 最佳學員原創研究獎

<b>Chairman</b> 主席	Prof. Clement Chee-yung Tham 譚智勇教授		
<b>Members</b> 委員	Dr. Ralph Koon-ho Cheung 張冠豪醫生	Prof. Raymond Hang-wun Li 李幸奐教授	Prof. Edward Chin-man Lo 盧展民教授
	Prof. Paul Kwok-ming Poon 潘國明教授	Dr. Stanley Sau-ching Wong 黃守正醫生	

## Hong Kong Academy of Medicine Press 香港醫學專科學院出版社

### Editorial Board (Focus) 編輯委員會 (季刊Focus)

<b>Editor</b> 編輯	Prof. Martin Chi-sang Wong 黃至生教授		
<b>Members</b> 委員	Mr. Aaron Chung-hang Cheng 鄭仲恒先生	Dr. Yu-fat Chow 周雨發醫生	Dr. Adrian Chi-heng Fung 馮智衡醫生
	Prof. Philip Kam-tao Li 李錦滔教授		

## Editorial Board (Hong Kong Medical Journal) 編輯委員會 (《香港醫學雜誌》)

<b>Editor-in-Chief</b> 總編輯	Prof. Martin Chi-sang Wong 黃至生教授		
<b>Senior Editors</b> 高級編輯	Prof. Leung-wing Chu 朱亮榮教授	Prof. Michael Garnet Irwin 艾明高教授	Dr. Bonnie Ching-ha Kwan 關清霞醫生
	Dr. Eric Chun-hung Lai 賴俊雄醫生	Dr. Kwok-yin Leung 梁國賢醫生	Prof. Anthony Chi-fai Ng 吳志輝教授
	Dr. Regina Wing-shan Sit 薛詠珊醫生		
<b>Editors</b> 編輯	Dr. Ivy Hau-yee Chan 陳巧兒醫生	Dr. Kin-sang Chan 陳健生醫生	Dr. Sherry Kit-wa Chan 陳喆燁醫生
	Prof. Jason Pui-yin Cheung 鍾培言教授	Dr. Kelvin Kam-lung Chong 莊金隆醫生	Dr. James Chung-hang Chow 周重行醫生
	Dr. Wing-sun Chow 周榮新醫生	Dr. Jacqueline Pui-wah Chung 鍾佩樺醫生	Dr. Adrian Chi-heng Fung 馮智衡醫生
	Dr. Brian Sze-ho Ho 何思灝醫生	Prof. Ellis Kam-lun Hon 韓錦倫教授	Dr. Jun-jie Huang 黃俊杰博士
	Dr. Wai-ka Hung 熊維嘉醫生	Dr. Wang-chun Kwok 郭宏駿醫生	Dr. Ho Lam 林賀醫生
	Dr. Ka-on Lam 林嘉安醫生	Dr. Rex Pui-kin Lam 林沛堅醫生	Dr. Pui-yau Lau 婁培友醫生
	Dr. Danny Wai-hung Lee 李偉雄醫生	Prof. Wai-keung Leung 梁惠強教授	Dr. Kenneth Kai-wang Li 李啟煌醫生
	Dr. Janice Yee-chi Lo 羅懿之醫生	Dr. Herbert Ho-fung Loong 龍浩鋒醫生	Dr. Abdul Rashid Nok-shun Lui 雷諾信醫生
	Dr. James Ka-hay Luk 陸嘉熙醫生	Dr. David Christopher Lung 龍振邦醫生	Dr. Henry Ka-fung Mak 麥嘉豐醫生
	Prof. Billy Wai-Lung Ng 吳濂龍教授	Dr. Martin Wai Pak 白威醫生	Dr. Jeremy Yuen-chun Teoh 張源津醫生
	Dr. Ka-yu Tse 謝嘉瑜醫生	Prof. Harry Hao-xiang Wang 王皓翔教授	Dr. Andus Wing-kuen Wong 黃永權博士
	Dr. Kenneth Kak-yuen Wong 黃格元醫生	Dr. Hao Xue 薛浩醫生	Dr. Jason Cheuk-sing Yam 任卓昇醫生
	Dr. Tsz-kok Yau 遊子覺醫生	Dr. Kelvin Kai-hang Yiu 姚啟恒醫生	Prof. Claire Chenwen Zhong 鍾陳雯教授
<b>Epidemiology Advisors</b> 流行病學顧問	Dr. Edmond Siu-keung Ma 馬紹強醫生	Prof. Shelly Lap-ah Tse 謝立亞教授	Dr. Esther Yee-tak Yu 餘懿德醫生
	Dr. Hunter Kwok-lai Yuen 袁國禮醫生		

<b>Statistical Advisors</b>	Dr. Marc Ka-chun Chong	Dr. Eddy Kwok-fai Lam	Dr. Carlos King-ho Wong
統計學顧問	莊家俊博士	林國輝博士	黃競浩博士
<b>Honorary Advisors</b>	Dr. David Vai-kiong Chao	Prof. Paul Bo-san Lai	
名譽顧問	周偉強醫生	賴寶山教授	

#### **Expert Advisory Panel on Social Media 社交媒體專家諮詢小組**

<b>Chairman</b>	Prof. Martin Chi-sang Wong		
主席	黃至生教授		
<b>Convener</b>	Dr. Jeremy Yuen-chun Teoh		
召集人	張源津醫生		
<b>Members</b>	Dr. Sunny Chi-lik Au	Dr. Sherry Kit-wa Chan	Dr. Jason Pui-yin Cheung
委員	區自力醫生	陳喆燁醫生	鍾培言醫生
	Dr. Abdul Rashid Nok-shun Lui	Dr. Jianchao Quan	Dr. Enoch Chi-tak So
	雷諾信醫生	全劍超醫生	蘇智德醫生
	Dr. Jason Cheuk-sing Yam		
	任卓昇醫生		

#### **International Editorial Advisory Board (Hong Kong Medical Journal)**

##### **國際編輯顧問委員會 (《香港醫學雜誌》)**

<b>Members</b>	Prof. Sabaratnam Arulkumaran	Prof. Peter Cameron	Prof. Daniel Kam-yin Chan
委員	Prof. David Christiani	Prof. Andrew Coats	Prof. Willard Fee, Jr.
	Prof. Michael Kidd	Prof. Arthur Kleinman	Prof. Stephen Leeder
	Dr. Sheyu Li	Prof. Xiaoping Luo	Prof. William Rawlinson
	Prof. Jonathan Samet	Prof. Yaojing Shi	Prof. Wanghong Xu
	Prof. Atsuyuki Yamataka	Prof. Homer Yang	Dr. Jin-hong Yoo
	Dr. Faming Zhang		

**Jockey Club Institute for Medical Education and Development**  
**賽馬會醫學教育發展中心**

**Steering Committee 督導委員會**

<b>Chairman</b> 主席	Prof. Clement Chee-yung Tham 譚智勇教授		
<b>Members</b> 委員	Dr. Yu-fat Chow 周雨發醫生	Prof. Gilberto Ka-kit Leung 梁嘉傑教授	Dr. Wing-cheong Leung 梁永昌醫生
	Prof. Philip Kam-tao Li 李錦滔教授	Prof. Eric Wai-choi Tse 謝偉財教授	Prof. Martin Chi-sang Wong 黃至生教授

**Operation Committee 營運委員會**

<b>Chairman</b> 主席	Dr. Benny Chun-pong Cheng 鄭振邦醫生		
<b>Members</b> 委員	Dr. Lawrence Chi-ngong Chan 陳子昂醫生	Dr. Albert Kam-ming Chan 陳錦明醫生	Dr. Ping-tak Chan 陳平德醫生
	Mr. Aaron Chung-hang Cheng 鄭仲恒先生	Dr. Ralph Koon-ho Cheung 張冠豪醫生	Dr. Yu-fai Choi 蔡宇暉醫生
	Dr. Carmen Ka-man Lam 林嘉雯醫生	Dr. Chun-tat Lui 雷俊達醫生	Dr. Neeraj Ramesh Mahboobani 馬承志醫生
	Dr. Hing-yu So 蘇慶餘醫生	Dr. Abraham Ka-chung Wai 衛家聰醫生	Dr. Jian Yang 楊鑒博士

### *eLearning and Technology Subcommittee* 線上學習與技術小組委員會

<b>Chairman</b> 主席	Dr. Chun-tat Lui 雷俊達醫生		
<b>Vice-Chairman</b> 副主席	Dr. Neeraj Ramesh Mahboobani 馬承志醫生		
<b>Members</b> 委員	Dr. Lawrence Chi-ngong Chan 陳子昂醫生	Mr. Jason Chi-shing Chan 陳志誠先生	Dr. Jacky Chun-kit Chan 陳俊傑博士
	Dr. Albert Kam-ming Chan 陳錦明醫生	Dr. Kenny King-chung Chan 陳勁松醫生	Mr. Calvin Tin-chun Cheung 張天俊先生
	Dr. Alvin Po-ngai Chu 朱圃毅醫生	Prof. Patrick Ho-yu Chung 鍾浩宇教授	Dr. Shing Ko 高晟醫生
	Dr. Kenneth Hoi-ming Kwok 郭凱銘醫生	Dr. Christopher Koon-chi Lai 賴貫之醫生	Prof. Simon Hung-san Lam 林鴻生教授
	Prof. Walter Yu-hang Lam 林宇恒教授	Dr. Edwin Chi-ho Lau 劉智豪醫生	Dr. Alex Kwok-keung Law 羅國強醫生
	Prof. Sheung-wai Law 羅尚尉教授	Dr. Matthew Man-hei Luk 陸文熹醫生	Dr. Karen Ng 吳嘉詠醫生
	Dr. George Wing-yiu Ng 吳榮耀醫生	Dr. Paul Kwok-ming Poon 潘國明醫生	Dr. Kendrick Co Shih 施愷迪醫生
	Dr. Jonathan Chun-han Tsoi 蔡臻恒醫生		

### *Quality Management Subcommittee* 質量管理小組委員會

<b>Chairman</b> 主席	Dr. Carmen Ka-man Lam 林嘉雯醫生		
<b>Vice-Chairman</b> 副主席	Dr. Ralph Koon-ho Cheung 張冠豪醫生		
<b>Members</b> 委員	Dr. Tony Hau-yin Chan 陳校然醫生	Dr. Marco Tsz-yeung Chan 陳子揚醫生	Dr. Yu-fai Choi 蔡宇暉醫生
	Mr. Chun-pong Leung 梁振邦先生	Dr. Lok-hang Leung 梁樂行醫生	Dr. Shirley Pui-ching Ngai 魏佩菁博士
	Dr. Bill Man-lung Tsang 曾文龍醫生	Dr. Kin-yip Yeung 楊健業醫生	

### Research Subcommittee 研發小組委員會

<b>Chairman</b> 主席	Dr. Abraham Ka-chung Wai 衛家聰醫生		
<b>Vice-Chairman</b> 副主席	Dr. Jian Yang 楊鑒博士		
<b>Members</b> 委員	Dr. Jacky Chun-kit Chan 陳俊傑博士	Dr. Yu-fai Choi 蔡宇暉醫生	Dr. Dominic Chi-chung Foo 傅志聰醫生
	Dr. Shirley Pui-ching Ngai 魏佩菁博士	Dr. Christopher Yew-hong See 施由鴻博士	Dr. Hing-yu So 蘇慶餘醫生
	Prof. Arkers Kwan-ching Wong 王鈞正教授	Dr. George Kwok-chu Wong 黃國柱醫生	
	Prof. Janet Yuen-ha Wong 黃婉霞教授		

### Training and Faculty Development Subcommittee 培訓及師資發展小組委員會

<b>Chairman</b> <b>主席</b>	Dr. Albert Kam-ming Chan 陳錦明醫生			
<b>Vice-Chairman</b> <b>副主席</b>	Dr. Ping-tak Chan 陳平德醫生			
<b>Members</b> <b>委員</b>	<b>Community Medicine</b> <b>社會醫學</b>	Dr. Thomas Wai-hung Chung 鍾偉雄醫生	<b>Otorhinolaryngologists</b> <b>耳鼻喉科</b>	Dr. Sylvia Suet-ying Yu 余雪瑩醫生
	<b>Dental Surgeons</b> <b>牙科</b>	Dr. Paul Yun-wah Lau 劉潤華醫生	<b>Paediatricians</b> <b>兒科</b>	Dr. Frankie Wai-tsoi Cheng 鄭偉才醫生
	<b>Emergency Medicine</b> <b>急症科</b>	Dr. Chun-tat Lui 雷俊達醫生	<b>Pathologists</b> <b>病理科</b>	Dr. Rock Yuk-yan Leung 梁毓恩醫生
	<b>Family Physicians</b> <b>家庭醫學</b>	Dr. Ken Ka-ming Ho 何家銘醫生	<b>Physicians</b> <b>內科</b>	Dr. Hoi-yee Kwan 關凱怡醫生
	<b>Obstetricians and Gynaecologists</b> <b>婦產科</b>	Dr. Kwok-keung Tang 鄧國強醫生	<b>Psychiatrists</b> <b>精神科</b>	Dr. Chi-wing Law 羅志榮醫生
	<b>Ophthalmologists</b> <b>眼科</b>	Dr. Carmen Kar-mun Chan 陳嘉敏醫生	<b>Radiologists</b> <b>放射科</b>	Dr. Kevin Kin-fen Fung 馮建勳醫生
	<b>Orthopaedic Surgeons</b> <b>骨科</b>	Dr. Albert Yung-chak Hsu 許榕澤醫生	<b>Surgeons</b> <b>外科</b>	Dr. Peggy Sau-kwan Chu 朱秀群醫生

## Key Members 主要成員

<b>Honorary Director</b> 名譽總監	Dr. Benny Chun-pong Cheng 鄭振邦醫生		
<b>Honorary Deputy Directors</b> 名譽副總監	Dr. Albert Kam-ming Chan 陳錦明醫生	Dr. Carmen Ka-man Lam 林嘉雯醫生	Dr. Chun-tat Lui 雷俊達醫生
	Dr. Abraham Ka-chung Wai 衛家聰醫生		
<b>Honorary Assistant Directors</b> 名譽助理總監	Dr. Ping-tak Chan 陳平德醫生	Dr. Ralph Koon-ho Cheung 張冠豪醫生	Dr. Neeraj Ramesh Mahboobani 馬承志醫生
	Dr. Jian Yang 楊鑒博士		

## SZ-HK Medical Specialist Training Centre 深港醫學專科培訓中心

## Executive Committee 執行委員會

<b>Members</b> 委員	Prof. Philip Kam-tao Li 李錦滔教授	Dr. Yu-fat Chow 周雨發醫生	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
	Mr. Aaron Chung-hang Cheng 鄭仲恒先生	Prof. Anne Wing-mui Lee 李詠梅教授	Prof. Kenneth Man-chee Cheung 張文智教授
	Mr. Xiao-ping Xu 徐小平先生		

## Appendix 2

### 附錄二

#### Representation of the Academy

#### 醫專的代表

#### Representatives of the Academy in Other Organisations 醫專在其他機構內的代表

Organisation 機構	Committee 委員會	Representative(s) of the Academy 醫專的代表
Department of Health, HKSAR Government 香港特區政府衛生署	Medical Device Division – Medical Device Advisory Panel 醫療器械科－醫療器械顧問小組	Prof. Philip Kam-tao Li 李錦滔教授
Department of Health, HKSAR Government 香港特區政府衛生署	Advisory Committee for Regulatory Standards for Private Healthcare Facilities 私營醫療機構規管標準諮詢委員會	Prof. Clement Chee-yung Tham 譚智勇教授
Fire Services Department, HKSAR Government 香港特區政府消防處	Paramedic Development and Accreditation Advisory Committee 輔助醫療發展及認證諮詢委員會	Prof. Philip Kam-tao Li 李錦滔教授
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	Institute for Medical Advancement and Clinical Excellence 醫學實證與臨床卓越研究所	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	Health and Medical Research Fund-Grant Review Board 醫療衛生研究基金－評審撥款委員會	Prof. Philip Kam-tao Li 李錦滔教授
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	High Level Steering Committee on Antimicrobial Resistance 抗菌素耐藥性高層督導委員會	Prof. Philip Kam-tao Li 李錦滔教授
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	Task Group on New Medical School 籌備新醫學院工作組	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	Working Group on Legal, Privacy and Security Issues 法律、私隱及保安問題工作小組	Dr. Danny Wai-hung Lee 李偉雄醫生
Health Bureau, HKSAR Government 香港特區政府醫務衛生局	Working Group on Data and Information Standards 資料及信息標準工作小組	Dr. Julian Chun-yan Fong 方俊仁醫生
Hong Kong Academy of Nursing & Midwifery 香港護理及助產專科學院	Honorary Advisor 榮譽顧問	Prof. Philip Kam-tao Li 李錦滔教授
Hong Kong Museum of Medical Sciences 香港醫學博物館	Honorary Advisor 義務顧問	Prof. Philip Kam-tao Li 李錦滔教授
Hong Kong Tourism Board 香港旅遊發展局	Hong Kong Convention Ambassador 香港國際會議大使	Prof. Philip Kam-tao Li 李錦滔教授

Organisation 機構	Committee 委員會	Representative(s) of the Academy 醫專的代表
Hospital Authority 醫院管理局	Forum on Training Collaboration Between Hospital Authority and Hong Kong Academy of Medicine 醫管局與醫專的培訓合作的專題討論 平台	Dr. Yu-fat Chow 周雨發醫生 Dr. Wing-cheong Leung 梁永昌醫生 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Clement Chee-yung Tham 譚智勇教授
Hospital Authority 醫院管理局	Hospital Authority Convention 2025 - Scientific Programme Committee 2025醫院管理局研討大會－程序委員 會	Prof. Philip Kam-tao Li 李錦滔教授
Hospital Authority 醫院管理局	Task Force on Limited Registration Scheme 有限度註冊計劃專責小組	Prof. Philip Kam-tao Li 李錦滔教授
Hospital Authority 醫院管理局	Hong Kong Children's Hospital – Research Steering Committee 香港兒童醫院科研督導委員會	Prof. Hugh Simon Hung-san Lam 林鴻生教授
Hospital Authority 醫院管理局	Selection Panel of The D. H. Chen Foundation Clinical Research Fellowship Program 陳廷驊基金會臨床科研獎學金計劃評 審委員會委員	Dr. Sut-yee Tse 謝雪兒醫生
International Academy for CPD Accreditation 國際持續專業發展認證學院	Member 會員	Prof. Gilberto Ka-kit Leung 梁嘉傑教授 Prof. Philip Kam-tao Li 李錦滔教授
International Association of Medical Regulatory Authorities (IAMRA) 國際醫療監管機構協會	Management Committee 管理委員會	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
The Dental Council of Hong Kong 香港牙醫管理委員會	Membership 委員	Dr. Jerome Yu 虞積龍醫生
The Dental Council of Hong Kong 香港牙醫管理委員會	Continuing Professional Development Committee 持續專業發展委員會	Dr. Daniel Tak-sang Fang 方德生醫生
The Dental Council of Hong Kong 香港牙醫管理委員會	Education and Accreditation Committee 教育及評審委員會	Dr. Daniel Tak-sang Fang 方德生醫生

Organisation 機構	Committee 委員會	Representative(s) of the Academy 醫專的代表
The Dental Council of Hong Kong 香港牙醫管理委員會	Examination Committee and Board of Examiners 考試委員會及考試主任小組	Dr. Tsang-tsang She 佘崢崢醫生 Dr. Tsz-leung Wong 黃子良醫生
The Medical Council of Hong Kong 香港醫務委員會	Accreditation Exercise of the Medical Education and Training of the Chinese University of Hong Kong and the University of Hong Kong 香港中文大學和香港大學醫學教育及訓練評審工作—評審小組	Dr. Yu-fat Chow 周雨發醫生
The Medical Council of Hong Kong 香港醫務委員會	Education and Accreditation Committee 教育及評審小組	Prof. Clement Chee-yung Tham 譚智勇教授 Dr. Clara Wing-yee Wu 胡詠儀醫生
The Medical Council of Hong Kong 香港醫務委員會	Panel of Assessors 審裁顧問委員團	Dr. Frankie Wai-tsoi Cheng 鄭偉才醫生 Dr. James Shing-ping Chiu 趙承平醫生 Dr. Christopher Koon-chi Lai 賴貫之醫生 Dr. Hing-yu So 蘇慶餘醫生 Dr. Barbara Sau-man Tam 譚秀雯醫生 Dr. Maureen Mo-lin Wong 黃慕蓮醫生
The Medical Council of Hong Kong 香港醫務委員會	Policy Meeting 香港醫務委員會 (政策會議)	Dr. Chin-pang Cheung 張展鵬醫生 Dr. Yu-fat Chow 周雨發醫生 Dr. Danny Wai-hung Lee 李偉雄醫生 Prof. Martin Chi-sang Wong 黃至生教授
The Medical Council of Hong Kong 香港醫務委員會	Special Registration Committee 特別註冊委員會	Prof. Philip Kam-tao Li 李錦滔教授
University Grants Committee 大學教育資助委員會	Member of Research Assessment Exercise (RAE) 2026 2026年研究評審工作—成員	Dr. Julian Chun-yan Fong 方俊仁醫生

**Representatives of the Academy in Scientific Meetings and Activities  
(Chinese Mainland and Overseas)**  
出席學術會議及活動（中國內地及海外）之醫專代表

<b>Date (DD/MM/YYYY) 日期(日/月/年)</b>	<b>Chinese Mainland / Overseas Scientific Meeting 中國內地/海外學術會議</b>	<b>Organiser 主辦機構</b>	<b>Representative(s) of the Academy 醫專的代表</b>
11-12/09/2024	Cologne Consensus Conference 2024 2024科隆共識會議	International Academy for CPD Accreditation 國際持續專業發展認證學院	Prof. Philip Kam-tao Li 李錦滔教授
16/11/2024	The Fifth Postgraduate Medical Education Forum in Guangdong – Hong Kong – Macao Greater Bay Area 第五屆粵港澳畢業後醫學教育大會	Chinese Doctors Association 中國醫師協會	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
09-11/03/2025	Delegation Visit to Beijing 醫專代表團訪問北京	Hong Kong Academy of Medicine 香港醫學專科學院	Dr. Wing-cheong Leung 梁永昌醫生 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Clement Chee-yung Tham 譚智勇教授 Prof. Eric Wai-choi Tse 謝偉財教授 Prof. Martin Chi-sang Wong 黃至生教授
16-21/03/2025	Hong Kong-Shenzhen-Shanghai Young Specialists' Study and Exchange Summit 港深滬年青專科醫生學習交流峰會	HKAM Young Fellows Chapter & The Shenzhen-Hong Kong Medical Specialist Training Centre 醫學專科學院年青院士分會及深港醫學專科培訓中心	Prof. Philip Kam-tao Li 李錦滔教授
03-05/04/2025	ACP Internal Medicine Meeting 2025 內科會議2025	American College of Physicians 美國內科醫學院	Prof. Philip Kam-tao Li 李錦滔教授
03-06/05/2025	2025 Royal Australasian College of Surgeons Annual Scientific Congress 澳洲皇家內科醫學院週年科學會議2025	Australasian College of Surgeons 澳洲皇家內科醫學院	Prof. Philip Kam-tao Li 李錦滔教授
22-24/08/2025	58 <sup>th</sup> Malaysia – Singapore Congress of Medicine (MSCM) cum 5 <sup>th</sup> AMM-AMS-HKAM Tripartite Congress of Medicine 第五十八屆馬來西亞及新加坡醫學聯合會議暨第五屆新加坡、馬來西亞及香港三方醫學會議	Academy of Medicine of Malaysia, Academy of Medicine, Singapore, and Hong Kong 新加坡、馬來西亞及香港的醫學專科學院	Dr. Wing-cheong Leung 梁永昌醫生 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Clement Chee-yung Tham 譚智勇教授 Prof. Eric Wai-choi Tse 謝偉財教授 Prof. Martin Chi-sang Wong 黃至生教授 College representatives 分科學院代表

## Representatives of the Academy in Scientific Meetings and Activities (Local) 出席本地學術會議及活動之醫專代表

Date (DD/MM/YYYY) 日期(日/月/年)	Local Scientific Meeting / Activity 本地學術會議/活動	Organiser 主辦機構	Representative(s) of the Academy 醫專的代表
15/09/2024	Hong Kong and Macao Medical Frontier Forum 2024 2024海峽兩岸暨港澳地區醫學前沿論壇	National Health Commission, and the Hospital Authority 國家衛生健康委員會及醫院管理局	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
26/09/2024	Visit by the delegation of National Health Commission 國家衛生健康委員會到訪	National Health Commission & Ministry of Education 國家衛生健康委員會及教育部	Prof. Gilberto Ka-kit Leung 梁嘉傑教授 Prof. Martin Chi-sang Wong 黃至生教授
12/10/2024	Fellowship Conferment of the Hong Kong Academy of Nursing & Midwifery 2024 香港護理及助產專科學院院士頒授儀式	The Hong Kong Academy of Nursing & Midwifery 香港護理及助產專科學院	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
27/10/2024	Annual Scientific Meeting 2024 of the Federation of Medical Societies of Hong Kong 香港醫學組織聯會2024年週年科研大會	The Federation of Medical Societies of Hong Kong 香港醫學組織聯會	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
12/11/2024	Memorandum of Understanding Signing Ceremony for Quadripartite Medical Education Conference 香港體育學院及醫專合作備忘錄簽署儀式	The Hong Kong Sports Institute (HKSI) and Hong Kong Academy of Medicine (HKAM) 香港體育學院及醫專	Prof. Gilberto Ka-kit Leung 梁嘉傑教授 Prof. Philip Kam-tao Li 李錦滔教授
26/11/2024	Visit by the delegation of Ministry of Education & National Health Commission 國家衛生健康委員會及教育部到訪	Ministry of Education & National Health Commission & Ministry of Education 國家衛生健康委員會及教育部	Prof. Gilberto Ka-kit Leung 梁嘉傑教授 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Martin Chi-sang Wong 黃至生教授
20/01/2025	Delegates visit of Zhejiang University 浙江大學代表團到訪	Zhejiang University 浙江大學	Prof. Philip Kam-tao Li 李錦滔教授

Date (DD/MM/YYYY) 日期(日/月/年)	Local Scientific Meeting / Activity 本地學術會議/活動	Organiser 主辦機構	Representative(s) of the Academy 醫專的代表
12/03/2025	Visiting by the WHO Regional Director for the Western Pacific 世界衛生組織西太平洋 區域主任到訪	World Health Organization 世界衛生組織	Dr. Wing-cheong Leung 梁永昌醫生 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Martin Chi-sang Wong 黃至生教授
25/01/2025	Guest of Honour of Climate Change Forum for Medical Practitioners 氣候變化醫學論壇	Council for Carbon Neutrality and Sustainable Development 碳中和及可持續發展委 員會	Prof. Gilberto Ka-kit Leung 梁嘉傑教授
17/04/2025	Hong Kong's Integration into the National Healthcare Development Forum 香港融入國家衛生健康 發展大局研討會	The Hong Kong University of Science and Technology 香港科技大學	Prof. Philip Kam-tao Li 李錦滔教授
10/05/2025	International Nurses Day Celebration Dinner – Hong Kong 2025 國際護士節慶祝晚宴— 香港2025	The Hong Kong Academy of Nursing & Midwifery Limited 香港護理及助產專科學院	Prof. Philip Kam-tao Li 李錦滔教授
21/06/2025	Teachers' and Students Awards Presentation Ceremony 2025 傑出老師及獎學金典禮	The Chinese University of Hong Kong 香港中文大學	Prof. Philip Kam-tao Li 李錦滔教授
22/06/2025	Union Hospital 30 <sup>th</sup> Anniversary Medical Symposium 仁安醫院30週年醫學研討會	Union Hospital 仁安醫院	Prof. Philip Kam-tao Li 李錦滔教授
11/08/2025	Doctors Festival 2025 – Hong Kong Session 2025「中國醫師節」香港 慶祝大會	Hong Kong Chinese Doctors Association 香港中華醫學會	Dr. Wing-cheong Leung 梁永昌醫生 Prof. Philip Kam-tao Li 李錦滔教授 Prof. Clement Chee-yung Tham 譚智勇教授 Prof. Martin Chi-sang Wong 黃至生教授

# Appendix 3


## 附錄三

### Fellowship Statistics

#### 院士數據

(as of August 2025 截至2025年8月)

Academy College 分科學院		No. of Fellows 院士數目
Anaesthesiologists	麻醉科	690
Community Medicine	社會醫學	229
Dental Surgeons	牙科	337
Emergency Medicine	急症科	474
Family Physicians	家庭醫學	604
Obstetricians and Gynaecologists	婦產科	561
Ophthalmologists	眼科	361
Orthopaedic Surgeons	骨科	587
Otorhinolaryngologists	耳鼻喉科	205
Paediatricians	兒科	771
Pathologists	病理科	364
Physicians	內科	2,183
Psychiatrists	精神科	493
Radiologists	放射科	713
Surgeons	外科	1,144
<b>Total</b>	<b>總數</b>	<b>9,716</b>



Note: 91 Fellows possess two or more Fellowships in different specialties.

註：九十一位院士擁有兩個或以上的專科院士資格

## Appendix 4

### 附錄四

#### List of New Fellows in 2024

#### 2024年的新增院士名單

(Names of new Fellows as printed on Hong Kong Identity Cards 院士名稱與香港身份證上所列相同)

#### New Fellows admitted at the Extraordinary General Meeting on 20 June 2024 在2024年6月20日舉行之特別會員大會上納入的新增院士

The following nominations were approved by Council on 20 June 2024 (Total: 136 Fellows)。

以下提名已於2024年6月20日獲院務委員會批准 (共136位院士)。

#### The Hong Kong College of Anaesthesiologists (9 Fellows)

#### 香港麻醉科醫學院 (9位院士)

CHAN, Kwan Dik Claud 陳昀迪	CHOW, Kei Yan 周琪忻	HO, Hing Shing 何慶誠
LAI, Ka Po 黎嘉寶	LAI, Shun Yan Sherri 黎舜蕙	LIU, Chun Ying Janice 廖雋盈
TANG, Tsz Ha 鄧子霞	WAI, Ho Harrison 韋皓	WONG, Siu Lun 黃兆麟

#### Hong Kong College of Community Medicine (9 Fellows)

#### 香港社會醫學學院 (9位院士)

LI, Wing Sum 李榮森	MAK, Kin Mei 麥鍵美	POON, Sin Ting 潘善婷
QUAN, Jianchao 全劍超	TSANG, Hau Fung Flora 曾巧峰	TSANG, Hoi Fai 曾凱暉
TSUI, Wing Yin Alice 崔詠妍	WONG, Yu Fai 黃宇暉	YU, Hoi Yan 余海欣

#### The College of Dental Surgeons of Hong Kong (2 Fellows)

#### 香港牙科醫學院 (2位院士)

LAM, Ka Yan 林嘉欣	LAM, Pui Ying Phoebe 林珮盈
--------------------	-----------------------------

#### Hong Kong College of Emergency Medicine (6 Fellows)

#### 香港急症科醫學院 (6位院士)

CHAN, Pak Yan Ella 陳柏茵	CHAN, Tsz Kit 陳梓傑	CHAN, Yu Tai 陳宇泰
LUNG, Ka Yan 龍嘉欣	WONG, Yiu Nam 黃耀南	YU, Chun Hiu 余春曉

---

**The Hong Kong College of Family Physicians (10 Fellows)****香港家庭醫學學院 (10位院士)**

---

CHAN, Kam Sheung  
陳錦嫦

CHAN, Yuen Ching  
陳婉晴

CHAU, Yiu Shing  
巢耀城

CHOI, Sze Wai Michelle  
蔡思慧

CHUNG, Hiu Yeung  
鍾曉陽

HO, Wing Yan Olivia  
何詠恩

LUK, Sze Wan Candy  
陸詩韻

MA, Man Ki  
馬汶琪

NG, Pui Pui Amy  
吳珮佩

WONG, Hin Hei Henry  
黃衍熹

---

**The Hong Kong College of Obstetricians and Gynaecologists (4 Fellows)****香港婦產科學院 (4位院士)**

---

CHAN, Hey Yin Aaron  
陳希賢

HO, Ka Wun Karen  
何嘉蘊

LIU, Fangzi  
劉芳子

NG, Shu Man Carmen  
吳樹泯

---

**The College of Ophthalmologists of Hong Kong (4 Fellows)****香港眼科醫學院 (4位院士)**

---

CHAN, Ying Lun Jonathan  
陳應倫

CHEUNG, Sui Lam Stephanie  
張萃琳

LI, Ka Hin Gabriel  
李嘉軒

WONG, Yee Kiu  
黃意喬

---

**The Hong Kong College of Orthopaedic Surgeons (24 Fellows)****香港骨科醫學院 (24位院士)**

---

CHAN, Chi Kit 陳志傑	CHAU, Ming Hong 周鳴康	CHAU, Tsz Ching 周子正
CHENG, Chun Wai 鄭俊慧	CHEUNG, Percy 張柏斯	DAO, Wei Hei 杜煒熙
LAM, Cho Wai 林楚淮	LAM, Wai Him 林瑋謙	LEUNG, Ching Ngai 梁正毅
LEUNG, Hiu Yan 梁曉昕	LEUNG, Hok Wai Brian 梁學維	LEUNG, Ka Chun 梁家俊
LEUNG, Lik Hang Brian 梁力恒	LEUNG, Odin Tymon 梁浩天	LEUNG, Tai Pong 梁棣邦
MAK, Wang Fung Rex 麥泓峰	MAN, Lok Chun 文樂駿	NG, Chun Kiu 吳津僑
TANG, Pui Kit Stephen 鄧沛傑	TONG, Chi Him 唐智謙	WONG, Cham Kit 王湛傑
WONG, Kwok Hei Arthur 黃國羲	WONG, Yan Yu Ruby 黃昕愉	YAM, Oching Joyce 任翺晴

---

**Hong Kong College of Paediatricians (5 Fellows)****香港兒科醫學院 (5位院士)**

---

CHEUNG, Yan Shi Clara 張燕詩	KWONG, Yi Lee 鄺伊莉	LING, Wan Hei Janet 凌允希
TSANG, Chi Yau Alice 曾子柔	WONG, Lok Hei 王諾熙	

---

**The Hong Kong College of Pathologists (2 Fellows)****香港病理學專科學院 (2位院士)**

---

LAM, Tony 林百通	YEUNG, Ka Pik Vivian 楊嘉璧
------------------	-----------------------------

---

**Hong Kong College of Physicians (20 Fellows)****香港內科醫學院 (20位院士)**

---

CAI, Ganhui 蔡干慧	CHAN, Chun Hin 陳俊軒	CHAN, Tin Ho Dennis 陳天浩
CHENG, Kim Fung 鄭劍峰	CHEUNG, Ching Lam Chris 張清林	CHOW, Hiu Cheong 周曉昌
HO, Chi Wai 何志威	HUANG, Xinqian 黃欣倩	HUI, Chi Hou Samuel 許智豪
LAU, Pui Hong Kendrick 劉沛康	LEE, Ching Him 李政謙	LEUNG, Cheuk Cheung Derek 梁卓彰
LEUNG, Wang Hei Ricky 梁宏禧	MAK, Yiu Hang Peter 麥耀恆	MAN, Ho Yin 文浩賢
NGAN, Ho Ting Abe 顏浩霆	SO, Ching Hei 蘇正熙	WONG, Man Chi 王文志
YEUNG, Ka Ho 楊嘉豪	YUEN, Kwan Yuk Jacqueline 阮君毓	

---

**The Hong Kong College of Psychiatrists (5 Fellows)****香港精神科醫學院 (5位院士)**

---

AU YEUNG, Wing Yin Renee 歐陽穎賢	CHAN, Ka Wai 陳家偉	CHAN, Lok Yan Tammy 陳樂欣
LAM, Kei Fung 林紀峰	WONG, Yuk Ling 黃玉玲	

---

**Hong Kong College of Radiologists (24 Fellows)****香港放射科醫學院 (24位院士)**

---

CHAN, Cheuk Yan Cherry 陳卓忻	CHAN, Hoi Ling 陳凱玲	CHAN, Lok Hei Derek 陳樂義
CHAN, Yi Lam Priscilla 陳伊琳	CHEUNG, Claudia 張樂人	CHEUNG, Pui Lam 張沛林
CHEUNG, Sze Nga 張詩雅	CHOI, Chuen Wai 蔡雋煒	FUNG, Kiu-jing James 馮喬政
HUNG, Long Ching Jessica 孔朗程	KWOK, Po Lam 郭寶琳	KWOK, Sing Hon 郭星翰
LAW, Wing Chung 羅穎聰	LEUNG, Kwan Ho 梁君豪	LIU, Tsz Chim 廖芷霑
LO, Hong Yip 盧劭業	MAK, Yan Sin 麥恩善	SUEN, Chun Hong 孫振航
TAM, Wing Yan Catherine 譚穎欣	WAN, Fong Ying 尹芳盈	WO, Bar Wai Barry 胡伯衛
WONG, Dicken 王迪勤	WONG, Chun Yip Henry 黃進業	YU, Suet Mui 於雪梅

---

**The College of Surgeons of Hong Kong (12 Fellows)****香港外科醫學院 (12位院士)**

---

CHEUNG, Fu Ho Victor 張富浩	FOK, Chi Ying Jacquelyn 霍智盈	FUNG, Hei Wai Michelle 馮曦慧
FUNG, Tsz Ching 馮祉呈	HO, Si Lyn 何詩林	HUI, Ka Wing 許嘉詠
HUNG, Pui Long Wilson 洪培朗	LEUNG, Ka Wai 梁家偉	LIU, Yuk Ho 廖昱皓
WONG, Ching Yiu 黃靖瑤	WONG, Ting Fung 王庭峰	YEUNG, Man Hon Andrew 楊文翰

## New Fellows admitted at the 31<sup>st</sup> Annual General Meeting on 6 December 2024 在2024年12月6日舉行之第三十一屆周年大會上納入的新增院士

The following nominations were approved by Council on 6 December 2024 (Total: 219 Fellows)。  
以下提名已於2024年12月6日獲院務委員會批准 (共219位院士)。

### The Hong Kong College of Anaesthesiologists (17 Fellows)

#### 香港麻醉科醫學院 (17位院士)

CHEUNG, Hei Lok Emmanuel 張熙諾	CHEUNG, Lam Chi 張琳知	HO, Chun Long Gregory Ignatius 何雋朗
HUI, Chi Kit 許智傑	KWONG, Ka Woon Calvin 鄺加桓	LAU, Hon Wai 劉漢威
LEONG, Tak Kei 梁德基	LEUNG, Wing Hei 梁穎曦	LI, Lok Yin 李樂然
LIU, Ka Wai 廖嘉慧	LUI, Ho Kwan 呂浩昆	TANG, Chi Chun 鄧子俊
WAN, Yiu Kei Michael 溫耀基	WONG, Chuk Kwan Edith 黃築筠	WONG, Yin Kwan Gabriel 黃彥鈞
YAM, Yin Lam Jeffrey 任彥霖	YAU, Jing May Justine Marie 邱靜美	

### Hong Kong College of Community Medicine (3 Fellows)

#### 香港社會醫學學院 (3位院士)

LAM, Mei Yee 林美怡	LAM, Yu Yuk Christy 林瑜玉	YIM, Wing Lam 嚴穎琳
---------------------	----------------------------	----------------------

### The College of Dental Surgeons of Hong Kong (6 Fellows)

#### 香港牙科醫學院 (6位院士)

CHEUNG, Ka Yan 張嘉恩	HO, Cheuk Hin 何綽軒	LAM, Ching 林晶
MA, Hai Leong 馬熹亮	TAM, Ching Yan 譚鈺鋤	WANG, Rui 汪睿

---

**Hong Kong College of Emergency Medicine (20 Fellows)****香港急症科醫學院 (20位院士)**

---

CHAN, Ngo Tin James 陳翱天	CHENG, Ho Man 鄭浩民	CHEUNG, Kwun Lok 張鈞樂
CHUI, Ka Kam Kenneth 徐嘉淦	CHUN, Hon 秦瀚	CHUNG, Ho Lam 鍾浩林
HON, Siu Kei Sam 韓兆基	LAM, Chi Pang 林志鵬	LAU, Wing Hung 劉穎熊
LEUNG, Ka Yee 梁嘉儀	LEUNG, Shing Tak 梁成德	LEUNG, Shuen Yi 梁舜頤
LO, Kwong Tat 盧廣達	SO, Chun Kit 蘇俊傑	SUEN, Wing Yan 孫永欣
WENG, Jiacheng 翁佳誠	WONG, Chun Yiu 黃雋曜	WONG, Ka Yin Karen 王嘉賢
YU, Ho Kun Adrian 余焯寅	YUEN, Lok Sang 原樂生	

---

**The Hong Kong College of Family Physicians (17 Fellows)****香港家庭醫學學院 (17位院士)**

---

CHAN, Ki Fung Dickson 陳祺峯	CHANG, Ting Ting 張婷婷	CHOI, Yan Tak 蔡恩德
CHOW, Hoi Kei Jessica 周愷琦	CHUANG, Chi Kit 莊志傑	HUN, Pek I 禰碧儀
LAM, Kang 林庚	LAM, Wai Yiu 林煒堯	LEUNG, Nelson 梁景昭
LI, Anne Beatrice 李沛昕	NG, Pui Yee Beatrice 吳沛誼	PANG, Sze Ching Esther 彭詩情
SUEN, Gee Kwang Victoria 孫芷筠	WONG, Chung Ming 黃宗明	WONG, Wing Ning Rosanna 黃泳寧
YAU, Chi Yan 丘志仁	YEUNG, Lok Ki 楊樂祺	

---

**The Hong Kong College of Obstetricians and Gynaecologists (13 Fellows)****香港婦產科學院 (13位院士)**

---

CHAN, Lorraine 陳敏暄	EU, Khin Shwe 姚健瑞	HO, King Dat Stanton 何勁達
LAI, Kit Yan Francesca 賴潔恩	LAU, Yin Tung Roxana 劉燕瞳	LEUNG, Tsz Ching 梁芷晴
SUM, Hiu Yan Tiffany 岑曉欣	TAM, Yuet Man Cheryl 譚悅文	TSANG, Ling Yin 曾令賢
WAI, Kar On Joan 衛家安	WONG, Chun Kit 黃俊傑	WONG, Siu Chung 王紹聰
YIU, Mei Sin 姚美先		

---

**The College of Ophthalmologists of Hong Kong (1 Fellow)****香港眼科醫學院 (1位院士)**

---

KWOK, Hiu Wai Stephanie  
郭曉慧

---

**The Hong Kong College of Otorhinolaryngologists (2 Fellows)****香港耳鼻喉科醫學院 (2位院士)**

---

LEE, Wah Yan 李樺欣	LI, Wei Yan Levina 李蔚欣
---------------------	---------------------------

---

**Hong Kong College of Paediatricians (22 Fellows)****香港兒科醫學院 (22位院士)**

---

CHAN, Long Kiu Kelvin 陳朗翹	CHAN, Sau Ching 陳秀靖	CHAN, Sin Yi Cindy 陳倩怡
CHAN, Suk Yan 陳淑欣	CHIU, Chi Ying Jaime 趙芝瑛	CHUNG, Ka Shing 鍾嘉成
CHUNG, Wai Hung 鍾偉鴻	FAN, On Ki 樊安琪	HAU, Siew Yun 侯兆恩
HO, Chun Lok 何俊樂	HO, Chung Sum Samuel 何頌琛	KWOK, Wing Sze 郭詠詩
LEE, Yuen Lam 李沅霖	LEUNG, Hoi Huen 梁愷萱	LEUNG, Yuk Chi 梁育芝
LI, Wai Yin Vivien 李慧妍	LIM, Qin Ying 林沁穎	LU, Ruoyun Evelyn 陸若雲
MA, Ming Yin Justin 馬銘賢	WONG, Ka Lim Carlin 黃家廉	WONG, Siu Yui 王紹銳
YUNG, Vivian Queenie 容君怡		

---

**The Hong Kong College of Pathologists (12 Fellows)****香港病理學專科學院 (12位院士)**

---

CHAN, Chun Hei 陳進希	CHENG, Shui Kuen 鄭瑞娟	CHIANG, Valerie 姜穎彤
CHOW, Kin Yi 周健怡	FONG, Nga Yee 方雅儀	HO, Cheuk Lam 何焯林
LAU, Cheuk Hei 劉卓熙	LI, Po Yin 李寶賢	LUI, Yin Wing 雷賢穎
LUNG, Chee Heng Cheryl 龍芷荇	TSANG, Chui San Zara 曾鶴齡	WU, Wing Gi 胡詠之

## Hong Kong College of Physicians (61 Fellows)

### 香港內科醫學院 (61位院士)

CHAN, Cheuk Ming 陳倬銘	CHAN, Kai Chun 陳啟俊	CHAN, Kam Wa 陳錦華
CHAN, Tin Long Kelly 陳天朗	CHAN, Yat Kwan 陳逸鈞	CHAO, Chien Wei Amelia 曹千惠
CHAO, Chun 趙峻	CHENG, Yau 鄭由	CHEUNG, Chung Yin 張仲然
CHEUNG, Pak Nung Rocco 張柏農	CHEUNG, Pui Hin Rebekah 張珮軒	CHIU, Ka Ho Oscar 趙嘉浩
CHOI, Ka Him 蔡嘉謙	CHOI, Yan Wing 蔡忻穎	CHOW, Wing Kar Edith 周穎嘉
CHOY, Kai Tung Annabel 蔡啟彤	CHU, Tsz Fung 朱梓豐	CHU, Wing Ming 朱穎銘
FENG, Ye 馮燁	FU, Tung Yi 符冬兒	FUNG, Chun Yu 馮振宇
FUNG, Yuk Kiu Chloe 馮鈺喬	HO, Hiu Yan Agnes 何曉欣	HO, Ting Hin 何霆軒
IP, Chi Ching Edric 葉智程	IP, Chin Tung Whitney 葉展彤	KO, Hon Yeung 高瀚揚
KONG, Shing Pak 江誠栢	KWAN, Chung Ming 關仲明	KWAN, Wai Sze 關慧思
KWOK, Chun Yeung 郭雋揚	KWOK, Yuan Jing George 郭原禎	LAI, Chin Wai 黎千慧
LAI, Wing Ki Winky 賴詠祈	LAM, Ka Yau Bryce 林珈右	LAM, Cheuk Ting 林卓婷
LAM, Fung 林峰	LAM, Sze Man Cindy 林斯敏	LAU, Chun Ling 劉俊靈
LAU, Wing Tung 劉穎彤	LEE, Min Yao Cynthia 李敏瑤	LEUNG, Ka Chun Jackson 梁嘉駿
LO, Wing Ho Vincent 盧永浩	LUK, Wing Lam Fion 陸詠琳	MA, King Him 馬競謙
MOK, Kit Shun Kevin 莫傑舜	SHEK, Pui Shan Karen 石珮珊	SIU, Ming Fai 蕭明輝
SO, Hao Yu Clarence 蘇昊宇	TAM, Wai Lam Rana 譚慧琳	TANG, Chi Kin 鄧子健
TANG, Ho Cheung Arthur 鄧浩樟	TANG, Jingliang 唐景梁	TSOI, Man Ho 蔡文皓
WONG, Chun Yin 黃俊賢	WONG, Ho On Leo 王浩安	WONG, Ling Na 黃玲娜
WONG, Sum Lung 黃心龍	WU, Wing Kwan Claudia 胡詠琚	XIE, Bingjiao 謝冰皎
YU, Shing Yiu Anthony 餘承耀		

### The Hong Kong College of Psychiatrists (13 Fellows)

#### 香港精神科醫學院 (13位院士)

CHAN, Chin Tsung 陳展樅	CHAN, Wang Him Jason 陳泓謙	CHEUNG, Hon Kit 張漢傑
CHOW, Hoi Kin 周凱建	LAI, Tsz Him 黎梓謙	LAM, Ho Yin 林浩然
LAU, Ting Yi Domily 劉定宜	LAW, Sin Wai 羅倩慧	LEUNG, Nga Fung Michelle 梁雅楓
NG, Kwun Hang 吳冠衡	WAN, Chun Wah 尹俊驊	YEUNG, Tsz Ying 楊子盈
YIP, Kin Yan Kimberly 葉健欣		

### Hong Kong College of Radiologists (3 Fellows)

#### 香港放射科醫學院 (3位院士)

LAM, Lok Yee 林樂宜	LUI, Huo Zheng Daniel 呂活證	SO, Hin Kwan 蘇衍鋸
---------------------	------------------------------	---------------------


### The College of Surgeons of Hong Kong (29 Fellows)

#### 香港外科醫學院 (29位院士)

AU-YEUNG, Kit Ying 歐陽潔瑩	CHAN, Mei Yi 陳美怡	CHAN, Yan Lilian 陳昕
CHEUNG, Ling Kit 張齡傑	CHEUNG, Pak Long 張柏朗	CHEUNG, Wing Lok 張永樂
CHEUNG, Yuk Hong Eric 張旭康	CHOW, Hin San 周顯榮	CUI, Yushi Tracy 崔語詩
HUNG, Ho Ching 孔顯程	IP, Ho Wai 葉豪威	KONG, Fung Yuen Gloria 江豐苑
KWAN, Cheuk Hang 關卓恆	KWONG, Tsz Fung 鄺梓峰	KWONG, Wai Yin Pearl 鄺慧妍
LAI, Kai Ming 黎啟明	LAU, Ming 劉銘	LEE, Long Yiu 李朗耀
LEUNG, Wai Fu 梁偉富	LI, Cheuk Lun Michael 李卓倫	LIM, Kevin 林諾賢
MAK, Kit Ying Queenie 麥潔盈	MOK, Chung Ying 莫仲瑩	POON, Ho Ting Samuel 潘皓庭
TAM, Dick Sang 譚迪生	TO, Hoi Man 杜凱雯	WONG, On Wai 黃安偉
WONG, Yat Chung 王逸聰	YEUNG, Shu Yan Jennie 楊書恩	

### Organisational Structure of the Academy

### 醫專的組織架構







Hong Kong Academy of Medicine Jockey Club Building,  
99 Wong Chuk Hang Road, Aberdeen, Hong Kong  
香港黃竹坑道99號香港醫學專科學院賽馬會大樓

Tel 電話: (852) 2871 8888

Fax 傳真: (852) 2505 5577

Email 電郵: [hkam@hkam.org.hk](mailto:hkam@hkam.org.hk)

Website 網址: [www.hkam.org.hk](http://www.hkam.org.hk)

